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8SUMMARY
Ischemic cardiovascular disease and cancer are life-threatening disorders in human
mortality. Intensive studies on the etiology of and therapeutics for the diseases are
ongoing. One of the most intriguing and promising fields for studies in both disorders
is angiogenesis. Ischemic myocardium and cancer are closely associated with
hypoxia and require de novo blood vessels for tissue survival. However,
therapeutically, angiogenesis needs to be induced in the ischemic myocardium
whereas it ought to be suppressed in cancer. For both purposes, a thorough
understanding of the mechanisms of hypoxia-induced angiogenesis is indispensable.
Angiogenesis, in response to ischemia, requires factors that sense hypoxia and that
relay the signals to effectors. Mammalian target of rapamycin (mTOR), a key energy-
sensor for cell survival, has recently been shown to be involved in hypoxic signaling.
It remains unclear whether mTOR acts as part of the oxygen-sensing machinery and
how mTOR regulates the hypoxia-induced signaling transducers. On the other hand,
transcription factor hypoxia-inducible factor-1α (HIF-1α) is critical for hypoxic-driven
induction of angiogenic molecules. Again, it is unclear how mTOR affects HIF-1α
function. To unravel these questions, we have assessed mTOR activity as well as its
relationship to HIF-1α in rat aortic endothelial cells (RAECs) in response to hypoxia.
Previous studies in the lab had found that hypoxia potentiates angiogenesis of
explants from rat aorta in an mTOR dependent way. In this study, we have extended
this observation to proliferation of RAEC in vitro and a RAEC-spheroid sprouting
assay (angiogenesis in vitro). Rapamycin, an inhibitor of mTOR, inhibited
proliferation of RAEC and sprouting of endothelial cells in vitro under hypoxia.
Interestingly, upon hypoxic stimulation, mTOR is highly phosphorylated; both mTOR
and phospho-mTOR accumulate in cell nucleus, as does HIF-1α. However, S6k and
4E-BP1, two downstream targets of mTOR that are involved in translational control
are hypophosphorylated at the same time. In low O2 tension (1% O2), increased
nuclear HIF-1α  levels are observed over time as well as with decreased O2
saturation. Similarly, the growth factor PDGF-BB induces HIF-1α  nuclear
accumulation under normoxic conditions. Hypoxia and PDGF-BB synergistically
enhance HIF-1α nuclear levels. mTOR inhibition strongly reduces nuclear HIF-1α
levels under hypoxia or/and PDGF-BB stimulation while MEK1/2 blockage only
9reduces PDGF-BB-induced nuclear HIF-1α accumulation in normoxia. Neither JNK
nor p38 inhibition alters nuclear HIF-1α protein levels. HIF-1α mRNA levels remain
stable under different oxygen saturations and upon mTOR or MEK1/2 inhibition.
Notably, rapamycin-decreased HIF-1α  nuclear accumulation can be rescued by
proteasomal inhibition under hypoxia. Finally, mouse embryonic fibroblasts lacking
HIF-1α significantly decreased proliferation rates under hypoxia when compared to
wild type cells. However, mTOR over expression restores and further augments
hypoxia-triggered proliferation both in HIF-1α wild type and in HIF-1α deficient cells.
Taken together, hypoxia activates both HIF-1α-dependent and HIF-1α-independent
regulation of cell proliferation and angiogenesis. Hypoxia-induced mTOR activation
reduces S6K1 and 4E-BP1 phosphorylation. mTOR activity is required for protecting
HIF-1α from proteasomal degradation. Further investigations on mTOR and HIF-1α
during hypoxia in RAEC proliferation, spheroid sprouting assays, and angiogenesis in
vivo are required. Thus, targeting mTOR to enhance or reduce angiogenesis in
response to hypoxia may be clinically relevant.
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1. INTRODUCTION
1.1. Growth of new blood vessels
Three distinct forms of vessel formation have been described so far. Vasculogenesis
refers to the formation of blood vessels by endothelial progenitors (angioblasts)
arising from various embryonic regions or the adult bone marrow (BM). This process
involves differentiation, proliferation, migration and association of primitive
endothelial cells. Angiogenesis refers to the generation of new capillary blood
vessels by sprouting or longitudinal division from pre-existing ones, whilst
arteriogenesis contributes to the stabilization of these sprouts by mural cells for the
transformation of a small arteriole into much larger conductance artery. Angiogenesis
involves the enlargement of venules, which sprout or become divided by pillars of
periendothelial cells (intussusceptions) or by transendothelial cell bridges, which then
split into individual capillaries. Collateral growth stands for the formation of collateral
bridges between arterial networks by expansive growth and remodeling of pre-
existing vessels upon occlusion of a supply vessel for example by thrombosis.
Recruitment of monocytes to the shear stress-activated endothelium plays a critical
role in this process 4-6 (Figure 1).
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Figure 1. Mechanisms of vessel growth in adult. (a) Vasculogenesis refers to the recruitment of bone marrow-
derived endothelial progenitors, which become incorporated into nascent vessels or stimulate new vessel growth by
releasing pro-angiogenic factors. (b) Angiogenesis is characterized by the sprouting of new endothelial cell-lined
vessels from preexisting vessels; arteriogenesis refers to the subsequent stabilization of these nascent vessels via
recruitment of smooth muscle cells. (c) Collateral growth denotes the expansive growth of pre-existing collateral
vessels upon occlusion of a supply vessel. Adapted from 4.
1.1.1. Angiogenesis
Angiogenesis can be initiated in response to stimuli like hypoxia, ischemia,
inflammation, and blood coagulation. These factors trigger the release of angiogenic
molecules (activators and inhibitors) that activate endothelial cells to induce a set of
transcriptional events. Consequently, the activities cause conformational changes of
the microvasculature.
Angiogenesis is preceded by vasodilation, which is partially induced by nitric oxide
(NO). NO and vascular endothelial growth factor (VEGF) induced in response to
angiogenic stimuli cause an increase in vascular permeability. This together with the
inhibition of endothelial cell receptor Tie-2 (tyrosine kinase with immunoglobulin and
EGF homology domains) by Angiopoietin-2 (Ang-2) loosens the extracellular matrix
(ECM) surrounding microvessels. In turn, proteases degrade the subendothelial
basement membrane and the surrounding ECM which process facilitates endothelial
cell migration and liberates activators for angiogenesis. These processes
concurrently allow endothelial cells that constitute the inner layer of vessels to
migrate and to proliferate. Following migration into the ECM, endothelial cells
proliferate, assemble into solid cords, and acquire lumens. The primitive vascular
networks (or plexa) are remodeled through branching, sprouting, and pruning of the
vascular endothelium. As new vessels form, Ang-2 is withdrawn and Ang-1 is
induced from mesenchymal cells so as to recruit pericytes that form single cell layers
around endothelial capillaries and to recruit vascular smooth muscle cells (VSMCs)
that coat veins and arteries 6-8 (Figure 2).
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Figure 2. a) Sequential events of angiogenesis in comparison with vascular genesis. The processes have been
explained in the text. Adapted from 6. b) Sequential events in angiogenesis. (1) Basement membrane disintegration
opens the way for (2) endothelial cell migration. (3) Cords of cells proliferate and (4) define a new vascular channel.
(5) Cessation of cell migration and proliferation coincides with the recruitment of perivascular support cells (6) with
the formation of a new basement membrane and vessel maturation and stabilization. Adapted from 8.
Angiogenesis happens in both physiological and pathological conditions. It plays
essential roles during embryogenesis, normal tissue repair in adult, and the
remodeling of the female reproductive organs (menstrual cycle, ovulation and
placental development). In an in vitro model, filopodia at the tips of vascular sprouts
were shown to build intervascular bridges in the growing vascular plexus of the area
vasculosa at embryonic day 3 9. Examination of wound drainage fluid from
postoperative patients was shown to contain both promoters and inhibitors of
angiogenesis. This suggests that the local balance between them may control
angiogenesis during healing 10. Moreover, wound healing is probably regulated by
growth factors like FGF-2 and VEGF, and macrophages participate in the process by
releasing angiogenic factors 11-13. Angiogenesis is cyclically regulated in the ovary 14.
A recent study shows that estrogen induces villous placental angiogenesis via
stimulating trophoblast VEGF expression for fetal growth and development in early
primate pregnancy 15. Although angiogenesis is the principal process in
neovascularization, effective neovascularization may further require mobilization and
in situ differentiation of bone marrow-derived endothelial progenitor cells 16,17.
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Angiogenesis is also turned on in inflammatory, ischemic and cancerous diseases.
The rate of angiogenesis is increased in human synovium with rheumatoid arthritis
(RA) which may cause subsequent destruction of the articular cartilage 18. Synovial
inflammation and angiogenesis are enhanced in a substantial proportion of patients
with osteoarthritis (OA) 19. Synovial fluids from patients with OA may stimulate
endothelial tube formation in vitro 20. The angiogenic pathway VEGF/flk-1 (KDR) may
play an important role in the pathogenesis of RA and OA 21. Moreover, insufficient
angiogenesis presents in peri-infarct area in ischemic coronary heart disease or in
ischemic skeletal muscle in peripheral artery disease 22-24. The contribution of
angiogenesis to tumor development has been intensively studied for years. The
investigations cover mechanistic studies of tumor growth and metastases as well as
therapeutic studies against cancer25. Defects in angiogenesis have been considered
as etiological components in the inheritance of high blood pressure. The relationships
between angiogenesis and hypertension, cardiovascular diseases and tumor will be
addressed subsequently in more details.
1.1.2. Angiogenesis and hypertension
Hypertension causes characteristic microvascular arteriolosclerosis, which may
impair coronary haemodynamics and facilitate development of adaptive myocardial
hypertrophy 26. In addition, reduced microvascular density, namely rarefaction of
arterioles and capillaries has been identified in both rodent hypertensive models and
in human hypertensives 22,27. Furthermore, late-onset hypertension is associated with
a lack of coronary angiogenesis and also with a decrease in dilator reserve despite of
the absence of myocardial hypertrophy 28. Therefore, inadequate angiogenesis is
closely related to hypertension per se and hypertension-dependent target organ
damage 29,30. Studies in this respect suggest that impaired angiogenesis in
hypertensives, besides high blood pressure itself, may be due to reduced nitric oxide
(NO) biosynthesis, activation of the Renin-Angiotensin-Aldosterone System (RAAS),
and other factors 31,32.
Local delivery of human tissue kallikrein gene rescued rat endothelial dysfunction
caused by arterial hypertension and microvascular rarefaction caused by diabetes
mellitus 33. 17β-estradiol, a steroid hormone, has been shown to upregulate the
production of endothelial nitric oxide (EDNO), which in turn may induce endothelium-
dependent relaxation of coronary arteries as well as anti-atherosclerotic effect 34.
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Similarly, 17β-estradiol increased EDNO-mediated vasodilation both in female
hypertensive rats and in large coronary conductance arteries as well as coronary
microvascular resistance arteries of postmenopausal women 35,36. In concordance
with these findings, 17β-estradiol and other ovarian hormones may stimulate
angiogenesis 34.
Angiotensin II (Ang II) is a key regulator of blood pressure, body fluid homeostasis
and the final active messenger of the RAAS. Maintenance of Ang II at normal levels
during periods of hypertension or high-salt diet completely eliminates rarefaction of
vessels in hypertensive rats 37,38. This process is thought to be mediated via the AT1
and AT2 receptors 37,38. In contrast, AT receptor antagonist, losartan, did not affect
VEGF and sFlt-1 serum levels in hypertensive patients 39. Moreover, a decrease of
circulating Ang II by enalapril, an angiotensin-converting enzyme (ACE) inhibitor, or
losartan induces in vivo angiogenesis in mice implying an inhibitory effect of ANG II
40. Thus, the angiotensin II pathway can both stimulate and inhibit angiogenesis
depending on the tissue and the receptors activated 41.
1.1.3. Angiogenesis and cardiovascular diseases
In cardiovascular diseases, angiogenesis is closely related to ischemic heart disease.
Myocardial ischemia, a condition of reduced oxygen supply to heart tissue, is a
common consequence of narrowing or occlusion of coronary arteries due to
atherosclerosis, and may lead to myocardial infarction. To overcome ischemia, the
heart develops collateral circulation so as to provide a bypass for blood supply to the
ischemic myocardium 42.
Formation of collateral passes to the ischemic tissue in the heart is supposed to
involve angiogenesis and collateral recruitment 43,44. Unfortunately, natural
neovascularization does not fully restore blood flow into the ischemic region of the
heart 45. In this process, ischemia-induced decrease in the partial pressure of cellular
oxygen is a potent stimulator of neovascularization 42. Both myocardial ischemia and
hypoxia upregulate expression of angiogenic growth factors 45.
Therapeutic angiogenesis can be induced by administration of proteins of angiogenic
factors, viruses expressing genes for angiogenic factors, undifferentiated or
differentiated embryonic stem cells, and finally endothelial progenitors derived from
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BM or umbilical cord blood. The clinical use of growth factors to enhance or promote
collateral blood vessels in ischemic tissue has been considered a promising
possibility for therapeutic angiogenesis 46. Angiogenic growth factors in the form of
recombinant proteins or of the genes encoding these proteins are often administered
through a variety of delivery methods including intravenous, selective intracoronary,
intramyocardial (transendocardial and transepicardial) and intrapericardial application
47,48. The earliest clinical reports assessing therapeutic angiogenesis in myocardium
have used recombinant FGF-1 protein and naked plasmid DNA encoding VEGF,
respectively 49,50. Recombinant protein delivery has been associated with side effects
such as hypotension, edema, anemia, thrombocytopenia and renal toxicity. Gene
transfer provides a more precise way of growth factor administration with the
disadvantage of vector-induced cytotoxicity 45,48.
Hypoxia-inducible factor-1α  (HIF-1α ), a transcription factor for a set of genes
involved in angiogenesis, has been defined as a marker of early response of
myocardium to ischemia and hypoxia. An alternative strategy of using transgenes
encoding angiogenic growth factors is targeting HIF-1α to regulate the expression of
multiple angiogenic genes (see below) 42,47.
1.1.4. Angiogenesis and tumor
Angiogenesis is critical for tumorigenesis. Tumor growth and metastasis require new
blood vessel growth, namely angiogenesis 51. Though tumor type-dependent, a tumor
surpassing the size of 0.2-2 mm hardly grows without an adequate vasculature 52,53.
Therefore, angiogenesis is associated with prognosis and the risk of metastasis 54,55.
Therapeutically, inhibition of angiogenesis may retard tumor growth, metastasis and
may cause tumor regression 56,57.
Angiogenesis is switched on during preneoplastic stages in the development of a
tumor. Tumor-induced angiogenesis is switched on due to the production of pro-
angiogenic growth factors such as VEGF by the tumor cells, which initiate
angiogenesis (Figure 3).
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Figure 3. Models of tumor angiogenesis. a) Model of avascular tumor initiation b) tumor initiation involving host
vessel co-option. Involvement of some angiogenic factors has been displayed in the sequential processes. Adapted
from 25.
Understanding mechanisms of tumor angiogenesis greatly facilitates the
development of anti-tumor strategies. These include interfering with angiogenic
ligands, their receptors and downstream signaling transduction, upregulating
endogenous or delivering exogenous inhibitors for angiogenesis, and direct targeting
tumor vasculature 58. Hexapeptides designed to inhibit the interaction of VEGF (165)
with VEGF receptor abrogate proliferation of endothelial cells and block
angiogenesis, tumor cell growth and metastasis in animal models 59. This is
supported by using antibodies against VEGF to block tumor angiogenesis in clinical
trials 60-62. Targeting endothelial-specific receptor, Flk-1 and Tie2, to impair tumor
vascularization also elicit promising results 63,64. Intrinsic angiogenesis inhibitors such
as angiostatin and endostatin as well as administration of extrinsic anti-angiogenic
agents offer new insights in anti-tumor therapy 56,57,65. Ombretastatin A-4 prodrug, a
compound designed to target tumor vasculature, decreases tumor blood flow and
tumor perfusion 66.
Although promising, anti-angiogenic therapy against tumors has problems. First, the
frequently used subcutaneous model of tumor growth does not accurately predict
responses in human tumors. Secondly, tumor regression does not rule out relapse.
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Third, tumor models used for preclinical studies often use highly proliferative cells.
These may be different from slowly growing tumors found in humans 58. Finally, given
the diversity of angiogenic molecules secreted from tumors and the heterogeneity of
microvascular endothelial cells, anti-angiogenic treatment of tumors should probably
be carried out with mixtures of agents 58,62.
1.2. Hypoxia
Hypoxia potently influences the expression of about 1% of the genes in the genome
67. However, there is no defined line between hypoxia and normoxia within a
mammalian body and tissues. Under normoxic conditions (1 ATA-atmosphere
absolute, or 158 mmHg), with the air one breathes into the lung containing about
21% O2, cells in our body live in an O2 concentration
 ranging from 12% to 0.5%. The
extents of the two extremes varies in different organs or tissues. For example, O2 is
about 14% in circulating arterial blood, and less than 10% in the myocardium 68.
Organs like liver or tissues as skin, cartilage, bone marrow and lens of eyes, amniotic
cavity stay within the O2 range of 2% to 8% 
67. The heterogeneity of oxygen
concentrations in a healthy individual creats difficulties in defining hypoxia.
A practical definition, which is close to biophysiological and clinical settings, is that
hypoxia stands for a state when oxygen delivery does not meet the demand of an
organ, tissue or cell 67. Hypoxia appears when 1) O2 partial pressure is low in arterial
blood due to pulmonary diseases or high altitude (hypoxemic hypoxia); 2) the
capacity of O2 in blood is reduced as a result of anemia, methemoglobin formation,
 or
carbon monoxide poisoning (anemic hypoxia); 3) insufficient blood perfuses to
tissues (circulatory or ischemic hypoxia); 4) the diffusion geometry is altered such as
increased diffusion distances, concurrent versus countercurrent blood flow within
microvessels (diffusional hypoxia); 5) intoxication causes cells unable to use O2 as in
cyanide poisoning (histotoxic or cytotoxic hypoxia) 69,70.
Hypoxic areas with O2 saturation close to zero often occur in ischemic heart tissue.
Bordering this hypoxic core, the region short of O2 extends up to several millimeters
with increasing O2 concentration to the biophysiological normoxic domain 
71. Under
this circumstances, mild hypoxia is associated with a 30% to 60% decrease (1% to
3% O2) in PO2 
68. As in the ischemic myocardium, the O2 gradient exists as well in
solid tumors. Tumors thrive on about 1% to 3% O2 though this range is somehow
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tumor type-dependent 69,70. For experimental cell culture, hypoxia is routinely defined
as 0.5-2.0% O2 (usually complemented with 5% CO2, the rest nitrogen). At this level
toxicity and growth-inhibition to cells are not present, and cellular responses to
hypoxia such as induction of HIF-1α can be triggered 67.
1.2.1. Hypoxia and angiogenesis
Once an organism or a single cell is exposed to hypoxia, it may react with switching
on mechanisms that regulate responses to hypoxia and adapt to changes in oxygen
tension. The switch from aerobic to anaerobic metabolism is mediated by the
induction of glycolytic enzymes and glucose transporters. Hypoxia and other yet
poorly defined stimuli drive tumoral, inflammatory, and connective tissue cells to
generate angiogenic molecules 30. These adaptive alterations may lead to the
improvement of oxygen delivery 72. No matter how the regulatory mechanisms differ
among various organisms or cells, the fact that they work through hypoxia-induced
molecules is obvious. Interestingly, the hypoxia-dependent generation and regulation
of these molecules, to a large extent, are managed at the transcriptional level by
hypoxia-inducible factors (HIFs).
As described in the last chapter, numerous disorders are in close correlation to either
an excess or insufficient number of vessels. The angiogenic effect mediated by HIF
is particularly important in certain cell types such as endothelial and smooth muscle
cells because of their role in building up the neovasculature. An increase in the level
of HIF-1/HIF-1 alpha subunit (HIF-1α) is an early response to myocardial ischemia or
tumor growth. Thus, HIF-1α is a useful temporal marker of jeopardized myocardium
and solid tumors 42,73. More importantly, understanding of HIF-1 regulation opens
promising opportunities for clinical applications.
1.2.2. Hypoxia-inducible factor (HIF) family
Hypoxia-inducible factors are mainly responsible for cellular adaptation to oxygen
deprivation. The family of HIF has been growing since the first oxygen-regulated
transcriptional factor, HIF-1, was identified more than a decade ago 74. In general,
HIFs function as heterodimeric transcription factor consisting of one of the alpha (α)
subunits and one of the beta (β) subunits, which is more precisely called aryl
hydrocarbon receptor nuclear translocator (ARNT). Both α  and β groups of the
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subunits belong to a protein superfamily called basic helix-loop-helix-Per/Arnt/Sim
(bHLH-PAS). When oxygen tension drops below physiological level, HIF-α subunits
translocate to the nucleus and dimerize with HIF-β subunits 75,76. In turn, the dimers
combine with other cofactors to form functional transcriptional complexes, which bind
to hypoxia response elements (HREs, 5’-RCGTG-3’) located in the promoter or
enhancer regions of hypoxia-inducible genes and thereby activate transcription of
target genes 77. The basic characteristics of HIF family members defined so far have
been summarized in Table 1.
Protein name Aliases Gene name Chromosome Main domain Function
HIF-1α
HIF-2α
HIF-3α
HIF-1β
HIF-2β∗
hypoxia-inducible
factor-1 alpha, HIF-1
alpha, ARNT
interacting protein,
member of PAS
protein 1 (MOP-1)
endothelial PAS
domain protein 1
(EPAS-1), member of
PAS protein 2 (MOP-
2), hypoxia-inducible
factor-2 alpha (HIF-2
alpha), HIF2 alpha,
HIF-1 alpha-like factor
(HLF), HIF-related
factor (HRF)
hypoxia-inducible
factor-3 alpha,
Inhibitory PAS domain
protein, IPAS
ARNT protein, aryl
hydrocarbon receptor
nulcear translocator,
Dioxin receptor
nuclear translocator,
hypoxia-inducible
factor 1 beta (HIF-1
beta)
ARNT protein 2, aryl
hydrocarbon receptor
nuclear translocator 2
HIF1A, MOP1,
PASD8, HIF-1 alpha,
HIF1-ALPHA
EPAS 1, HIF2A,
MOP2, PASD2
HIF3A, HIF-3A IPAS,
MOP7, PASD7,
HGNC: 15825
ARNT, HIF1B,
TANGO, HIF1BETA,
HIF-1 beta
ARNT2, KIAA0307
14 (human), 6 (rat), 12
(mouse)
2 (human), 6 (rat), 17
(mouse)
19 (human), 1 (rat), 7
(mouse)
1 (human), 2 (rat), 3
(mouse)
15 (human), 8/1 (rat),
7 (mouse)
DNA binding, HLH,
PAS1, PAS2, PAC,
ODD, NTAD, ID,
CTAD, Nuclear
translocator
DNA binding, HLH,
PAS1, PAS2, PAC,
ODD, NTAD, CTAD,
Nuclear translocator
HLH, PAS1, PAS2,
PAC, Nuclear
translocator, ODD,
NTAD
DNA binding, HLH,
PAS1, PAS2, PAC,
Nuclear translocator
DNA binding, HLH,
PAS1, PAS2, PAC,
Nuclear translocator
heterodimerizes with HIF-
1β or/and HIF-2β for active
transcription mainly in
responses to hypoxia
75,78;DNA enhancer binding
for active transcription 79;
histone acetyltransferase
binding for transcriptional
activity 80.
heterodimerizes with HIF-
1β or/and HIF-2β for active
transcription mainly in
responses to hypoxia
79,81,82; DNA enhancer
binding for active
transcription 79; histone
acetyltransferase binding
for transcriptional activity 80.
Heterodimerizes with HIF-
1β for transcriptional
activity in response to
hypoxia 83; inhibitory or
complementary effects on
other HIF family
transcriptional factors 84-86
required for activity of the
Ah (dioxin) receptor 87,88;
herterodimerizes with AHR,
HIF-1α, HIF-2α or/and HIF-
3α for transcriptional
activity 75,79,81,83,88;
coactivator for transcription
88.
has ARNT activity; able to
heterodimerize with HIF-
1α, HIF-2α for
transcriptional activity 78,82
* nomenclature is unclear HLH: helix-loop-helix,
AHR: aryl hydrocarbon
receptor
PAS: Period (Per)-Aryl
hydrocarbon receptor
nuclear translocator (Arnt)-
Single-minded protein
(Sim),
PAC: PAS-associated C-
terminal domain
ODD: oxygen-dependent
degradation domain
N(C)TAD: N(C)-terminal
transactivation domain, ID:
inhibitory domain
Table 1: Basic characteristics of HIF family members.
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The β subunits of HIF are constitutively present while the α subunits are induced
especially in response to hypoxia although other stimuli such as growth factors,
cytokines or chemical compounds may contribute to their induction as well 75,82,89-91.
Among the HIF-α subunits, HIF-1α is the most ubiquitously and abundantly induced
in tissues and cells under hypoxic conditions compared to HIF-2α and HIF-3α. Still,
the existence of the splice variants of HIF-α subunits enriches the complexity of the
HIF family as well as the combination of the functional subunits 86,92-96.
Structurally, most of the variant HIF-α subunits are similar in their bHLH and PAS
domains but differ in their Tran activation domains which may explain the presence of
overlapping yet distinct transcriptional target genes 86. Besides, most of the HIF-α
variants share a high degree of homology in their oxygen-dependent degradation
domains (ODD), including the two critical proline residues (Pro402 and Pro564) that
account for O2 tension-associated stabilization of the proteins. This provides
theoretical support for the degradational regulation of the proteins and their
responsiveness to hypoxia 86,93. In addition, the highly conserved 50 amino acids
located at the C-termini of some HIF-1α forms and HIF-2α are important for O2-
regulated interaction with the transcriptional coactivator p300 76.
Functionally, less is known about HIF-2α  and HIF-3α  than that for HIF-1α .
Recognition of the similar core HREs in the hypoxia responsive genes elicits
common readouts for HIF-1α, -2α and –3α activation. The N-terminal transactivation
domain (NTAD) and the C-terminal transactivation domain (CTAD) synergistically
mediate the transcriptional activity of HIF-1α and –2α. Though it might be cell type-
dependent, the existence of the inhibitory domain (ID) between NTAD and CTAD
potentially counteracts the tansactivational activity of CTAD 97. However, HIF-3α
variants lack the CTAD domain, hence may substantially reduce transcriptional
activities in response to hypoxia. IPAS (inhibitory PAS domain protein), a splicing
variants of HIF-3α, isolates the dimerizational interaction between HIF-1α and HIF-1β
implying the antagonizing role of HIF-3α in the HIF system 84,85. Despite of this, HIF-
3α transcription is induced by hypoxia in multiple organs while mRNA levels of HIF-
1α, -1β, and -2α remain unaffected evidencing a reactive aspect of HIF-3α in
protection against hypoxic damage 98. Still, HIF-1α  knockout mice exhibit mid-
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gestation lethality with severe blood vessel defects indicating a critical role for HIF-1α
in embryonic development, hypoxic responses and vascular formation 99.
1.2.2.1. HIF-1alpha (HIF-1α)
Being one of the most important hypoxia-driven factors, HIF-1α (∼120 kDa) is often
coupled with HIF-1β (91-94 kDa) to form a HIF-1 dimer 75. This action together with
the selective coactivators targeting the different domains in the protein and the target
DNA binding of the complex may trigger a series of transcriptional activities for a set
of genes involved in the regulation of erythropoiesis, angiogenesis, vasomotor
control, and energy metabolism, etc (Table 2).
Function                                                          Genes
Amino acid metabolism                            Transglutaminase 2
Angiogenesis                                              EG-VEGF, ENG, LEP, LRP1, TGF-β3, VEGF
Apoptosis                                                        NIP3, NIX, RTP801
Cell proliferation                                           Cyclin G2, IGF2, IGF-BP1, IGF-BP-2, IGF-BP3, WAF-1, TGF-α, TGF-β3, ET1
Cell adhesion                                     MIC2
Cell survival                                                    ADM, EPO, IGF2, IGF-BP1, IGF-BP2, IGF-BP3, NOS2, TGF-α, VEGF
Cytoskeletal structure                                KRT14, KRT18, KRT19, VIM
Drug resistance                                             MDR1
Energy metabolism                                     LEP
Erythropoiesis                                              EPO
Extracellular matrix metabolism            CATHD, Collagen type V (α1), FN1, MMP2, PAI1, 4-PH alpha-1, UPAR
Epithelial homeostasis                               Intestinal trefoil factor
Glucose metabolism                                   HK1, HK2, AMF/GPI, ENO1, GLUT1, GAPDH, LDHA, PFKBF3, PFKL, PGK1, PKM, TPI, ALDA, ALDC
Iron metabolism                                            Ceruloplasmin, Transferrin, Transferrin receptor
Motility                                                               ANF/GPI, c-MET, LRP1, TGF-α
Nucleotide metabolism                              Adenylate kinase 3, Ecto-5‘-nucleotidase
PH regulation                                                 Carbonic anhydrase 9
Regulation of HIF-1 activity                     P35srj
Transcriptional regulation                         EC1, DEC2, ETS-1, NUR77
Vascular tone                                                  α1B-adrenergic receptor, ADM, ET1, HO1, NOS2
ADM, adrenomedullin; ALDA, aldolase A; ALDC, aldolase C; AMF, autocrine motility factor; CATHD, cathepsin D; EG-VEGF, endocrine gland-derived
VEGF; ENG, endoglin; ET1, endothelin 1; ENO1, enolase 1; EPO, erythropoietin; FN1, fibronectin 1; GLUT1, glucose transporter 1; GLUT3, glucose
transporter 3; GAPDH, glyceraldehyde-3-p-dehydrogenase; HK1, hexokinase 1; HK2, hexokinase 2; HO1, haem oxygenase 1; IGF2, insulin-like growth
factor 2; IGF-BP1, IGF-binding protein 1; IGF-BP2, IGF-binding protein 2; IGF-BP3, IGF-binding protein 3; KRT14, keratin 14; KRT18, keratin 18;
KRT19, keratin 19; LDHA, lactate dehydrogenase A; LEP, leptin; LRP1, LDL receptor-related protein 1; MDR1, multidrug resistance 1; MMP2, matrix
metalloproteinase 2; NOS2, nitric oxide synthesis 2; PAI1, plasminogen-activator inhibitor 1; PFKBF3, 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3; PFKL, phosphofructokinase L; PGK1,  phosphoglycerate kinase 1; 4-PH alpha-1, prolyl 4-hydroxylase alpha-1; PKM, pyruvate kinase
M; TGF-α, transforming growth factor, alpha; TGF-b3, transforming growth factor, beta3; TPI, triosephosphate isomerase; VEGF, vascular endothelial
growth factor; UPAR, urokinase plasminogen activator receptor; VEGFR2, VEGF receptor 2; VIM, vimentin.
Table 2. HIF-1 target genes. Adapted from 100.
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Involvement of HIF-1α in hypoxic response is an instantaneous event. Jewell and
colleagues were able to show that HIF-1α protein accumulates in HeLaS3 cells
nucleus within 2 minutes of hypoxic exposure, and HIF-1 DNA-binding activity
appears earlier in this time range as well 101. Though the bHLH domain is an
indispensable participant in these process, the PAS domains may serve as sensors
of oxygen and perform as transducers of signals by protein–protein interactions 102. In
addition, the oxygen-dependent degradation (ODD) domain is fully required for the
stabilization and function of HIF-1α since it contains two prolyl residues (Pro402 and
Pro564 in human) for hydroxylation, a lysine 532 residue for acetylation and is
overlapping with the N-terminal tansactivation domain. The NTAD and CTAD are
very important for HIF-1α to exert transcriptional activity since they provide docks for
co-activators as p300/CBP, SRC-1 and Ref-1. The ID domain is suggested to
repress the activity of CTAD under non-hypoxic conditions. However, other ID-
independent but hypoxia-dependent mechanisms may modulate NTAD and CTAD as
well 97,103,104. Besides, the undefined region for phosphorylation and the hydroxylation
of the asparagine 803 within the CTAD provide more possibilities for promoting or
abolishing the transactivation of HIF-1 97 (Figure 4).
Figure 4. Domain structure and structural location of the posttranslational modifications of HIF-1α and β
bHLH, basic helix-loop-helix; PAS, PER-ARNT-SIM; ODDD, oxygen-dependent degradation domain; PHD, prolyl
hydroxylase domain; ARD1, ARrest Defective-1 protein; N-TAD and C-TAD, N- and C-terminal activation domains;
FIH-1, factor inhibiting HIF-1. Adapted from 105.
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1.2.2.2. Biological regulation of HIF-1α
Many post-translational modifications regulate the functions of HIF-1α. HIF-1α  is
degraded in normoxia, and stabilized under hypoxia when no other forces are
involved. Stimuli other than O2 such as growth factors, oncogenic mutations or
chemicals are able to increase HIF-1α cellular levels.
1.2.2.2.1. Oxygen-dependent regulation of HIF-1α
Alterations between normoxia and hypoxia may switch on or off the modification
processes to HIF-1α  including phosphorylation, hydroxylation, ubiquitination,
acetylation, sumoylation, and S-nitrosation (summarized in Figure 6).
Phosphorylation of HIF-1α or its coactivators has been reported in several studies
and is related to enhanced transcriptional activities 106-109. However, the specific
residues within HIF-1α for phosphorylation have yet to be identified. Still, MAPK has
been shown to phosphorylate HIF-1α at the residue(s) of 531-826, 796, and 530-744
respectively 107-109. Though HIF-1β may bind preferentially to the phosphorylated form
of HIF-1α, it is controversial whether the enhanced transcriptional activity is directly
caused by the phosphorylation of HIF-1α  or due to the phosphorylation of its
coactivator p300 106,109. There is no evidence for c-Jun N-terminal kinase (JNK) in the
phosphorylation of HIF-1α, and data are contradictive about the involvement of p38
kinase 106,107.
Hydroxylation of HIF-1α involves two similar yet distinct subsets of 2-oxoglutarate
dioxygenases from the iron (II)- and 2-oxoglutarate-dependent oxygenases
superfamily. The prolyl-targeting set of dioxygenase in humans are termed Prolyl
Hydroxylase Domain (PHD) proteins and contain three members, PHD1, PHD2, and
PHD3 110,111, which hydroxylate specific prolyl residues (Pro402 and/or Pro564) in the
ODD domain of HIF-1α with differential efficacy in the presence of O2. PHD1 and
PHD2 modify both of the prolyl sites while PHD3 preferentially hydroxylates Pro564
111. Interestingly, siRNA silencing of PHD2 but not PHD1 or PHD3 gene is sufficient
to stabilize HIF-1α under normoxic conditions illustrating the critical role of PHD2 in
the process of HIF-1α hydroxylation 112. Prolyl hydroxylation leads to binding of von
Hippel-Lindau protein (pVHL) containing E3 ligase complex and subsequent
ubiquitination and proteasomal degradation of HIF-1α  113-115 (Figure 6). In addition,
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another dioxygenase called Factor Inhibiting HIF-1 (FIH-1) is known to hydroxylate
asparagine residue 803 in the C-terminal transactivation domain of HIF-1α  in
normoxia. This modification attenuates the interaction of HIF-1α with its co-activator
CBP/p300 therefore abolishing the transcriptional activity of HIF-1 116-118 (Figure 5).
Figure 5. Two independent hydroxylation pathways regulate HIF activity in response to cellular oxygen level.
In normoxia, oxygen availability enables PHD-dependent prolyl hydroxylation of the HIF-α ODD. This hydroxylation
allows binding of the VHL E3 ligase leading to ubiquitylation and degradation of HIF-α subunits. Oxygen availability
also enables FIH-dependent asparaginyl hydroxylation of the C-TAD, blocking interaction with the p300/CBP co-
activator. In hypoxia, the PHD and FIH enzymes are inactive and the lack of hydroxylation results in stable HIF-α
able to form a DNA-binding heterodimer with HIF-β and recruit p300/CBP at the C-TAD. Adapted from 119.
Acetylation and deacetylation histones have been linked to the regulation of
transcriptional activity 120. Recently, HIF-1α was also reported to be acetylated. This
modification favours its interaction with pVHL and thus destabilizes HIF-1α 105. A
putative acetyltransferase, ARest Defective-1 protein (ARD1), is able to acetylate
lysine 532 in the ODD domain of HIF-1α 121. The proteasomal inhibitor MG132
increases levels of acetylated HIF-1α in normoxia than that in hypoxic conditions 121.
In accordance with this, ARD1-acetylated wild type ODD protein showed increased
interaction with pVHL whereas ARD1-acetylated ODD-K532R mutant protein did not,
indicating that the acetylation of Lys532 by ARD1 is potentially involved in the pVHL-
ubiquitin complex mediated proteasomal degradation of HIF-1α  121. Moreover, a
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global inhibitor of deacetylases, butyric acid, is capable of inducing HIF-1α
degradation in a way causing an anti-angiogenic effect 122.
Ubiquitination of a target protein is a stepwise process consisting of activation of the
E1 enzyme, conjugation of E2, and the consecutive ubiquitin transfer to the target
and leading to protein degradation. Normoxic degradation and hypoxic stabilization of
HIF-1α have been closely linked to the protein ubiquitination and proteasomal
destruction processes. After prolyl hydroxylation and acetylation, HIF-1α  is
recognized and bound to the β domain of pVHL, which is in a E3 ligase complex 123.
Moreover, another E3 ubiquitin ligase, Murine Double Minute 2 (MDM2), was
proposed to ubiquitinate HIF-1α upon p53 and HIF-1α interaction under hypoxia
evidencing the role of p53 as a tumor suppressor 124. Furthermore, Jab1 (Jun
activation domain-binding protein-1) is able to compete with p53 and interact with the
ODD domain of HIF-1α leading to the stabilization and upregulation of the activity of
HIF-1α under hypoxic conditions 125.
In mammalian cells, sumoylation post-translationally modifies certain proteins by
attaching SUMO (small ubiquitin-like modifier) covalently to specific lysine residues
within the proteins, a process involving three SUMO proteases, E1, E2 and E3 126.
Four SUMO gene-encoded proteins, SUMO-1, -2, -3, -4 have been identified so far
127,128. In some circumstances, the SUMOs may work in concert to make the
sumoylation forming polySUMO chains 129. Sumoylation has been shown to be
engaged in nucleocytoplasmic trafficking and signaling of some proteins as well as
negative regulation of transcription in most of the cases 126. Though sumoylation
imposes direct modification on some transcriptional factors, the process could also
affect transcription by modulating the coactivators or corepressors for assembling the
transactivating complex 130. For example, sumoylation represses the activity of p300
by enabling the recruitment of the HDAC6 histone deacetylase which, to some
extent, may explain the negative role of sumoylation on HIF-1a transactivational
function 131. Furthermore, sumoylation of HIF-1β abrogates its transcriptional activity
by preventing it from interacting with its coactivators such as PML (promyelocytic
leukemia protein). Despite the negative roles of sumoylation in these regards,
covalently modifying of two lysine residues 391, 477 within HIF-1α ODD domain by
sumoylation is capable of enhancing the stability of HIF-1α thereby upregulating its
transcriptional activity under both normoxic and hypoxic conditions 132.
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S-nitrosation has recently been described as an additional post-translational
modification to HIF-1α. The action is fulfilled via exogenously and endogenously
produced nitric oxide (NO) 133. S-nitrosation of cysteine 800 in the C-terminal
transactivation domain of HIF-1α augments the interaction between HIF-1α and p300
and promotes HIF-1α transcriptional activity 134. Therefore, S-nitrosation appears as
a positive regulator of HIF-1α stability and transactivating activity.
Figure 6. Intracellular localization and functional consequences of the different posttranslational
modifications of HIF-1α. Refer the details of the explanations to the context. Adapted from 105.
Apart from the post-translational modifications mentioned above, other alternative
ways could also contribute to O2-dependent mediation of HIF-1α. The inhibitory PAS
domain protein (IPAS) as a product of hypoxia-induced splice variant of HIF-3α may
interact with HIF-1α and negatively regulate the expression of its target genes 84.
P35srj (also called MRG1, CITED2), a CBP/p300 interacting protein, is markedly
upregulated in response to hypoxia or deferoxamine, and binds to the CH1 motif of
p300 hence blocks the access of HIF-1α to CBP/p300 for the transcriptional activity
135. Also, hypoxia-triggered increase of HIF-1α could eventually trigger autocrine
signaling to reinforce the transcriptional efficacy of HIF-1α 100.
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1.2.2.2.2. Oxygen-independent regulation of HIF-1α
Insulin and insulin-like growth factor-1 (IGF-1) were reported to induce upregulation
of HIF-1α in a way different from the hypoxic pathway. Besides, growth factors as
PDGF, EGF, FGF-2, IGF-2, TGF-1β, HGF, TNFα, IL-1β have been found to increase
HIF-1α levels through receptor-mediated pathways 136,137. Moreover, Angiotensin II
(ANG II) and Thrombin enhance HIF-1α levels and its transcriptional activity 138,139.
Coincidently, these exogenous factors seem to stimulate HIF-1α  synthesis via
activating similar signaling transduction cascades, i.e., the phosphatidylinositol 3-
kinase (PI3K) and/or the mitogen-activitated protein kinase (MAPK) pathways 100.
Mammalian target of rapamycin (mTOR), a known energy sensor as well as a
downstream target of PI3K for growth control, has been implicated in hypoxic
signaling and HIF-1α regulation 140-143. However, by which ways mTOR regulates
HIF-1α is not known yet. Interestingly, ANG II could increase HIF-1α  by a post-
transcriptional mechanism via AT(2) receptors, and the increase is likely caused by a
downregulation of PHD3 144. Thus, growth factors may upregulate HIF-1α at different
levels.
Some oncogenic mutations influence HIF-1α expression and function too. Gain of
function of ERBB2 (HER2/neu), a gene encoding a member of epidermal growth
factor (EGF) receptor family, leads to increasing HIF-1α synthesis and expression of
its downstream angiogenesis-inducing genes. The process was suggested to be
PI3K/AKT/mTOR signaling dependent 145. Loss of function of the tumor suppressor
gene von Hippel-Lindau (VHL) brings about a remarkable increase in HIF-1 activity
due to impaired VHL-mediated ubiquitination and proteasomal degradation of HIF-1α
and HIF-2α  100. Reintroduction of pVHL into VHL-/- cell lines rescues oxygen-
dependent regulation of hypoxia-inducible genes and suppresses tumor formation in
mouse xenograft assay 146. PTEN, another tumor suppressor gene, is known to
abrogate hypoxia-induced HIF-1α stabilization in a PI3K/AKT signaling-dependent
way. PTEN loss and regain function mediates HIF-1α-regulated gene expression 147.
Finally, some of the transition cation-containing chemicals (e.g. Co2+, Ni2+) or iron
chelators (e.g. DFX – desferrioxamine) are capable of increasing HIF-1α levels in
normoxia. This is though to occur by displacing the Fe2+ from the Fe2+ binding site in
28
the oxygenases 148,149. Besides, direct binding of Co2+ to the ODD domain of HIF-1α
was reported to modulate of HIF-1α regulation 150. Similarly, by chelation of Fe2+, the
antimycotic compound ciclopirox olamine (CPX) is able to stabilize HIF-1α  in
normoxia resulting in enhanced angiogenic gene expression and angiogenesis 91,151.
Recently, arsenite was shown able to increase HIF-1α levels in a mTOR-dependent
pattern 152.
1.2.2.3. HIF-1α targeting and clinical implications
The important role of HIF-1α in adaptation to cellular oxygen alterations makes it a
good candidate for therapeutic targeting. A growing body of evidence has tied
hypoxia and HIF-1α to a magnitude of human diseases and the therapeutics against
them. Different strategies targeting pathways regulating HIF-1α , HIF-
1α transcriptional effectors, and co-activators of HIF-1α are ongoing.
Transgenic expression of ODD-defective HIF-1α  in the skin of mice results in a
phenotype with markedly induced VEGF isoforms and massively increased blood
vessels, which are not associated with leaking and tissue edema 153. Similarly, a
transcriptional active protein produced by hybridized HIF-1α key elements and
herpes simplex virus VP16 profoundly improved angiogenic indices of ischemic
hindlimbs in a rabbit model 154. Targeting HIF-1α  degradation by using a
macrophage-derived peptide PR39 successfully improved the myocardial vasculature
in mice 155. Increased levels and transcriptional activity of HIF-1α  as well as
enhanced vascularization were observed after using prolyl 4-hydroxylase inhibitors in
a rat sponge model 156. Chetomin, a synthetic compound originally from fungus
metabolite, attenuates hypoxia-inducible gene expression and inhibits tumor growth
by interrupting the interaction between HIF-1α and CBP/p300 in mouse model 80.
Intratumoral transfer of an anti-sense HIF-1α plasmid downregulates HIF-1α levels,
VEGF expression and decreases tumor microvessel density 157. Furthermore,
clinically relevant agents aiming at inhibiting either HIF-1α transduction pathways or
HIF-1α activity have also been under development (Table 3).
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Table 3. Novel therapeutic agents that inhibit HIF-1α activity. RAF, MAP3K (a v-raf-1 murine leukemia viral
oncogene homolog); mTOR, mammalian target of rapamycin; COX2, cyclooxygenase 2; MEK, MAPK/ERK kinase;
EGFR, epidermal growth factor receptor; BCR-ABL, breakpoint cluster region-Abelson leukemia; PDGFR, platelet-
derived growth factor receptor; HSP90, heat shock protein 90. Adapted from 100.
1.3. Growth factors and angiogenesis
Growth factors are pivotal for the formation of functional blood vessels. Therefore,
modulating angiogenesis by targeting growth factors and their receptors is
extensively studied. Among more than 20 known angiogenic growth factors, Vascular
Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF),
Fibroblast growth factors (aFGF, bFGF), and transforming growth factor-beta (TGF-
β) are the most common and well-studied ones 158-163. Certainly, the reciprocal roles
of Angiopoietin-1 (Ang-1), Angiopoietin-2 (Ang-2), the pro- and anti-angiogenic
function of TGF-β as well as other angiogenic growth factors and inhibitors should
not be overlooked in the process of angiogenesis. Here, we will focus on the
characteristics of VEGF and PDGF.
1.3.1. Vascular endothelial growth factor (VEGF)
VEGF, also known as vascular permeability factor (VPF), is a heparin-binding
glycoprotein specific for vascular endothelial cells. It is secreted from hypoxic,
ischemic or malignant cells as a homodimer, and is able to induce angiogenesis 164-
167.
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Belonging to the vascular endothelium-specific growth factor super family, the VEGF
family has five members, i.e., VEGF-A, -B, -C, -D, and placental growth factor (PIGF)
165,166,168-171. An orf virus-encoded VEGF isoform, VEGF-E was also found 172,173. The
most abundant and biologically active form of VEGF is VEGF165, which is a VEGF-A
splice variant (others are VEGF121, 145, 189, 206). VEGF expression is generally
low in adults with the exception of the female reproductive organ 174. Expression is
increased in some pathological situations such as certain inflammatory diseases,
myocardial ischemia, atherosclerosis, and tumor growth 175-177.
To be functional, the various VEGF forms need to bind to their receptor tyrosine-
kinases (RTKs) or non-RTKs, Flt1 or VEGFR1, KDR or VEGFR2 (mouse equivalent,
Flk-1), Flt4 or VEGFR3. Though Flt1 and KDR regulate blood vessel formation by
different means, they are a prerequisite for vasculogenesis and angiogenesis
whereas VEGFR3 specifically mediates lymphangiogenesis 178-180. The different
forms of VEGF, VEGFR as well as the activating relationships are shown in Figure 7.
Figure 7. VEGF family ligands and receptors. The RTKs that specifically recognize VEGF-A, Flt1 (VEGFR1) and
KDR (VEGFR2), possess an extracellular domain containing seven Ig-like loops, a single hydrophobic membrane-
spanning domain, and a cytoplasmic domain comprising a single kinase domain that is interrupted by a non-catalytic
region, called the kinase insert. VEGF C, D and E also bind to KDR, while PlGF and VEGF-B bind to Flt1 only. Flt4
(VEGFR3) is a related receptor for VEGFs C and D. NP-1 is a non-RTK receptor for VEGF165, the PlGF-2 isoform,
VEGF-B and VEGF-E. NP-1 (neuropilin-1) comprises an extracellular region with MAM (meprin, AS, m tyrosine
phosphatase), a and b domains, a transmembrane region, and a short cytoplasmic domain. Adapted from 181.
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VEGF stimulates angiogenesis by binding to its specific receptors on nearby blood
vessels. This is in concert with actions of other vascular-specific growth factors
(Figure 2). Thus, VEGF and the corresponding receptors are targeted therapeutically.
Dominant-negative expression of Flk-1 inhibits the growth of a range of solid tumors
in rodents 182. Clinical intra-arterial gene transfer of human plasmid phVEGF165 can
improve blood supply to the ischemic limb 183. A designed single-chain antibody was
shown to inhibit VEGF-induced KDR phosphorylation and VEGF-stimulated DNA
synthesis in human umbilical vein endothelial cells 184. Bevacizumab (Avastin), a
monoclonal antibody against VEGF has been proven clinically effective to metastatic
colorectal cancer 62. The importance of VEGF receptors and other endothelial-
specific receptors is also exemplified in receptor knock out studies as shown in
Figure 8.
Figure 8. Lessons from gene-knockout mice. The endothelial cell-selective RTKs VEGF-R1, VEGF-R2, Tie1, and
Tie2 have all been ablated in gene-knockout mice. Each RTK knockout produced embryonic lethality with vascular
defects. However, their distinctive phenotypes indicate that each of these tyrosine kinases controls a specific,
complementary function in endothelial cells that collectively can account for a significant part of endothelial cell
morphogenesis into functional vessels. Adapted from 6.
VEGF is a classical hypoxia-inducible gene. Transactivation of VEGF by HIF and its
stabilization mechanisms in hypoxia as well as the normoxic activation via many
oncogenes, epidermal growth factor receptor and erbB2 account for marked
upregulation of VEGF in tumor tissues and are of prognostic importance 185-189.
Several studies have shown the close relationship of high serum levels of VEGF with
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poor prognosis in cancer patients 190-192. Therapeutic methods directly targeting
VEGF cause vascular hyperpermeability and inflammation. In contrast, regulating
VEGF upstream target HIF-1α can improve tissue ischemia with less side effects
153,193,194. This has been exemplified in other studies, for example the HIF-1α/VP16
hybrid gene transfer in vivo significantly improved functional angiogenesis and
perfusion of the hindlimb ischemia in a rabbit model 154.
1.3.2. Platelet-derived growth factor (PDGF)
PDGF was initially purified as a factor from platelets that promotes the proliferation of
mesenchymal cells 195,196. Five biological isoforms of PDGF, PDGF-AA, -BB, -AB, -
CC, and -DD, have been found so far 196-203. Two types of receptors, type A and type
B PDGF receptor for one or more of the known PDGF isoforms, were also
discovered 2,204-206 (Figure 9). As familial members of the tyrosine kinase receptors,
PDGF receptors undergo homo- or/and heterodimerization and autophosphorylation
for activation upon binding of the dimeric ligands to the two subunits (α and β) of the
receptors. The activation of the receptors further allows binding, phosphorylation and
activation of downstream signaling transduction molecules that are associated with
the receptors 207.
PDGF
Figure 9. Mammalian
PDGF/PDGFR binding
interactions. Homo-
and heterodimeric
PDGF ligands differ in
their ability to bind and
activate the different
receptor dimers in vitro.
Adapted from 2.
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PDGFA and PDGFRα are broadly required during embryogenesis, whereas PDGFB
and PDGFRß are essential for the development of support cells in the vasculature
(Figure 2). PDGF-CC and PDGF-DD are secreted in inactive forms, and are
activated upon cleavage of the N-terminal CUB domains 2. They are implicated in
vascular smooth muscle cell proliferation, vascularization, wound healing, and
tumorigenesis 208. Besides the function of inducing proliferation of fibroblasts,
microglia, and smooth muscle cells, PDGF drives cell survival, migration, and the
deposition of extracellular matrix (ECM) and tissue remodeling factors 2 (Table 4).
PDGF is synthesized in different cell types with the principle sources from platelets,
endothelial cells and placenta 209. Its synthesis is often increased in response to
external stimuli, e.g. growth factors and cytokines 210, thrombin 211,212, low oxygen
tension 213.
PDGFR-β                                                               PDGFR-α
turnover of PI and IP*                                                                      turnover of PI and IP*
Ca2+ fluxes                                                              Ca2+ fluxes
membrane ruffles                                                     membrane ruffles
cytoskeletal rearrangements                                    cytoskeletal rearrangements
migration                                                                  migration
proliferation                                                              proliferation
angiogenesis                                                           Timing of differentiation
*IP, inositol phosphatases
Table 4. Biological responses transduced by PDGF receptors. Adapted from 214
A growing body of data supports the role of PDGF and its receptors angiogenesis
and as targets for pro- or anti-angiogenic therapies 160,215-220. In a murine limb
ischemia model, PDGFRalpha-p70S6K pathway was shown to be essential for FGF-
2-mediated therapeutic neovascularization 221. PDGF B-chain deficient mouse
embryos developed numerous capillary microaneurysms that ruptured at late
gestation because the endothelial cells of the sprouting capillaries in the mutant mice
were unable to attract PDGFRβ-positive pericyte progenitor cells to form part of the
capillary wall 222. A polyclonal antibody against PDGF is capable of blocking the
induced development of an intimal lesion in the carotid artery of athymic nude rats by
inhibiting neointimal smooth muscle accumulation 218. Inhibitors of PDGFRβ
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enhanced the antitumor effect of Taxol on s.c. KAT-4 tumors in SCID mice 220.
However, less is known about PDGF induced hypoxic signaling with regards to
endothelial cell proliferation and angiogenesis.
1.4. Rapamycin and Target of rapamycin (TOR)
Rapamycin (RPM) is a lipophilic macrolide originally produced by a strain of
Streptomyces hygroscopicus isolated from a soil sample obtained from the Vai Atore
region of Easter Island (Rapa Nui). Firstly identified during antibiotic screening at
Ayerst Research Laboratories, RAP (C51H79NO13) was subsequently found bearing
immunosuppressive and tumoricidal activities besides the growth-inhibitory effect on
yeast and filamentous fungi 223. Rapamycin and analogs such as CCI-779 (Wyeth
Ayerst), RAD001 (Novartis Pharmaceutical Inc; Basel, Switzerland), and AP25373
(Ariad Pharmaceuticals Inc; Cambridge, MA) have shown remarkable efficacies in
preclinical and clinical trials treating organ transplant rejection, autoimmune diseases
as well as tumors 224,225.
To be effective, RPM needs to bind to its intracellular receptors, the FK506 binding
proteins (FKBPs). RPM binds to FKBP12 two-fold more tightly than FK506. The
coupled RPM-FKBP12 complex then targets the FKBP12-rapamycin binding region
(FRB) in the C-terminus of target of rapamycin (TOR) protein and thereby decreases
their activities and inhibits the downstream signaling events 223,224,226.
Genetic, structural and functional understanding of TOR has increased after the
discovery of the TOR1 and TOR2 genes in yeast during a screen for mutants
resistant to rapamycin 226. Genetically, TOR is conserved among species ranging
from yeast (TOR1 and TOR2), through fungi (TOR1), plants (AtTOR), worms
(CeTOR), flies (dTOR), to mammals (mTOR) 227. In general, the TORs (from the N-
terminal to the C-terminal) contain 20 tandem HEAT (for amino-acid sequence motif
identified in Huntingtin, Elongation factor 3, A subunit of PP2A and TOR1) repeats, a
FAT (for FRAP, ATM, TRRAP) domain, a FRB (for FKBP12-RPM binding) site, a
kinase domain, and a FATC (for FAT carboxy-terminal domain) 227,228 (Figure 10).
The HEAT domain (1200 amino acids) provides a large hydrophobic surface for
protein-protein interactions. Moreover, it is responsible for localization of yeast TOR2
to the plasma membrane by interacting with membrane-associated proteins 229. The
FAT domain may act as a structural scaffold or a protein binding site whereas the
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FATC domain is key to TOR activity, and the two domains may interact to modulate
the kinase function of TOR 230. The FRB domain provides a docking site for the
FKBP12-rapamycin complex 231. The kinase domain of TOR shares significant
homology with lipid kinases, and belongs to the phosphoinositol kinase-related
protein kinase (PIKK) family 228. Structural analysis of TOR1 and TOR2 in yeast
indicates that their carboxy-terminal kinase motifs are functionally interchangeable
while the other parts within the respective protein are not 232. To be fully functional in
vivo, the TORs form complexes with other partner-proteins. So far, two TOR
complexes, TORC1 and TORC2, have been identified in yeast and mammals,
respectively. The yeast TORC1 is composed of TOR1 or TOR2, kontroller of growth
1 (KOG1), and lethal with sec thirteen (LST8); TORC2 contains TOR2, Adheres
Voraciously to TOR2-1 (AVO1), AVO2, AVO3, and LST8 (Figure 10) 227,233. The
mammalian counterpart of TORC1 (mTORC1) consists of mTOR, mKOG1 (raptor,
regulatory associated protein of TOR), and mLST8 (GβL, G protein β–subunit-like
protein) whereas mTOR, mAVO3 (rictor, rapamycin-insensitive companion of mTOR)
and mLST8 form the mTORC2 234-238. Deletion studies of the TOR partners, KOG1,
AVO1, AVO3, LST8 within the TOR complexes in yeast showed phenotypes
mimicking TOR deficiency indicating the indispensable roles the TOR partners play.
AVO2, however, seems to act as a chaperone for supporting roles in the TORC2 233.
The existence of the two distinct yet compatible TOR complexes reflects the diversity
of TOR signaling. The fact that TOR2 appears in both TORC1 and TOR2 while TOR1
is only in TORC1 may imply a notion that TOR2 plays a more broader role in TOR
signaling than TOR1 does 233. A description of kinase signaling cascades centered
on TOR and the related biological significance are described in the next chapter.
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Figure 10. a) Structural domains of TOR and its binding partners. HEAT, an amino-acid sequence motif that was
first identified in huntingtin, elongation factor 3, regulatory A subunit of PP2A and TOR1; FAT, a domain that was
found in the FRAP (mTOR), ATM and TRRAP proteins; FRB, the binding site for FKBP12–rapamycin; FATC, FAT
carboxy-terminal domain; Raptor is the mammalian ortholog of KOG1. The RNC (raptor N-terminal conserved)
domain consists of highly conserved residues that are found in all KOG1/raptor orthologues. The structural domain of
LST8 consists of seven WD40 repeats (a sequence of about 40 amino acids with a central Trp-Asp motif). AVO,
adheres voraciously to TOR2; Regions in AVO1 and AVO3 have homology to the Ras-binding domain (RBD) and
RasGEFN domain, respectively. AVO2 contains five ankyrin repeats. b) Composition of two distinct TOR
complexes: TORC1 and TORC2 models do not reflect the stoichiometries and interactions of subunits within each
complex. Adapted from 227,233.
1.4.1. Mammalian target of rapamycin (mTOR)
mTOR is the mammalian intracellular target of the FKBP12 and rapamycin complex,
and was identified independently with initially different names besides mTOR 239,
FKBP12-rapamycin associated protein (FRAP), rapamycin and FKBP12 target
(RAFT), rapamycin target (RAPT), Sirolimus effector protein (SEP), respectively 240-
243. mTOR is a 289 kDa (2549 amino acids) serine/threonine protein kinase belonging
to the PIKK family with the gene mapping to chromosome 1p36.2 in human, 5q36 in
rat, and 4E1 in mouse 225,244. Human, rat, and mouse mTOR proteins share 95%
identity at the amino acid level, but only 45% identical to yeast TOR2, and 42%
identical to yeast TOR1 239.
The FKBP12-rapamycin complex binding site spanning the residues 2025-2114 in
mTOR has been identified, and a point Ser2035 within the range (homologous to the
Ser1972 and Ser1975 in yeast TOR1 and TOR2, respectively) is critical for the binding
245. The targeting of the drug-receptor complex to mTOR accounts for the inhibition of
a
b
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mTOR mediated cell cycle transition from G1 to S phase 240. Moreover, mTOR
modulates the signaling from nutrients and growth factors in mammalian cell growth.
Recent data suggest that rapamycin inhibits mTOR signaling by competing with the
mTORC1 partner raptor (mKOG1), which is either in ‘constitutive’ or in ‘nutrient-
sensitive’ interaction with mTOR. The constitutive interaction is required for mTOR to
function. The nutrient-sensitive interaction results in inhibition of mTOR kinase
activity upon nutrient-depletion 235. To some extent in consistence with this mTOR-
raptor interaction model, raptor has been shown to bind to the TOR signaling motifs
(TOS) within 4E-BP1 and p70 S6K, and the bindings present the two targets in a
more effective way for mTOR to phosphorylate.
1.4.2. mTOR and cellular sensing for survival
To survive and develop, mammalian cells need both nutrients and growth factors.
mTOR has a pivotal role in sensing these stimuli. Correspondingly, mTOR signaling
is mediated through a big variety of upstream inputs and downstream outputs.
1.4.2.1. Common triggers for mTOR signaling
The stimulatory inputs include nutrients such as amino acids, glucose and fatty acids,
energy such as ATP, growth factors such as insulin, IGF and PDGF, oxidative stress,
hypoxia, and DNA damage caused by chemical compounds or radiation.
As will be discussed later, mTOR positively regulate ribosome biogenesis and mRNA
translation, the processes that require a large amount of amino acids. The
observations that some neutral amino acids contribute to the phosphorylation state of
S6K1 and elF-4E binding protein 1 (4E-BP1), two downstream targets of mTOR,
provide a link between cellular demand of amino acids and mTOR signaling 246-248.
Moreover, experiments suggest a basal requirement of essential amino acids for
mTOR to respond to growth factors. Thus, different amino acids in culture medium
may influence mTOR signaling. Among the essential branched-chain amino acids,
leucine appears to be most effective to induce mTOR signaling, and may function
independent of insulin or growth factors 247,249. Interestingly, leucine-induced
phosphorylation of S6K1 could be attenuated by interfering an mTOR partner raptor
235. Thus, the interaction between mTOR and raptor is of great importance for the
regulation of the downstream targets in response to amino acids.
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Insulin triggers the phosphorylation of 4E-BP1 and S6K1 in a rapamycin sensitive
way. This provides evidence for a link between mTOR and glucose modulation 250.
Moreover, activation of mTOR by glucose needs support from amino acids, and
glucose increases DNA synthesis, a process that can be blocked by rapamycin 251.
Phosphorylation of mTOR downstream targets triggered by insulin may be mediated
by metabolites or energy generated from glucose and not glucose per se 250.
Interestingly, mice genetically deficient in S6K1 are mildly intolerant to glucose on
normal (low fat) rodent diet mainly due to insufficient production of insulin resulting
from decreased pancreatic beta-cell mass 252. On the other hand, glucagon, an
opposite regulator to insulin on glucose metabolism, repressed both basal and amino
acid-induced signaling through mTOR. However, the process may involve activation
of other kinases such as AMPK 253. More recently, it has been shown that mTOR
inhibits the transcription of insulin receptor substrates (IRS), a family of adaptor
proteins that are essential both for PI3K activation and for mediating the pleiotropic
effects of insulin thereby imposing a negative feedback to insulin stimulated signaling
254.
The impact of fatty acids on mTOR signaling is proposed to be tissue-dependent.
Free fatty acid (FFA)-modulated phosphorylation of mTOR downstream targets S6K1
and 4E-BP1 appears in tissues that depend on oxidative metabolism, but not in the
ones that rely on glycolytic metabolism 255. Interestingly, phosphatidic acid (PA),
which harbors fatty acid chains, has been implicated in mitogenic activation of mTOR
by interacting with the FRB domain within mTOR 256.
Ribosome biogenesis and mRNA translation not only require amino acids as
addressed before, but also need large levels of energy. Cellular energy, in the form
of ATP, is a prerequisite for mTOR signaling 257. Though mTOR was proposed as an
energy (ATP) sensor, the link between ATP availability and mTOR activation is not
fully clear yet 257. Despite of this, 5’AMP-activated protein kinase (AMPK), which is
more sensitive to alterations of cellular ATP levels than mTOR, was found to be
upstream of mTOR, and the activity of AMPK is negatively related to mTOR
activation and S6K1 phosphorylation 258. Therefore, it is plausible that a decrease of
intrinsic ATP levels in cells is sensed by AMPK, which in turn activates other protein
kinases that de-active mTOR. The recent finding that tuberous sclerosis complex 2
gene product TSC2 can be phosphorylated by AMPK and has inhibitory effect on
mTOR activity, fills the gap between AMPK and mTOR 259,260. Though mTOR itself
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contains phosphorylation sites for AMPK as well, and phosphorylation of Thr2446 may
cause the inability of Akt phosphorylation of Ser2448 in mTOR, direct ties between
AMPK and mTOR are still vague 261,262.
Besides insulin, other growth factors may activate mTOR downstream targets.
However, though growth factors could mildly cause mTOR phosphorylation at Ser2448
263, mutation of this site does not affect mTOR signaling to S6K1 and 4E-BP1 264. It is
possible that the in vitro studies of mTOR activities may not correctly reflect the in
vivo situations 265. The mitogen-activated phospholipase D (PLD) is able to mediate
mTOR activity by enzymatic induction of PA, which competes with rapamycin for the
FRB site in mTOR. This provides a potential link between growth factor and mTOR
signaling 256. In addition, Cdc42, a small Rho family G-protein, is capable of activating
S6K1 and 4E-BP1 by upregulating PLD induced PA, a process involves mTOR
activation 266. Moreover, rapamycin resistance is observed in breast cancer cell lines
expressing higher levels of PLD and PA, and the sensitivity to rapamycin is restored
upon PLD inhibition 267. Furthermore, growth factors often affect mTOR via complex
signaling pathways. For example, mutations in PDGFR and IRS-1 abrogate S6K1
phosphorylation by inactivation of PI3K cascades to mTOR 268. Our data show that
PDGF-BB induces HIF-1α expression via mTOR, and will be discussed later.
Effects of hypoxia , to some extent, are analogous to those caused by ATP
deficiency since oxidative metabolic function is closely related to ATP levels in cells.
Hypoxia potentiates vascular wall cell proliferation and angiogenesis, which can be
attenuated by rapamycin implying a role of mTOR in hypoxic signaling 140. In line with
this, HIF-1α activation by hypoxia was blocked by rapamycin in prostate cancer cells
(PC-3) suggesting a positive role of mTOR on HIF-1α activation 141,143. It is worth to
note that the PC-3 cells are highly sensitive to rapamycin possibly due to the
enhanced proliferative potency 269. However, it remains unclear how hypoxia triggers
mTOR, and how mTOR regulates HIF-1α.
Links between DNA damage and mTOR activity have been shown by several
studies. DNA-damaging agents like etoposide, cisplatin and mitomycin-C may impair
mTOR signaling as dephosphorylation of p70 S6K and 4E-BP1 was observed
preceding apoptosis in certain cell lines 270. In murine erythroleukemic cells, a
constitutively active form of p53 selectively impedes the phosphorylation of 4E-BP1
and p70 S6K suggesting an inhibitory effect of p53 on mTOR signaling 271. Tyrosine
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kinase c-Abl, which can be activated by ionizing radiation, was shown to be able to
phosphorylate mTOR and inhibit its kinase activity 272. Radiation increased 4E-BP1
binding to eIF-4E in wild type MEF cells but not in c-Abl-lacking cells 272. UV radiation
on DNA damage is known. Though mTOR may play a role in UV induction of
collagenase and stromelysin-1 (a matrix-degrading enzyme) 273, UV could activate
p70 S6K1 via JNKs 274. Still, the function of mTOR in DNA damage caused cellular
changes remains an open question.
1.4.2.2. Upstream transduction regulators of mTOR
The potential roles of AMPK, PLD and p53 in upstream activation of mTOR have
been described above. Besides, there are other defined transduction mediators such
as PI3K/PTEN (phosphatidylinositol 3-kinase/phosphatase and tensin homolog
deleted from chromosome 10), Akt (also known as protein kinase B, PKB),
TSC1/TSC2 (tuberous sclerosis complex 1 and 2, also called hamartin and tuberin),
Rheb (Ras homolog enriched in brain), and REDD1 (for regulated in development
and DNA damage responses) involving in mTOR upstream transduction.
PI3K and PTEN: As mentioned before, growth factor-triggered mTOR signaling
involves PI3K activation. On one hand, this is substantiated by studies using PI3K
inhibitors such as LY294002 and wortmannin, which are able to attenuate
phosphorylation of S6K1 and 4E-BP1 268,275. Though the inhibitors could directly
inhibit mTOR in vitro, high concentrations of the drugs are needed for the effects, and
much lower concentrations are required for blocking the phosphorylation of S6K1 and
4E-BP in vivo 261. Overexpression of an activated catalytic subunit of PI3K, p110,
induces rapamycin-sensitive phosphorylation of 4E-BP1 in the absence of growth
factors 276, and overexpression of a dominant-negative form of the regulatory subunit
of PI3K, p85, inhibits the phosphorylation of S6K1 induced by insulin 277. On the other
hand, the PI3K activity counteractor, PTEN (also known as mutated in multiple
advanced cancers, MMAC1 or TGFβ-regulated and epithelial cell-enriched
phosphatase, TEP1) negatively regulates PI3K pathways by dephosphorylating PI3K
lipid products phosphatidylinositol 3,4,5-trisphosphate (PIP3) 278. PTEN-deficient cells
exhibit enhanced phosphorylation of S6K1 and 4E-BP1 implying an active mTOR
signaling in these cells 269.
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Akt (PKB): Recruitment of Akt to the plasma membrane by the PI3K product PIP3 is
required for full activation of Akt. Thus, Akt is a downstream effector of PI3K 261.
Several experimental data place Akt upstream of mTOR. Activated Akt augments
phosphorylation of 4E-BP1 in a wortmannin-resistant and rapamycin-sensitive
manner 276. Overexpression of a dominant-negative form of Akt abrogates growth
factor-induced 4E-BP1 phosphorylation 276. In contrast, conditional activation of
recombinant Akt fusion protein results in mTOR phosphorylation and activation 279.
Besides, Akt has been shown to directly phosphorylate mTOR at its Thr2446 and
Ser2448 sites 263,264. However, the two phosphorylation points for Akt reside in the
‘negative regulatory domain (NRD)‘ of mTOR 264. Moreover, transfection of HEK 293
cells with mutated mTOR at Thr2446 or/and Ser2448 does not affect insulin- or active
Akt-stimulated S6K1 activation and 4E-BP1 phosphorylation 264. Furthermore, these
Akt phosphorylation sites are not conserved in dTOR 261. These data challenge the
concept of an upstream positive role of Akt upon mTOR activation.
TSC1/TSC2: A link between Akt and mTOR is the TSC1/TSC2 complex. Tuberous
sclerosis (TSC), an autosomal dominant disorder characterized by hamartomas with
very large cells in many organs, is caused by mutations of the putative tumor
suppressor genes, TSC1 and TSC2 280. Coexpression of TSC1 and TSC2 represses
4E-BP1 phosphorylation and S6K1 activity. 280. Both mammalian and Drosophila
TSC2 are directly phosphorylated and inactivated by Akt 259,281,282. TSC2 regulates
S6K1 and 4E-BP1 activities by negatively mediating mTOR activation 259. These
results render TSC2 as one of the upstream regulators of mTOR. Interestingly, in
Akt1/Akt2-deficient cells, mTOR activity towards 4E-BP1 is dramatically decreased
although TSC2 phosphorylation is not impaired, suggesting a TSC2-independent Akt
regulation of mTOR activity 283.
Rheb: The search for TSC2 downstream targets for mTOR regulation revealed
selective GAP activity of TSC2 on Rheb. RNA interference (RNAi) of Rheb inhibits
(but not 17 other GTPases) S6K1 phosphorylation 261. Drosophila cells losing Tsc2
resulted in persistent phosphorylation of S6K whereas loss of Rheb abolished S6K
phosphorylation regardless of the presence of amino acids. Besides, S6K remained
dephosphorylated in the absence of both Tsc2 and Rheb indicating that Rheb is
epistatic to Tsc2 for S6K phosphorylation 284. Moreover, Over-expression of Rheb
promotes the activation of S6 kinase in a rapamycin-dependent manner suggesting
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that mTOR is downstream of Rheb 285. Furthermore, based on knock-out studies, the
TSC1/2 complex blocks mTOR by inhibiting Rheb activity 286.
1.4.2.3. Downstream signaling effectors of mTOR
mTOR executes several functions through its downstream target proteins. eIF4E-
binding proteins (4E-BPs), Ribosomal protein S6 kinase 1/2 (S6K1 and S6K2), type
2A phosphatase (PP2A), Kip1 (cyclin-dependent kinase inhibitor 1, also called p27 or
p27Kip1), and RNA polymerases are common downstream effectors for mTOR
signaling.
4E-BP: 4E-BP (also known as phosphorylated heat and acid-stable protein regulated
by insulin, PHAS-I) is a family of repressor proteins for translation initiation. It targets
and impedes eIF4G from binding to eIF4E and hence the dissociation of the eIF4F
complex 223,225,261. Among the mammalian 4E-BPs, 4E-BP1 appears to be the most
active and best studied in signaling cascades 261. Thr37 and Thr46 in 4E-BP1 are
directly phosphorylated by mTOR followed by sequential phosphorylation of the Thr70
and Ser65 sites both in vitro and in vivo 287. These consecutive phosphorylation
events are considered to work in concert to dislodge 4E-BP1 from eIF4E 261.
Moreover, phosphorylation of the Ser/Thr sites in 4E-BP1 is sensitive to rapamycin
288, and PI3K, Akt, mTOR may interact upstream to induce 4E-BP1 phosphorylation
in the presence of serum or growth factors 276.
S6K: The ribosomal protein S6 kinases (S6Ks) are pivotal for ribosomal S6 protein
phosphorylation, which is required for ribosome assembly and for recruiting 5’TOP
mRNAs to ribosomes 289. However, amino acids and growth factors may activate the
5’TOP mRNA translation in the absence of S6K 290. So far, two S6Ks termed S6K1
(p70 S6K) and S6K2 have been identified 291,292. S6K1 activity is inhibited by
wortmannin, LY294002, and rapamycin indicating that PI3K and mTOR are involved
in its activation 293. Interestingly, a truncated mutant S6K1 is rapamycin resistant
while it remains sensitive to wortmannin displaying the bifurcate signaling cascades
from mTOR and PI3K to S6K1 294. Multiple phosphorylation sites in S6K1 have been
found with Ser371 and Thr389 in the linker region essential for S6K1 activation 295.
The Thr389 site can be directly phosphorylated by mTOR in vitro 295. Moreover, this
site is potentially regulated by Tsc1/Tsc2, which links S6K1 and mTOR to the far
upstream mediators 259.
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Phosphatase: The observation that rapamycin causes dramatic dephosphorylation
of all sites in S6K1 including those not being phosphorylated by mTOR implicates
that rapamycin may activate phosphatases 296. Rapamycin treated cells increase the
calyculin A-sensitive PP2A activity towards 4E-BP1, and PP2A can bind to and
inactivate S6K1 296. Moreover, mTOR phosphorylates PP2A in vitro and thereby
prevents downstream dephosphorylation of 4E-BP1 and S6K1 296.
Cyclin/cdk: Rapamycin strongly interferes with the cyclin D2- or cyclin D1-cdk
complexes in lymphoma cells or osteosarcoma cells. Although cyclin E-cdk2
complexes assembles in the rapamycin treated cells, the complexes bear no protein
kinase activity 223. Also, IL-2-induced cdk activation can be abolished by rapamycin
297. This suggests that rapamycin induces Kip1, a G1 cyclin cdk inhibitor, activation or
alternatively, prevents it from being targeted for destruction. The persistent
expression of Kip1 in rapamycin-treated T cells suggests that mTOR serves to mark
Kip1 for ubiquitin-dependent proteasomal degradation. mTOR might not execute the
function by itself, instead, it may control the translation of certain proteins that allow
the ubiquitin-proteasome system to recognize and degrade Kip1 223.
RNA polymerase: In accordance with the critical role of mTOR in translational and
cell cycle control, cellular transcriptional activities have been proved to be regulated
indirectly by mTOR 261. These activities include transcription of rRNA genes by RNA
polymerase I (Pol I), ribosomal protein genes by Pol II, and tRNA and 5S genes by
Pol III 261. For example, inhibition of rDNA transcription by rapamycin can be rescued
by TIF1A (a Pol I-specific transcription factor), and rapamycin can inhibit UBF (an
rDNA transcription factor) phosphorylation, which is required for its activity 261.
1.4.3. mTOR, cell growth and proliferation
Cell growth (an increase in cell mass and size through macromolecular biosynthesis)
and cell proliferation (an increase in cell number) are biologically coupled processes
critical for embryonal development, maintenance and remodeling of tissues, organs,
and neoplastic as well as tumor development. mTOR exhibits a broad range of
biological functions that can regulate both cell growth and cell proliferation. However,
the two functional readouts of mTOR are not in the same line of signaling control.
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They may either bifurcate from an upstream transduction point of mTOR or separate
upon mTOR activation by different signaling inputs.
A number of experiments support the role of mTOR in the control of cell size and
growth. Phosphorylation of mTOR at Ser2448 (possibly by Akt) is associated with
nonproliferative skeletal muscle hypertrophy 298. Overexpression of genetically
activated Akt in mice hearts results in enlarged cardiomyocytes and larger hearts,
which can be attenuated by rapamycin 299. In proliferating mammalian cells,
rapamycin is able to reduce both proliferation rate and cell size 140,300. mTOR
downstream target S6K-deficient mice are smaller in size when compared to the wild
type littermates 301. Since 4E-BP1, eIF4G, and eIF4B are involved in the regulation of
the rate-limiting translation process, mTOR may participate in cell growth and
proliferation by signaling to these molecules for translation initiation. eIF4E
overexpression increases cell size in human osteosarcoma cells. In addition,
coexpression of eIF4E and S6K1 synergistically increases cell size 300. eIF4E and
S6K have been implicated in cell cycle control as well 261. Activated 4E-BP1
abrogates the cells progressing through the G1 phase 302. The involvement of
TSC1/2 and Rheb in tumor development provides further evidence for mTOR
regulation of cell growth and proliferation 261. The diverse growth-associated readouts
regulated by mTOR are shown in Figure 11.
Figure 11. Growth-related
readouts controlled by yeast
and mammalian TOR. Green
arrows indicate activation, and
red bars indicate repression.
Adapted from 1
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1.4.4. mTOR and angiogenesis
Data from our group have shown that both growth factor and hypoxia could increase
vascular wall cell proliferation and ex-vivo angiogenesis in a rapamycin sensitive way
implying a role of mTOR in the biological processes 140. Consistent with these
observations, rapamycin has been shown to inhibit primary and metastatic tumor
growth by suppressing angiogenesis in mouse models, and the antiangiogenic effect
was suggested to be due to a blockage of VEGF production 303. VEGF is a principle
angiogenic factor in response to many pathophysiological stimuli including growth
factors and hypoxia. Therefore, it is plausible that mTOR is involved in angiogenesis
by regulating the angiogenic molecules.
As described before, HIF-1α levels have been considered as a pathological marker
for ischemic cardiovascular disease and tumor 42,73. mTOR has been linked to
regulation of HIF-1α  and the corresponding transcriptional targets. In human
transformed cells, inhibition of mTOR or the upstream mediator PI3K decreases both
HIF-1α and VEGF expression induced by growth factors. VEGF gene transcription is
abrogated by expression of dominant-negative Akt, PI3K, and wild-type PTEN
whereas expression of a constitutively active Akt or dominant-negative PTEN
upregulates the transcription 141. Wild type mTOR transfection of prostate cancer cell
lines enhances HIF-1α induction by hypoxia in a rapamycin-sensitive manner 143.
Despite of these interesting findings, it remains unclear at which level(s) mTOR
regulates HIF-1α and/or its target genes, how this is modulated, and how hypoxia
triggers and mediates mTOR signaling. A recent study in human embryonic kidney
cell lines showed that mTOR and its downstream targets S6K1, 4E-BP1, eIF4G as
well as ribosomal protein S6 are hypophosphorylated when exposed to hypoxia 304.
This suggests a HIF-independent cellular response to hypoxic stress, which is
mediated by mTOR.
1.5. Mitogen-activated protein kinase (MAPK) pathways
Regulation of cellular responses to growth factors, inflammatory cytokines, and other
mitogens often occurs via the major mitogen-activated protein kinase (MAPK)
pathways. Upon ligand binding to the G-protein-linked or intrinsic protein tyrosine
kinase receptors, downstream proteins such as Grb2, SOS, and Ras or Rac are
phosphorylated and activated 305. The active kinases consecutively phosphorylate
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other proteins, transmit and amplify signals to modulate a big variety of cellular
events including cell cycle progression, regulation of embryonic development, cell
movement, apoptosis, cell and neuronal differentiation 3,306.
The evolutionarily conserved MAPK pathways are organized in three levels of
regulation, a far upstream activator MAPK kinase kinase (MAP3K, MEKK), a step
down effector MAPK kinase (MAP2K, MEK), and a MAPK 3. This stepwise
transduction model contains at least three distinct MAPK signaling cascades
including the extracellular signal-regulated kinase 1 and 2 (ERK1/2, also known as
p44/p42 MAPK), the c-Jun N-terminal kinases/stress-activated protein kinases
(JNK/SAPK), and the p38 kinases (called HOG in yeast) 3. Each of these typical
signaling transmitters has several genetic splicing isoforms in mammals 307. A critical
and common feature of the MAPKs is that they are activated upon dual
phosphorylation within the threonine-X-tyrosine (TXY) consensus sequence present
in the catalytic domain 308-310. Interestingly, phosphorylation of only one of the two
sites does not activate the kinase 311. The hierarchical activation of the MAPKs leads
to a set of cellular events (Figure 12).
Figure 12. Schematic
overview of MAPK modules.
(A) In S. cerevisiae, five MAPK
modules regulate mating,
filamentation, high-osmolarity
responses, cell wall
remodeling, and sporulation.
(B) Mammalian MAPK
modules regulate cell growth,
differentiation, stress
responses, and development.
Abbreviations: MAPKK, MAPK
kinase; MAPKKK, MAPK
kinase kinase. Adapted from 3
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The ERK1/2 pathway is activated by growth and mitogenic factors. Downstream
targets of ERKs include p90 ribosomal S6 protein kinase (p90rsk), ELK1 (member of
the ETS oncogene family, a transcription factor), and signal transducer and activator
of transcription 3 (STAT3) 307,312. The JNK/SAPK and p38/HOG cascades can be
triggered by lipopolysaccharides, cytokines, UV or ionizing radiation, heat shock,
osmotic stress, and tumor promoters. Therefore, the two signaling pathways are
often involved in response to inflammation, cellular stress and apoptosis 3,305.
JNK/SAPK downstream targets include the transcription factors c-Jun and ATF-2.
p38 targeting proteins include ATF-2, Max, and CREB 313,314.
Opposite to activation of the MAPK pathways, negative regulation of the MAPK
superfamily members is mediated by protein phosphatases. The MAPK
phosphatases (MKPs) are divided into three major categories depending on their
preference for dephosphorylating tyrosine, serine/threonine (mono specificity) or both
the tyrosine and threonine (dual specificity). The proactive MAPKs and the mono-and
dual-specificity MKPs work in concert to modulate cellular responses to different
physiobiological stimuli.
1.5.1. MAPKs and hypoxia
MAPKs can be activated by hypoxia, and trigger activation of certain transcription
factors such as c-Jun, c-Fos, ATF-2, elk-1, and nuclear factor-kapaB (NF-κB), and
HIF-1α. However, results from different cell types and experimental conditions
provide controversial evidence regarding the role of MAPKs in hypoxia.
Hypoxic phosphorylation and activation of ERK1/2, JNK, and p38 was observed in
rats exposed to normobaric hypoxia (10% O2) where JNK showed an early activation
pattern, and ERK1/2 as well as p38 were activated in a far later stage. The laggard
activation of ERKs and p38 implicates the possible existence of secondary
responses of the two kinases, such as reaction to hypoxia-induced growth factors or
other mediators, to hypoxia 315. Increased phospho-MAPK proteins in large and small
intrapulmonary arteries during chronic hypoxia may account for hypoxia-induced
pulmonary arterial remodeling 315. However, a bit different from the above findings,
moderate hypoxia (5% O2) has no impact on JNK, p38 β, p38 β2 and p38 δ activities
while it activates p38 α , p38 γ , and ERK1/2 in rat pheocytochroma cells 316.
Interestingly, when the same strain of cells are incubated under severe hypoxic
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conditions (1% O2) for 6 hours, ERK1 activity is strongly increased and induces HIF-
2α activation 317. In addition, inhibition of ERK1/2 signaling by PD98059 impairs HIF-
1α transactivation activity whereas its stability and DNA binding activity remains
unaffected 318,319. In contrast, hypoxic activation of JNK and p38 and subsequent HIF-
1α expression as well as its DNA binding activity are sensitive to the blockage of the
kinases in squamous carcinoma cell lines 320. ERK1/2 may phosphorylate HIF-1α
both in vitro and in vivo 106. Still, other independent studies could not confirm this
effect 321. MAPKs could also activate other co-activators of HIF-1α, and other
signaling cascades may activate HIF-1α.
1.5.2. MAPKs and angiogenesis
As described above, MAPKs pathways are closely related to stress-induced cellular
responses including hypoxic induction of HIF-1α. Because of this, not only HIF-1α
but also its transcriptional target VEGF, which is involved in angiogenesis, has been
studied in relation to MAPK signaling.
Firstly, activation of ERK1/2 pathway rescues fibroblasts and epithelial cells from
apoptosis and promotes entry of endothelial cells into cell cycle. In addition, ERK1/2
kinase activity is required for controlling endothelial cell proliferation and growth
arrest under confluent conditions. Moreover, ERKs can increase VEGF transcription
by recruiting AP-2/Sp1 (activator protein-2) complex to its promoter region and by
phosphorylation of HIF-1α 322. Secondly, JNK and p38 overexpression or activation
by hypoxia augments HIF-1α and VEGF induction 320. ERKs may be required for the
initial stages of angiogenesis in addition to other receptor tyrosine kinases whereas
p38 is critical for the recruitment of mural cells during later stages of angiogenesis 323.
Inhibition of p38 results in the formation of naked endothelial tubes without mural
cells, and the blockage attenuates angiopoietin-1-induced mural cell recruitment 323.
Thus, p38 appears to be important for completing the angiogenic process, and the
other MAPKs may function in concert during this event.
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1.6. Rationale and aims of the investigations
Ischemic cardiovascular disease and tumors are of intensive concern due to their
high incidences and high degree of mortality nowadays. The common existence of
tissue hypoxia during progression of the diseases makes angiogenesis a two-bladed
sword. On the one hand, hypoxia induces angiogenesis so as to rescue the ischemic
myocardium. This natural process needs to be therapeutically enhanced. On the
other hand, hypoxia-triggered angiogenesis in tumors contributes to their growth and
metastasis and needs to be inhibited.
Hypoxia triggers angiogenesis naturally via HIF-1α. Mechanistic understanding and
planned therapeutic intervention have therefore accumulated on HIF-1α. HIF-1α  is
an important transcription factor that induces a set of key genes driving angiogenesis
and that is directly regulated by oxygen saturation. Therapeutic delivery of HIF-1α
gene has shown its potency to improve structure and function of the vasculature,
especially in ischemic tissues 153,154. Moreover, interrupting HIF-1α transactivity by
different means can be used to retain tumor growth and the associated
vascularization 80,157.
Cells involved in angiogenesis respond to hypoxia with an intrinsic oxygen- and
energy-sensing system. As a nutrient- and energy-sensing molecule, mTOR may
also play an important role in sensing oxygen saturation. Moreover, inhibition of
mTOR by rapamycin or other analogs and targeting mTOR-related pathways have
been proven to be effective against cell growth, proliferation, and angiogenesis
140,141,225,303.
The major aims of this thesis are to elucidate (i) the influence of hypoxia on mTOR
activation, i.e. whether mTOR participates in oxygen-sensing; (ii) the regulatory
relationship between mTOR and HIF-1α and the mechanisms of this interplay, and
(iii) the contribution of the latter interplay to cell proliferation and angiogenesis in
vitro. Furthermore, additional goals of this study are to assess other signaling
pathways such as mitogen- and stress-induced signaling pathways in the regulation
of HIF-1α nuclear accumulation. Data from this study will possibly help to improve
our understanding of cellular mechanisms for hypoxia-sensing and –transduction,
and may better delineate molecular targeting in diseases associated with ischemia
and tumor.
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2. MATERIALS AND METHODS
2.1. In vitro angiogenesis assay
Fibrin gels were prepared by mixing 3 mg fibrinogen (Sigma-Aldrich, Buchs,
Switzerland) per milliliter of serum-free DMEM (Oxoid AG, Basel, Switzerland) with
300 µg/ml of thrombin on ice. 48-well plates were coated with the prepared fibrin gel
at a volume of 100 µl/well and allowed to polymerize for about half an hour at 37°C.
Aorta excised from adult male Sprague-Dawley rat (around 200 g; Charles River
Laboratories, France) was cut into 1 mm2 squares, and the pieces were placed with
endothelium side down onto the coated gel. Then, another portion of fibrin gel was
overlaid over the aortic pieces. After gel polymerization at 37°C, 500 µl/well of serum-
free DMEM medium was loaded to the wells. Subsequently, different agonists or
antagonists were added to the medium every 3 days. 300 µg/ml α–amino caproic
acid was used every third day to protect the fibrin gel from degradation. Samples
were incubated in normoxia (21% O2) and hypoxia (1% O2), respectively. After 10
days of culturing, angiogenesis-like sprouts were photographed digitally on a light
microscope (Zeiss, Feldbach, Switzerland) for standardized scoring or for endothelial
cell isolation.
2.2. Cells and culture conditions
Rat aortic endothelial cells (RAECs) were derived from in vitro angiogenesis assay
as described above and submitted to cell culture. They were used for experimental
purposes during passages 4 to 10 after characterization with endothelial cell specific
immunofluorescent marker PECAM-1 (CD31, LabForce AG, Nunningen, Switzerland)
or von Willebrand Factor (VWF, LabForce AG). RAECs were cultured in DMEM
complemented with 10% fetal calf serum (FCS, Oxoid AG), 1% sodium pyruvate
(Oxoid AG), 1% non-essential amino acids (Oxoid AG), and 1% penicillin-
streptomycin (GIBCOTM, Invitrogen AG, Basel, Switzerland). For hypoxia, cells were
cultured in hypoxia incubator (Ismatec, Basel, Switzerland) with a gas mixture
containing 1% O2 and 5% CO2, balanced with nitrogen. Normoxic condition was
defined as 21% O2 and 5% CO2 with nitrogen as complement. Mouse embryo
fibroblast with HIF-1α (HIF-1α+/+) wild-type cells and knockout HIF-1α (HIF-1α-/-) cells
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(gifts from Prof. Max Gassmann, Zürich, Switzerland) were cultured in the same
condition as described above.
Following inhibitors were used: 5 - 500 nM rapamycin for mTOR, 5 - 80 µM PD98059
for MEK1/2, 5 - 200 nM JNK-Inhibitor II for Jun kinase, 0.1 - 3 µM SB203580 for p38
kinase, 0.1 - 10 µM epoxomicin for proteasome activity (all from Calbiochem,
Läufelfingen, Switzerland).
2.3. Endothelial cell spheroid sprouting assay
RAECs were washed and trypsinized. Centrifugation-collected cells were
resuspended in 10% FCS- and 0.25% (w/v) carboxymethylcellulose-containing
DMEM. After cell counting, cells were seeded in non-treated round-bottom 96-well
plates (Fisher Scientific AG, Wohlen, Switzerland) at the density of 1500 cells/well
and were subjected to incubation at 37°C for about 24 hours. The cells in each well
of the plates were capable of forming a single spheroid 324. The spheroids were then
embedded into bilayers of a fibrin gel and treated with different reagents as described
formerly in the in vitro angiogenesis assay. Sprouts from the spheroids were
analyzed and quantified by using a computerized system affiliated to an invert light
microscope (Zeiss, Feldbach, Switzerland).
2.4. Cell proliferation assay
Subconfluent cells in normoxic culture were washed twice in 37°C 1X PBS and
trypsinized for cell counting. Cells were then seeded and cultured in duplicate 96-well
cell culture plates at an initial density of 4.0 x 103 cells/well for 24 h under normoxic
condition followed by an additional 30 h normoxic culturing in serum-free DMEM
(starvation; FCS was substituted with 0.1% BSA). Then antagonists at different
concentrations were added to the medium and duplicate cultures were incubated in
normoxia and hypoxia, respectively for 1 h. Then agonists e.g. human recombinant
PDGF-BB (10 ng/ml, Bühlmann Laboratories AG, Basel, Switzerland) were added.
Each condition under observation in a plate was performed in octuplicate. After
another 24 h incubation, Cell Proliferation Reagent WST-1 (Roche Molecular
Biochemicals, Rotkreuz, Switzerland) was added to the cell-containing wells
according to the manufacturer’s instructions. Cell numbers were assessed by
quantifying the formazan dye produced by metabolically active cells on a microplate
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spectrophotometer (SPECTRAmax®190, Molecular Device Corporation, Sunnyvale,
California).
2.5. Cytosolic and nuclear protein extraction
Cells were seeded in tissue culture dishes (Becton Dickinson Labware Europe, Le
Pont De Claix, France) at an initial density of 4.0 x 106 cells/150 mm x 25 mm-dish.
Upon 70% confluence, cells were washed, starved, separately incubated in normoxia
or hypoxia, and inhibited where required as described before. Ciclopirox Olamine
(CPX) was used to induce HIF-1α as a positive control. Subsequently, agonist was
added to the cell culture dishes according to the experimental design. Finally, the
cultures were put back to the nomoxic and hypoxic conditions, respectively. After
culturing for 4.5 hours, extraction of nuclear proteins from the cell was performed.
Cells were rinsed twice in ice-cold 1X PBS, scraped into 2ml sterilized
microcentrifuge tubes and subjected to centrifugation at 1500 rpm and 4°C for 3
minutes. Consecutively, supernatant was aspirated and the pellet was resuspended
in 3 times pellet volume of freshly prepared cell lysis buffer (20 mM Hepes PH7.9,
10mM KCl, 0.1 mM Na3VO4, 1 mM EDTA, 1 mM EGTA, 0.2% NP-40, 10% glycerol, 1
mM DTT, 1 mM PMSF, Protease inhibitor cocktail tablet - Complete Mini from Roche
Diagnostics GmbH, Mannheim, Germany), and incubated on ice for 10 minutes with
periodical vortexing. After incubation and centrifugation, the cytosolic supernatant
was transferred into a new sterilized eppendorf tube, and nuclear proteins were
extracted by incubating the nuclei containing pellet in 2 times pellet volume of nuclear
extraction buffer (420 mM NaCl, 20 mM Hepes PH7.9, 10 mM KCl, 0.1 mM Na3VO4,
1 mM EDTA, 1 mM EGTA, 20% glycerol, 1 mM DTT, 1 mM PMSF, Protease inhibitor
cocktail tablet) on ice for 15 minutes with interval vortexing. The supernatant
containing nuclear proteins was transferred to a new sterilized eppendorf tube.
Finally, protein concentration was determined by using BCA protein assay reagent
(Socochim, Lausanne, Switzerland).
2.6. Western blotting
Equal amount of protein extracts were subjected to SDS-polyacrylamide gel
electrophoresis. Subsequently, proteins were transferred onto Polyvinylidene fluoride
(PVDF) membrane (Millipore Corporation, Bedford, U.S.A). The membrane was
blocked with 4% skim milk powder in TBS-Tween solution and probed stepwise with
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antibodies, chicken polyclonal antibody against HIF-1α  (gift from Prof. Max
Gassmann, University of Zürich), secondary anti-chicken IgY (Catalys AG,
Wallisellen, Switzerland); mTOR, Phospho-mTOR (Ser2448), Phospho-p70 S6 Kinase
(Thr389), Phospho-4E-BP1 (Thr37/46) rabbit polyclonal antibodies (all from Cell
Signaling Technology, MA) against the corresponding proteins, and HRP-linked anti-
rabbit IgG (Transduction Laboratories, San Diego, CA). After incubation with
antibodies and washing in 1X TBS-T solution, the membrane was subjected to ECL
western blotting reagents (Amersham, Buckinghamshire, England) for imaging with
X-ray films (Kodak, Geroldswil, Switzerland). ImageJ software (Wayne Rasband,
NIH, USA) was used for densitometrical quantification and analysis of the protein
bands appearing on images.
2.7. Immunofluorescence microscopy
RAECs were seeded on cover-slips at the density of 4.0 x 104 /well in 24 well tissue
culture testplates and cultured in normoxia. At 70% confluency, cells were starved,
exposed to antagonists or/and agonists, and incubated in 21% O2 or 1% O2,
respectively. After 4.5 hours of incubation, cells were rinsed and fixed with 4%
paraformaldehyde for 15 min at room temperature. The samples were blocked with
goat serum (Fluka, Buchs, Switzerland) in PBS with 0.25% BSA. The fixed cells were
probed consecutively with primary goat polyclonal IgG against HIF-1α, secondary
anti-goat Cy2-conjugated IgG (Santa Cruz Biotechnology, CA). TOTO-3 (Molecular
Probes, Eugene, USA) or Hoechst dye (Polysciences Europe GmbH, Eppelheim,
Germany) was used for nuclear staining. Finally, the cover-slips with cells were fixed
on slides and observed as well as analyzed under confocal Laser Scanning
Microscope (LSM 510, Axiovert 100M, Plan-Neofluar objectives; Carl Zeiss AG,
Feldbach, Switzerland).
2.8. Cellular total RNA isolation and cDNA synthesis
After 4.5 h conditioned culturing, RAECs were scraped off from culture dishes and
were collected into 1.5 ml sterilized Eppendorf tubes. The cells were pelleted by
centrifugation and resuspended with 1 ml TRIzol Reagent (Invitrogen AG). After
repeatedly pipetting up and down, the samples were incubated for 5 minutes at room
temperature (15 – 30°C). 0.2 ml of chloroform and 0.5 ml Isopropyl alcohol were
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used in turn to phase-separate and precipitate cellular RNA. Proceeding
centrifugation, the gel-like RNA pellet was washed with 75% ethanol and re-dissolved
in 30 µl Rnase-free water followed by 10 minutes of incubation at 55 – 60°C. For first-
strand cDNA synthesis, the solution-mixture, 1 µg of newly synthesized RNA, 0.5 µg
random primers, 5 µl of M-MLV RT buffer, 1 µl of M-MLV reverse transcriptase, 5 µl
of dNTP mix, 0.625 µl of Rnasin (Catalys AG) complemented with DEPC-treated
water to 25 µl, was incubated at 37°C for 1 h. Reverse transcriptase was deactivated
at 95°C for 5 minutes.
2.9. RT-PCR
Primers for HIF-1α RT-PCR (hot-start) analysis were designed as follows: forward
primer, 5‘-CGTGTGAGGAAACTTCTAGGTG-3‘; and reverse primer, 5‘-
GGCTCATAACCCATCAACTCA-3‘ for HIF-1α  to amplify a sequence of 599-bp.
Forward primer, 5‘-ATGGTGGGTATGGGTCAGAA-3‘; reverse primer, 5‘-
ACCCTCATAGATGGGCACAG-3‘ for β-actin (as internal control) to amplify a
sequence of 375-bp. 2 µl of the synthesized cDNA samples were denatured at 94°C
for 5 minutes in PCR tubes, proceeded with adding reaction solution A (Mg-free 10X
buffer 4 µl, 25 mM MgCl2 2.4 µl, primers 0.5 µl, dNTPs 6.1 µl, made up to 40 µl by
ddH2O). After covering with mineral oil and equilibrating the samples at 75°C for 2
minutes, solution B (Mg-free 10X buffer 1 µl, 25 mM MgCl2 0.6 µl, Taq polymerase
0.2 µl, made up to 10 µl by ddH2O) was added to the reaction solution mixture. RT-
PCR for both reactions were run as follows: 30 amplification cycles with each
consisting of denaturing at 94°C for 1 minute 10 seconds, annealing at 54°C for 1
minute 10 seconds, elongating at 72°C for 2 minutes. PCR products were separated
by 1% agarose gel electrophoresis and visualized by ethidium bromide staining
under a ChemiImager (5500-Rev D, Alpha Innotech, CA, USA). Finally, images were
taken and analyzed.
2.10. Real-Time RT-PCR
HIF-1α primers were designed by using Primer Express® version 2.0 software
(Applied Biosystems). Sequences of primers used for HIF-1α  cDNA were 5’-
GGCGAAGCAAAGAGTCTGAAGT-3’  for  sense s t rand and 5 ’ -
AGCTTTATCAAGATGGGAGCTCA-3’ for antisense strand. The concentrations of
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the primers were optimized for the lowest threshold cycle (CT) and maximum ΔRn.
SYBR Green PCR Master Mix (Applied Biosystems, Warrington, UK) had been
used to complement reactions. β-actin was used as an endogenous control for the
relative quantitations. Sequences of primers used for β-actin cDNA were 5’-
TTCAACACCCCAGCCATGT-3’ (sense) and 5’-GGAGCGCGTAACCCTCATAG-3’
(antisense). With the cDNA samples ready, Real-time PCR was performed on
GeneAmp® 5700 (AME Bioscience) to check up the changes of HIF-1α mRNA level
upon different stimuli in the studied settings. Relative standard curve method was
used to analyze the data derived from the PCR reactions.
2.11. Statistical analysis
Data were analyzed for normal distribution (one-way ANOVA), followed by Bonferroni
t test and the Student-Newman-Keuls test using the program SPSS (SPSS Inc.
Chicago, USA), and given as mean ± SEM. The number of samples examined is
indicated by n. A value of p < 0.05 was considered as significant.
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3. RESULTS
3.1. Hypoxia-enhanced endothelial sprout-formation and cell
proliferation is rapamycin sensitive
To date, most studies concerning the influence of hypoxia or/and mTOR on
angiogenesis and cell proliferation are done in highly proliferative cells or
transformed cells. In order to characterize the impact of low oxygen tension as well
as mTOR on these two activities in non-cancerous and non-transformed vascular
cells, we performed endothelial spheroids angiogenesis assays and endothelial
proliferation assays using RAECs in normoxia (21% O2) or severe hypoxia (1% O2).
Angiogenic-like sprouts from the endothelial spheroids were observed in both
normoxia and hypoxia. Hypoxia strongly enhanced endothelial sprout formation
(Figure 13A, top panels). Interestingly, the spheroids cultured in the rapamycin
(RPM)-containing media showed a strong decrease in the degree of sprouting
regardless of the different O2 saturation during incubation. However, RPM reduced
the sprouting from endothelial spheroids more profoundly under hypoxia than under
normoxia (Figure 13A). To quantify the differences of the sprouting in these
conditions, we used a computerized morphometric system after collecting data from
three individual experiments (Figure 13B). Endothelial sprout-formation in hypoxia
was more than doubled when compared to the response in normoxia, and the
spheroids under both conditions are significantly sensitive to RPM (p < 0.05).
A similar response was observed in RAEC proliferation assay. Hypoxia alone
increased RAEC proliferation to about 1.5 fold when compared to diluent normoxic
control and PDGF-BB enhanced proliferation about 1.7 fold under normoxia (Figure
14). Hypoxia together with PDGF-BB increased RAEC proliferation 2.4 fold. These
augmented proliferation rates could be effectively reduced by mTOR inhibition with
RPM. Low concentrations of rapamycin (2 nM) effectively inhibited proliferation under
hypoxia (with or without growth factor), whereas a higher concentration (20 nM RPM)
was required to completely inhibit PDGF-BB-induced proliferation under normoxia
(Figure 14). These data suggest that mTOR-signaling plays an important role in
angiogenesis in vitro and endothelial cell proliferation in response to hypoxia.
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Figure 13. Rapamycin effectively inhibits RAEC spheroid sprout-formation especially under hypoxia. A)
Typical micrographs of rat aortic endothelial spheroids after a 24 h incubation under normoxia (21% O2) or hypoxia
(1% O2) without (control) or with RPM. B) Quantification of endothelial sprouts from three independent experiments
(each containing about 30 spheroids per condition). Data are given as mean ± SEM, n = 3.
B
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Figure 14. Hypoxia or/and PDGF-BB increases RAEC proliferation in a rapamycin-sensitive way. Cell numbers
of RAEC were determined after 24 h culturing under normoxic (21% O2) or hypoxia (1% O2) with or without PDGF-BB
(10 ng/ml), in the absence (open bars) or presence (filled bars) of the indicated concentrations of rapamycin (RPM).
Y-axis represents the mean of cell number, compiled from three individual experiments with octuplicate samples.
Data are given as mean ± SEM, n = 3.
3.2. Hypoxia induces mTOR phosphorylation, nuclear accumulation,
and S6K1, 4E-BP1 hypophosphorylation
Next, we determined whether decreasing oxygen saturation modulates the activity of
mTOR, i.e., affects mTOR phosphorylation (Ser2448) and phosphorylation of mTOR
downstream targets p70/p85 S6K (S6K1) and 4E-BP1. Quiescent RAEC were
incubated under decreasing oxygen saturations (21%, 11%, 6%, 3% and 1% O2) for
12 h. This time period was used because HIF-1α was maximally induced in the
studied cell type after 12 h of hypoxia exposure (see data below). Western blot
analysis showed that under normoxia (21% O2), weak phosphorylation of mTOR at
Ser2448 and distinct phosphorylation of S6K1 and 4E-BP1 were detected in
cytoplasmic compartment of RAEC. mTOR-Ser2448 phosphorylation increased under
11% O2 and augmented further with lowering O2 saturations with a maximum at 1%
O2. In contrast, mTOR downstream targets S6K1 and 4E-BP1 were almost totally
dephosphorylated under any O2 saturation from 11% down to 1% (Figure 15). mTOR
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protein as well as β-actin protein levels were not affected by oxygen saturation.
These results illustrate a different phosphorylation as well as activation pattern of
mTOR and its two target effectors S6K1 and 4E-BP1.
Figure 15. Distinct phosphorylation pattern of mTOR on Ser2448 and of S6K1 as well as 4E-BP1 in hypoxia.
Decreasing O2 tension increases phosphorylation of mTOR on Ser
2448, abrogates phosphorylation of mTOR
downstream targets S6K1 and 4E-BP1. β-actin was detected as a protein loading control. mTOR-P (mTOR-Ser2448
phosphorylation); p85S6K-P/p70S6K-P (S6K1-Thr389 phosphorylation); 4E-BP1-P (4E-BP1-Thr37/46 phosphorylation).
Hypoxia-induced cytoplasmic Ser2448 phosphorylation of mTOR peaked at 1% O2.
Similarly, HIF-1α expression peaked at 1% O2. We therefore examined whether
hypoxia influences mTOR nuclear distribution under 1% O2 over time (0 – 24 h).
Whereas mTOR and phospho-mTOR levels were almost undetectable at time point
0, the two proteins already appeared in the nuclear fraction after 2 h of incubation.
The levels of both mTOR and phospho-mTOR remained stable with further
incubation under hypoxia (Figure 16). Thus, mTOR protein accumulates in the
nuclear compartment of RAEC after exposure to hypoxia.
Figure 16. Nuclear mTOR and phospho-mTOR (Ser2448) levels in hypoxia over time. Quiescent RAEC were
cultured for increasing periods of time (2 - 24 h) under conditions of 1% O2, or left in normoxia (time point = 0).
Nuclear extracts were prepared, and proteins were resolved by SDS-PAGE followed by immunoblotting using anti-
HIF-1α, -mTOR and -phospho-mTOR-Ser2448 (mTOR-P) antibodies.
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3.3. HIF-1α nuclear accumulation is oxygen saturation- and time-
dependent
As known, HIF-1α is a key element for cells to adapt to hypoxic conditions, and plays
an important role in angiogenesis. To be functional, HIF-1α needs to be translocated
into the nucleus in order to transactivate hypoxia-adaptive genes 76. We therefore
characterized HIF-1α nuclear levels in severe hypoxia (1% O2) over time (0 – 24 h).
In normoxia (Time point = 0), basal levels of HIF-1α were detected in nuclear
extracts. After 2 h of hypoxic exposure, HIF-1α protein levels consistently increased
and peaked after incubation between 12 and 24 h (Figure 17 top panel). We then
incubated RAECs in different oxygen saturation environments for 12 h to check for
nuclear HIF-1α levels. As shown, HIF-1α protein amount in RAEC nuclear extracts
enhanced almost linearly with decreasing oxygen saturation and peaked at oxygen
concentrations of 1% - 3% O2 (Figure 17 bottom panel). Thus, the optimal condition
for HIF-1α induction in RAEC is exposure to 1% O2 for 12 h. Most of the HIF-1α
protein levels were measured after 4.5 h of hypoxic/nomoxic incubation since HIF-1α
is already clearly detectable at this time point.
Figure 17. HIF-1α nuclear levels over time in hypoxia and over decreasing oxygen saturation. RAECs were
cultured in 1% O2 for time-dependent observation of HIF-1α levels in nuclear compartment by western-blotting
analysis (upper panel). Characterization of HIF-1α levels in RAEC nuclei over changes of oxygen tension from 21%
to 1% O2 (bottom panel).
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3.4. Hypoxia synergistically increases PDGF-BB-induced HIF-1α
nuclear accumulation
To further confirm HIF-1α distribution in the cells under distinct oxygen condition, i.e.
normoxia or hypoxia, and to assess how growth factors might interfere with this
process, quiescent RAEC seeded on cover-slips, were incubated for 4.5 h with or
without PDGF-BB under conditions of normoxia (21% O2) or hypoxia (1% O2). Cells
were fixed, immunostained for HIF-1α and nuclear compartment and analyzed by
confocal microscopy.
HIF-1α was barely detectable under conditions of normoxia (Figure 18A top-left
panel). However, the protein accumulated in the nuclei under conditions of hypoxia or
normoxia plus PDGF-BB (Figure 18A top-right and bottom-left panel). The highest
HIF-1α concentration in the nuclei was detected when RAEC were stimulated with
PDGF-BB (10 ng/ml) under conditions of hypoxia (1% O2) (Figure 18A bottom-right
panel).
To quantify HIF-1α nuclear accumulation under these conditions, nuclear protein
extracts were analyzed by SDS-PAGE and HIF-1α protein was detected by western
blotting. Densitometric quantifications of three individual experiments illustrate that
either hypoxia (1% O2) or PDGF-BB (10 ng/ml) alone induced considerable
accumulation of HIF-1α (4.2 fold and 5.2 fold, respectively, compared to normoxic
control) in RAECs’ nuclei. Nuclear HIF-1α protein accumulation was maximal (11.9
fold compared to normoxic control) when PDGF-BB stimulation was carried out under
1% O2 (Figure 18B). Thus, results from immunoblotting are in accordance with the
data from immunofluorescent staining both of which suggest an independent
induction of HIF-1α  in RAEC nuclei by hypoxia or PDGF-BB. Furthermore, a
synergistic effect of HIF-1α nuclear accumulation is observed under co-stimulation of
hypoxia and PDGF-BB.
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Figure 18. Hypoxia or PDGF-BB independently and the both synergistically induce HIF-1α nuclear
accumulation in RAEC. A) Confocal microscopy results: immunofluorescent staining of HIF-1α (red staining) and
nuclear compartment (blue staining) of RAEC stimulated with or without PDGF-BB (10 ng/ml) under conditions of
normoxia (21% O2) or hypoxia (1% O2). B) Densitometric quantification of Western blots of RAEC nuclear fractions
for HIF-1α. The inductions of nuclear HIF-1α by hypoxia, PDGF-BB as well as hypoxia plus PDGF-BB are
significantly higher than that of normoxic control group (P < 0.001, n = 3).
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3.5. mTOR inhibition abrogates hypoxia- and/or PDGF-BB-stimulated
HIF-1α nuclear accumulation
To assess an involvement of mTOR in HIF-1α regulation, we examined the effect of
mTOR inhibition on HIF-1α nuclear accumulation triggered by hypoxia or/and PDGF.
We treated RAECs with increasing doses of rapamycin. Under all tested conditions,
rapamycin considerably lowered HIF-1α nuclear protein levels under hypoxia alone
(64±3%), PDGF-BB stimulation under normoxia (86±4%) and hypoxia (76±4%). The
synergistic effect from hypoxia and PDGF-BB on HIF-1α nuclear accumulation
observed in this experiment was sensitive to rapamycin, however, rapamycin failed to
fully block HIF-1α nuclear accumulation to a basal level (Figure 19). These readouts
suggest a general role of mTOR in the modulation of HIF-1α nuclear accumulation.
Figure19. Rapamycin attenuates hypoxia- or/and PDGF-BB-induced nuclear accumulation of HIF-1α.
Quiescent RAECs were treated with mTOR inhibitor rapamycin (RPM), and nuclear protein fractions were separated
by SDS-PAGE and HIF-1α was detected at 120 kDa. Trace amount of HIF-1a was detectable on western blots (top-
left panel). Rapamycin markedly but not completely reduced the amount of nuclear HIF-1α induced by hypoxia (top-
right panel) or PDGF-BB (10 ng/ml) alone (bottom-left panel) as well as the two factors together (bottom-right panel).
3.6. MEK1/2 but not JNK or p38 inhibition impairs PDGF-BB-induced
HIF-1α nuclear accumulation only under normoxia
As common mitogen- or/and stress- activated protein kinase pathways, MAPK
signaling cascades have been implicated in cellular responses to hypoxia 315,318,319. In
order to test the involvement of these pathways in HIF-1α regulation, we used
PD98059, SB203580 and JNK-I-II to inhibit MEK1/2-, p38- and Jun kinase,
respectively, and detected nuclear HIF-1α by immunoblotting. MEK1/2 inhibition did
not reduce hypoxia- or hypoxia and PDGF-BB-induced HIF-1α nuclear accumulation.
However, under normoxic condition, the enhancement of nuclear HIF-1α induced by
HIF-1α
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PDGF-BB stimulation was dramatically reduced (by 86±3%) (Figure 20 top panels).
In contrast, neither blockage of JNK nor p38 was able to attenuate hypoxia- or/and
PDGF-BB-induced HIF-1α  nuclear accumulation (Figure 20 middle and bottom
panels). Thus, MEK1/2 pathway is reactive to PDGF-BB but not to hypoxia for HIF-
1α nuclear accumulation in RAEC.
Figure 20. Impact of inhibition of MAPK pathways on HIF-1α nuclear accumulation. Serum-starved RAECs
were treated with different inhibitors of MAPK transduction cascades and proceedingly cultured in normoxia or
hypoxia as described formerly for 4.5 h before subjecting to western blotting. MEK1/2 inhibitor (PD98059, 5-80 µM,
upper four panels); Jun kinase inhibitor (JNK-I-II, 5-200 nM, middle four panels); p38 kinase inhibitor (SB203580, 0.1-
3 µM, bottom four panels). HIF-1α was detected at 120 kDa. Only under normoxia, inhibition of MEK1/2 pathway
strongly reduces PDGF-BB-induced HIF-1α nuclear accumulation whereas JNK and p38 signaling do not play a role
at all.
3.7. HIF-1α mRNA levels remain stable over changes of oxygen
tension and upon mTOR or MEK1/2 inhibition
The data above have shown an involvement of mTOR or ERK1/2 signaling pathway
in the regulation of HIF-1α nuclear accumulation. We therefore assessed at which
levels the two pathways regulate HIF-1α. The increase of cellular HIF-1α may result
from transcriptional or translational upregulation as well as post-translational
stabilization. We therefore investigated the transcriptional activity of HIF-1α by
measuring its mRNA levels. PDGF-BB stimulation proceeding mTOR or MEK1/2
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inhibition of RAEC in normoxia or hypoxia was used because high HIF-1α nuclear
induction rates were observed in the former experiments. However, when normal RT-
PCR was primarily used for analysis, no differences in HIF-1α levels in the tested
settings were observed as shown in Figure 21A. Also, the Real-Time RT-PCR
followed by β-actin normalized quantification showed that HIF-1α mRNA levels were
constitutive after, i.e., were not significantly influenced by oxygen saturation or
inhibition of mTOR and MEK1/2 signaling, respectively (Figure 21B and C).
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Figure 21. Comparison of HIF-1α mRNA levels in normoxia and hypoxia under the conditions of mTOR or
MEK1/2 inhibition and growth factor stimulation. RAECs treated with rapamycin (5 – 500 nM) or PD98059 (5 – 80
µM) and stimulated with PDGF-BB (10 ng/ml) were cultured in normoxia or hypoxia for 4.5 h. cDNAs were
subsequently synthesized proceeding cellular total mRNA extraction. A) RT-PCR of a 599 bp fragment of HIF-1α and
a 375 bp fragment of b-actin (control) from the synthesized cDNAs of the designated cultures. B) Real-time RT-PCR
(using the same batch of cDNAs as described above) of HIF-1α mRNA levels depicted as fraction of internal β-actin
control.
3.8. Proteasomal inhibition rescues HIF-1α cellular accumulation
attenuated by mTOR blockage
In order to assess the proximal impact of rapamycin on HIF-1α proteasomal
degradation, RAECs were treated with the specific proteasome-inhibitor epoxomicin
(EPX, 1 µM) for different time points, and the cellular levels of HIF-1α were measured
under normoxic conditions. Cytosolic mTOR and phospho-mTOR-Ser2448 were used
as internal controls. Treatment with the proteasome inhibitor alone resulted in a
progressive increase in cellular HIF-1α levels with time (2-8 h, the cells showed an
unhealthy phenotype after 8 hours) presumably due to a congestion of ubiquitinated
HIF-1α intermediates. mTOR and phospho-mTOR levels were not affected by EPX
(Figure 22A). We then induced HIF-1α by exposing RAEC cells for 4.5 h to hypoxia
(1% O2) in the absence or presence of rapamycin (RPM, 100 nM). As expected, HIF-
1α levels of both nuclear and cytosolic compartments decreased by 60% to 70% in
the RPM treated samples. Phospho-mTOR but not mTOR showed a slight decrease
in cytosol. Notably, administration of increasing concentrations of EPX (0.1 – 10 µM)
to the rapamycin treated cultures abrogated the suppressive effect of rapamycin on
C
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hypoxia-induced HIF-1α nuclear accumulation. Again, there were no changes in
mTOR and phospho-mTOR levels (Figure 22B).
Figure 22. Proteasome inhibitor can rescue the decrease of HIF-1α by rapamycin in hypoxia. A) Proteasome
inhibition increases cellular HIF-1α but not mTOR and phospho-mTOR-Ser2448 (mTOR-P) levels in normoxia.
Epoxomicin (EPX, 1 µM) effectively blocked HIF-1α proteasomal degradation. B) EPX rescues both nuclear and
cytosolic HIF-1α accumulation attenuated by mTOR inhibition under conditions of hypoxia in RAEC.
3.9. mTOR enhances both HIF-1α-dependent and -independent cell
proliferation under hypoxia
Our data have shown that hypoxia and/or PDGF-BB stimulate both RAEC
proliferation (Figure 14) and HIF-1α nuclear accumulation (Figure 19) in an mTOR-
dependent manner. To assess the role of HIF-1α  in hypoxia-triggered and mTOR-
dependent proliferation we used mouse embryonic fibroblasts (MEFs) that lack the
HIF-1α gene (HIF-1α-/- MEFs) and wild type MEFs (HIF-1α+/+ MEFs) (Figure 23A
upper panels). Mice defective in HIF-1α are embryonically lethal at day E10.5 due to
severe cardiac and vascular malformations 325. Quiescent MEFs were incubated
under 21% and 1% O2, respectively. After 24 h cell numbers were measured as
A
B
68
described. Proliferation under hypoxia was significantly more enhanced in HIF-1α+/+
compared to HIF-1α-/- cells (n = 3; P < 0.001), suggesting that HIF-1α is required for
hypoxia-induced proliferation (Figure 23B). We then assessed proliferation in HIF-
1α+/+ and HIF-1α-/- MEFs overexpressing mTOR wild type protein. mTOR
overexpression compared to mock transfection significantly increased the capacity of
proliferation of both cell types to respond to hypoxia (p < 0.001, n = 3) (Figure 23B).
In HIF-1α+/+ cells, mTOR overexpression increased proliferation 3.0 fold under
hypoxia, and to a similar degree also under normoxia (2.8 fold) compared to the
respective mock values under hypoxia or normoxia (Figure 23B). Surprisingly, in HIF-
1α-/- cells, mTOR overexpression increased proliferation 4 fold compared to mock-
transfected HIF-1α-/- cells under hypoxia with no effect under normoxia (Figure 23B).
These findings indicate that HIF-1α is less required for the response to hypoxia.
However, mTOR is prerequisite for cell proliferation, and that mTOR overexpression
can potentiate proliferation of HIF-1α-deficient cells.
                    
A
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Figure 23. mTOR wild type overexpression potentiates proliferation of HIF-1α+/+ and HIF-1α-/- MEFs under
hypoxia. A) HIF-1α+/+ and HIF-1α-/- MEFs were stimulated with CPX and incubated in 1, 3 or 21% O2 to test for HIF-
1α protein expression (upper panel). These cells were transfected with pBABE retroviruses harboring no insert
(mock) or HA-tagged mTOR wild type (mTORwt). Immunoblotting shows expressed HA-tag at mTOR protein size of
about 250 kDa. B) Serum-deprived genetically modified and mTOR-non- or –overexpressing MEFs were incubated
under conditions of 21% or 1% O2 for 24 h and cell numbers were determined. Y-axis represents the mean of cell
number, compiled from three individual experiments with octuplicate samples. Data are given as mean ± SEM, n = 3.
B
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4. DISCUSSION
Hypoxia is a pathophysiological constituent of the major diseases causing mortality in
Western societies: heart attack, stroke, and cancer. The ability to sense and respond
to changes in oxygen availability is thus critical for many developmental,
physiological and pathophysiological processes including angiogenesis, cerebral and
myocardial ischemia and tumorigenesis. Many molecular mechanisms of hypoxia
sensing are conserved from unicellular prokaryotes to humans. In order to adapt to
low oxygen it is first necessary to be able to detect hypoxia, then to initiate the
appropriate defense mechanisms. In mammalian cells, exposure to hypoxia triggers
an evolutionarily conserved hypoxic response pathway centered on the regulated
expression of the hypoxia-inducible transcription factor (HIF). Accordingly, rat and
human HIF-1α mRNA sequences alignments are of 100% identical. HIF promotes
transcription of genes that mediate cellular adaptation to hypoxia through their roles
in glycolytic metabolism, cellular proliferation and survival, and oxygen delivery.
Angiogenesis is one of the major responses regulated by HIF. Proliferation of the
endothelial cells lining the pre-existing vessels is an important stage for the
angiogenic process 6,7. The study therefore was designed to use primary endothelial
cells so as to be close to biological relevance. According to the prior works in the lab,
rat aortic endothelial cells (RAECs) derived from in vitro angiogenesis assays were
selected for the experiments 140,326.
mTOR regulates both cell growth and proliferation in many cell types, and is
associated with in vitro and in vivo angiogenesis 140,298-300,303. However, related data
from primary endothelial cell studies are still rare, and the mechanisms about how
mTOR modulates hypoxic cell proliferation are unclear. We therefore conducted
experiments in order to improve the understanding of the role that mTOR plays in
hypoxia-stimulated endothelial cell proliferation and angiogenesis and to uncover the
regulating mechanisms.
This thesis demonstrates that mTOR signaling is an important component of the
cellular response to hypoxia. It describes, that both activating and inhibitory
modulations of mTOR occur in response to hypoxia simultaneously in primary
endothelial cells. At the same time we observed an increase of mTOR-dependent
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modulations that facilitate the formation of new microvessels in response to hypoxia,
including the stabilization of the conserved transcription factor HIF-1α.
4.1. mTOR is involved in regulating hypoxia-triggered endothelial
sprout-formation and cell proliferation
Endothelial spheroid sprouting provides an accurate method for in vitro observation
of endothelial cell angiogenesis. In accordance with earlier findings in another in vitro
angiogenesis assay in the lab 140, hypoxia markedly enhances endothelial spheroid
sprouting. This implies a direct and tight link between the hypoxia-input and the
angiogenisis-like-output. This link is possibly due to a metabolically adaptive switch
from aerobic to anaerobic conditions, and the change provides for example
glycolysis-related factors which in turn stimulate angiogenesis to occur 30. In addition,
hypoxia-induced angiogenic molecules produced by the autocrine and paracrine
mechanisms may concomitantly contribute to the angiogenic effect 30.
Augmented spheroid sprouting under hypoxia is associated with an increased
number and elongated shape of endothelial cells spreading outwards from the
spheroids, suggesting an improved proliferation rate of the primary endothelial cells.
Moreover, the sprouting can be reduced by rapamycin with a far higher effect under
hypoxic than normoxic conditions. But rapamycin in both cases is not able to fully
inhibit the sprout-formation. In line, the RAEC proliferation assay confirmed that
hypoxia potentiates cell proliferation. Interestingly, hypoxia and PDGF-BB are
capable of synergistically inducing RAEC proliferation to an even higher extent than
those induced by the respective stimulus. Furthermore, all these increases can be
brought down markedly but not fully by rapamycin. The inhibitory effect of rapamycin
on angiogenesis is also observed in vivo where tumor growth is abrogated, and the
abrogation was suggested to be due to an impaired VEGF production 303. These
observations implicate prominent involvement of mTOR in the regulation of
endothelial cell angiogenic and proliferative effects during hypoxia. These effects of
mTOR might be mediated through its upstream TSC1/2 or/and Rheb 261. It is also
possible that hypoxia or/and PDGF-BB triggers other pathways/factors such as PI3K
or Akt overlapping with mTOR signaling for the common readouts 1,268,279.
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4.2. mTOR and downstream targets S6K1 and 4E-BP1 are differentially
phosphorylated under hypoxia
We have observed a direct activating effect of hypoxia on mTOR: Decreasing oxygen
saturation lead to a sustained increase in mTOR-Ser2448 phosphorylation with a
maximum at the lowest oxygen saturation examined. The PKB consensus
phosphorylation site Ser2448 of mTOR has been proposed to increase mTOR kinase
activity 279. At the same time, we observed hypo-phosphorylation of mTOR
downstream targets and translational regulators S6K1 and 4E-BP1. Another
independent study in HEK293 cells showed that hypoxia led to mTOR-dependent
hypo-phosphorylation of p70/p85 S6 kinase and 4E-BP1 but no change in mTOR-
Ser2448 phosphorylation 304. A recent report in primary pulmonary artery adventitial
fibroblasts shows that hypoxia significantly increases mTOR-Ser2448 phosphorylation
327. In this study and our own experiments, cells were exposed to hypoxia under
serum-deprived conditions whereas experiments on HEK293 cells were carried out in
the presence of insulin 304. Insulin induces phosphorylation on mTOR Ser2448 via Akt
263,279, and might therefore have masked the effect of hypoxia on mTOR-Ser2448.
Although it is still controversial whether mTOR negative regulator TSC2 is
indispensable for Akt activation of mTOR 259,283, the TSC1/TSC2 complex seems to
be required for hypoxic inhibition of mTOR downstream targets S6K1 and 4E-BP1
292. Results from others and our own data show that hypoxia decreases
phosphorylation of p70 S6K and 4E-BP1 reflecting§ downregulated mTOR activity
towards the two downstream targets 304. The mechanisms about how hypoxia could
modulate mTOR signaling remain unclear. Recent studies using Tsc2 knockout and
knockdown cell types demonstrate that Tsc2 is required for downregulation of mTOR
by hypoxia and a de novo hypoxia-inducible gene REDD1 (RTP801) 292. In addition,
Redd1 knockout MEF cells failed to decrease S6K phosphorylation under conditions
of hypoxia indicating an indispensable role of REDD1 in hypoxic regulation of mTOR
292. However, though REDD1 appears as a upstream regulator of mTOR, its mRNA is
significantly downregulated by inhibitors of PI3K and mTOR, LY294002 and
Rapamycin, respectively in human prostate cancer cell lines 328. In accordance with
this, hypoxia-dependent REDD1 mRNA induction is controlled by HIF-1α since the
HIF-1α knockout mouse ES cells failed to express REDD1 329. These latter data
complicate the mTOR transduction network with potential feedback loops for
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adaptive signaling. In addition, the existence of two mTOR complexes (mTORC1 and
2) with mTORC2 insensitive to rapamycin, amino acids or serum depletion and
physiologically irrelevant to S6K1 and 4E-BP1 phosphorylation may explain the
ambivalent activation and inactivation of mTOR by hypoxia 234.
4.3. mTOR and phospho-mTOR accumulate in endothelial cell nuclei
in response to hypoxia
We show for the first time that mTOR and phospho-mTOR rapidly (within 2 h)
accumulate in the nucleus of RAEC in response to hypoxia under serum-free
conditions. Previous reports addressed that mTOR nuclear translocation was
promoted by serum 330. It has been suggested that mTOR cytoplasmic-nuclear
shuttling is required for its ability to activate cytoplasmic effectors (S6K1 and 4E-BP1)
as well as a nuclear effector (S6K2) 330,331. It is still unclear what the exact function of
mTOR in the nucleus is. It is worth noting that HIF-1α accumulates in the nucleus at
a similar time range upon hypoxic exposure. This coincidence may not be by chance
only. Cytoplasmic-nuclear shuttling may imply a coordination of multiple functions
that mTOR supports in various cellular compartments 330, and may contribute to HIF-
1α function. These results support the notion that the activities of mTOR, S6K1, and
4E-BP1 are changing over alterations of cellular oxygen tension, and therefore may
participate in the hypoxia-sensing process.
4.4. Hypoxia and PDGF-BB synergistically induce HIF-1α nuclear
accumulation
Nuclear residence is a prerequisite for HIF-1α to transactivate certain angiogenesis-
associated genes. It has been shown in transformed cells that HIF-1α accumulates in
nuclei and its DNA-binding activity appears within a very short time upon hypoxic
exposure 101. These characteristics of HIF-1α make it a good candidate for diagnostic
as well as prognostic purposes in ischemic heart diseases and solid tumors 42,73.
The current and other studies could show that HIF-1α is detectable in a very little
amount even under conditions of normoxia (Figure 17, 18). This is probably because
of the existence of pericellularly hypoxic microenvironment 332. Our immunoblotting
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and immunocytochemistry study illustrated that HIF-1α protein was already highly
stabilized and accumulated in RAECs’ nuclei after 4.5h exposure to hypoxia or/and
PDGF-BB stimulation, implicating a quick response of the RAECs to hypoxic
conditions and mitogens (Figure 17, 18). Furthermore, when hypoxia and PDGF-BB
acted as co-inducers, the amount of nuclear HIF-1α was not purely additive from the
value induced by each factor separately, indicating a synergistic effect of the factors
on HIF-1α accumulation (Figure 18). Growth factors including PDGF and its
receptors have been proven to be actively involved in angiogenesis 218,222, and PDGF
synthesis could be triggered by hypoxia 213. Thus, additional secretion of PDGF may
account for the synergistic effect on HIF-1α induction under hypoxia. Similarly, that
hypoxia and PDGF-BB acted in concert to upregulate the expression of HIF-1α
transcriptional target gene VEGF in other cell lines 333,334. The mechanisms hidden
behind these phenomena need to be investigated further.
4.5. mTOR is required for hypoxia- and/or PDGF-BB-induced HIF-1α
nuclear accumulation
As shown and discussed before, mTOR is involved in hypoxia-sensing, regulation of
hypoxia- as well as PDGF-BB-induced endothelial sprout-formation and cell
proliferation. On the other hand, both hypoxia and PDGF-BB induce HIF-1α nuclear
accumulation that ultimately leads to target gene transactivation. It is therefore
reasonable to infer a link between mTOR and HIF-1α nuclear accumulation.
Since HIF-1α is in a distal position for transactivating target genes, it is most likely
that mTOR imposes a regulatory function on HIF-1α. However, an opposite effect,
i.e., HIF-1α influences mTOR activity, cannot be excluded. The experimental results
from this study clearly show that mTOR inhibition by rapamycin strongly reduces
hypoxia- and PDGF-BB-induced HIF-1α  nuclear accumulation indicating an
upstream requirement of mTOR in HIF-1α regulation. This is supported by evidence
showing that inhibition of mTOR or the upstream mediator PI3K decreased both HIF-
1α  and VEGF expression induced by growth factors 141. Moreover, rapamycin
attenuated wild-type mTOR transfection-enhanced HIF-1α induction by hypoxia or
CoCl2 in prostate cancer cell lines while the rapamycin-resistant mutant mTOR
transfected cells have unaffected HIF-1α levels as well as transactivities 143. Thus,
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mTOR seems to play an indispensable role in protecting hypoxia- and/or PDGF-BB-
induced HIF-1α function.
4.6. MEK1/2 but not JNK or p38 regulates PDGF-BB-induced HIF-1α
nuclear accumulation only under normoxia
MAPKs have been implicated in cell signaling triggered by mitogens, growth
factors/cytokines or hypoxia. However, the sorts of MAPKs involved in the process
induced by hypoxia remain uncertain 307,315-317. Therefore, the involvement of MAPK
pathways in RAECs stimulated by hypoxia and/or growth factor has been
investigated in the study.
As shown in the results, inhibition of MEK1/2 by PD98059 attenuated PDGF-BB
induced HIF-1α nuclear accumulation only under normoxia, suggesting that MEK1/2
activity is not necessary for HIF-1α nuclear accumulation under hypoxia. This result
is in line with another observation showing that inhibition of ERK1/2 signaling impairs
HIF-1α transactivation activity with no impact on its stability and DNA binding activity
318,319. An explanation for the unaffected HIF-1α levels but the increased transactivity
upon ERK1/2 inhibition might be that ERK1/2 interacts with HIF-1α coactivators or
the factors that regulate them. On the other hand, similar to rapamycin, PD98059
was not able to completely inhibit HIF-1α nuclear accumulation. Thus, molecules in
addition to MEK1/2 may contribute to HIF-1α nuclear accumulation. It is possible that
mTOR and ERK1/2 pathways or even others interfere, overlap and cooperate during
growth factor induction of HIF-1α upregulation and nuclear accumulation. In the
study, both JNK and p38 inhibition showed no influence on enhanced HIF-1α nuclear
levels induced by hypoxia or/and PDGF-BB. Thus, JNK and p38 signaling do not
contribute to HIF-1α accumulation in rat aortic endothelial cells. Our observation fails
to support the results from other studies showing a JNK- and p38-dependent HIF-1α
regulation under hypoxia 315,320. It is possible that cell type and the type of genetic
transformation, and the intracellular signaling milieu may direct hypoxic signals
differentially to signal relays.
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4.7. HIF-1α cellular accumulation is regulated neither at transcriptional
nor at translational level
HIF-1α has been shown to be regulated at transcriptional, translational and post-
translational levels 105,139,145. So far, the regulation of HIF-1α in endothelial cells has
not been well characterized. In this study, we examined the potential modulation
levels for HIF-1α in RAEC.
Both R-T and Real-Time R-T PCR data demonstrate comparably stable HIF-1α
mRNA levels in normoxia and hypoxia, respectively. Also, rapamycin has no effect
on HIF-1α mRNA levels in growth factor-stimulated RAECs. These results suggest a
non-involvement of transcriptional regulation in HIF-1α cellular accumulation.
Meanwhile, the immunoblotting showed a decreased activation of the translation
regulators S6K1 and 4E-BP1 under hypoxia, implicating a reduced protein synthesis
in this circumstances and a non-involvement of translational modulation in HIF-1α
accumulation in RAEC. Therefore, unlike angiotensin II 139, hypoxia-triggered HIF-1α
stabilization and cellular accumulation, which are rapamycin sensitive, are not
mediated via transcriptional and translational mechanisms.
4.8. mTOR activity protects HIF-1α from proteasomal degradation
under hypoxia
HIF-1α  protein is modified in multiple ways that are thought to allow precise
regulation of its levels as well as its functions 105. We show that inhibition of
proteasomal activity rescued rapamycin-induced HIF-1α destabilization. Thus, mTOR
activity protects HIF-1α  from proteasomal degradation. Data from another
independent study showed that mTOR activity increases the steady-state level of
HIF-1α in both normoxic and hypoxic prostate cancer cells. Furthermore, this study
showed that the ODD domain of HIF-1α is involved in mTOR-dependent stabilization
of the HIF-1α protein during cellular exposure to hypoxia-mimetic agents 143.
Hypothetically, mTOR-dependent effects on HIF-1α stabilization may include one or
more post-translational modification(s) such as phosphorylation and sumoylation that
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protects HIF-1α from degradation 105. So far, there are no direct links between mTOR
and HIF-1α phosphorylation. In mammalian cells, sumoylation is involved in post-
translational modification of certain proteins by covalently attaching SUMO to specific
lysine residues within the proteins 126. By this way, sumoylation regulates various
cellular processes like nuclear transport, signal transduction, stress response and
cell cycle progression 126. But, in contrast to ubiquitination, sumoylation does not tag
proteins for degradation, but seems to enhance their stability or modulate their
subcellular compartmentalization 132. It has been shown that protein-sumoylation is
significantly increased in bovine aortic endothelial cells after exposure to hypoxia for
48 h 335. Furthermore, increased levels of SUMO-1 were shown to participate in the
modulation of HIF-1α function through sumoylation in hypoxic brain and heart. There,
SUMO-1 co-localizes in cell nuclei in vivo with HIF-1α in response to hypoxia 336.
Interestingly, we found that mTOR localized in endothelial nuclei after exposure to
hypoxia. Therefore, sumoylation might be a good candidate mechanism to protect
HIF-1α from proteasomal degradation. Possibly, mTOR has a function in sumoylation
and nuclear localization of HIF-1α under hypoxia.
4.9. mTOR enhances both HIF-1α-dependent and -independent cell
proliferation under hypoxia
As described earlier, mTOR is required for hypoxia-triggered endothelial cell
proliferation. Moreover, mTOR, acting upstream of HIF-1α, is involved in hypoxia
sensing. Still, it remains unclear how mTOR could interact with HIF-1α to regulate
cell proliferation. To study whether inhibition of HIF-1α function impairs mTOR-
dependent cell proliferation under hypoxia, we used mouse embryonic fibroblasts
(MEFs) derived from mice that are deficient in HIF-1α. The HIF-1α-deficient mice are
embryonically lethal at day E10.5 due to severe cardiac and vascular malformations
99.
The results demonstrate that HIF-1α  is not the unique effector of mTOR in the
response to hypoxia. HIF-1α-/- MEFs proliferate less than HIF-1α+/+ cells under
hypoxia. Therefore, HIF-1α certainly confers a growth advantage to cells under low
oxygen saturation. However, HIF-1α-/- MEFs overexpressing mTOR acquire the
capacity to proliferate under hypoxia but not under normoxia. We conclude that
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hypoxia-triggered signaling via mTOR involves downstream interactions with both
HIF-1α-dependent and HIF-1α-independent mechanisms.
HIF-1α-independent hypoxia effectors still need to be defined and may involve other
HIFs (HIF-2, HIF-3). With HIF-3α expression the most restricted, HIF-2α is more
widely expressed in vascular endothelial cells during embryo development and in
kidney fibroblasts, liver hepatocytes, epithelial cells of intestinal lumen, pancreatic
interstitial cells, heart myocytes and interstitial cells, lung type II pneumocytes, tumor
vascular cells as well as in a vast variety of tumor cells 76,337,338. Interestingly, it has
been shown recently that HIF-2α knockout mice are able to survive postnatally but
eventually die with defects in vascular system, lung maturation, and catecholamine
production. Moreover, bearing abnormalities, the genetically engineered HIF-2α
knockout mice is compatible with life 67,339. Though overlapping transcriptional targets
exist, HIF-1α and HIF-2α exert differential regulatory functions when low oxygen
tension appears 76. For example, HIF-1α but not HIF-2α is critical for glycol sis during
O2 deprivation. In renal carcinoma cells exclusively expressing HIF-2α, a number of
hypoxia-inducible genes can be induced without transactivation from HIF-1α 76.
Alternatively, mTOR may transduce hypoxic signals also via modulating cell cycle
regulators. In NIH 3T3 cells, degradation of newly synthesized cyclin D1 protein was
accelerated by rapamycin, a process prevented by inclusion of a proteasome
inhibitor 340. In transformed mouse 3T3 fibroblasts (BP-A31) rapamycin reduced the
level of total p21 (WAF1/CIP1) as well as that of p21 (WAF1/CIP1) associated with
the cyclin D1/cdk4 complexes 341. Besides its inhibitory activity toward cdk, p21
(WAF1/CIP1) has been recently found to participate in the formation, stabilization
and nuclear translocation of cyclin D1/cdk4 complexes 341. Thus, cyclin D1 and p21
appear to be regulated similarly to HIF-1α with respect to protein stability and nuclear
translocation. However, it is not known, whether cyclin D1 or p21 protein levels
increase under conditions of hypoxia, and if so, whether this increase might be
rapamycin (mTOR) sensitive. Possibly, these effectors are also regulated by mTOR-
mediated, protective protein modifications.
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4.10. Limitations
Most of the experiments were done in RAECs. It is difficult to predict whether the
effects of the studied molecules, e.g. mTOR and HIF-1α, are conserved in other
species, e.g. humans. It is unclear whether our data can be extrapolated to other cell
types and tissues. Besides, the readouts of the in vitro studies performed currently
may not reflect the in vivo situation. Therefore, caution should be taken when the
data are utilized to interpret in vivo or clinical phenomena.
A potential pitfall in this study is that the experiments conducted in the MEFs do not
reflect the situation in RAECs and angiogenesis in vitro, where mTOR and HIF-1α
may interplay differently for cell proliferation. In addition, phosphorylation of mTOR
may not be really in accordance with its signaling activity, and its downstream targets
S6K1 and 4E-BP1 could be mediated by upstream molecules other than mTOR. It is
likely that other pathways triggered by hypoxia interfere with the mTOR pathway to
induce the common readouts of HIF-1α.
The inefficiency of transfecting RAECs confined the process and depth of mTOR-
and HIF-1α-associated studies. This is in part due to the extensive size of the mTOR
gene. However, the findings of the upstream regulators of mTOR, TSC1/2, Rheb,
and REDD1, and the studies of the differential mTOR complexes as well as the
modifiers for HIF-1α  in other cell types will certainly facilitate to elucidate the
regulatory relationships between mTOR and HIF-1α.
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5. CONCLUSIONS, KEY POINTS
In conclusion, we have observed an increase of mTOR-dependent modulation that
facilitates endothelial cell angiogenic effect and proliferation in response to hypoxia.
Hypoxia imposes both activating and inhibitory modulations differentially but
concurrently on mTOR in rat aortic endothelial cells. On one hand, mTOR is
activated by phosphorylation and translocated into the nucleus. On the other hand,
translational regulators S6K and 4E-BP1 lying at least in part downstream of mTOR
are hypo-phosphorylated. Furthermore, mTOR augments nuclear HIF-1α levels by
protecting the protein from proteasomal degradation under hypoxia, and thereby
potentially reinsures oxygen supply by induction of neovascularization. mTOR may
also induce hypoxia-adaptive responses by effectors other than HIF-1α. Finally,
mTOR is fully required for cell proliferation, which can be reinforced by HIF-1α. Thus,
as a dominant and important transducer of the hypoxic response, mTOR acts via
downstream interaction with both HIF-1α-dependent and -independent mechanisms.
The main findings in this study are summarized as following key points:
1. Hypoxia is an active and positive trigger for endothelial sprout-formation and cell
proliferation, and mTOR is required for the process.
2. Hypoxia causes mTOR phosphorylation, phospho-mTOR-Ser2448/mTOR nuclear
accumulation, and hypo-phosphorylation of S6K1 and 4E-BP1.
3. Hypoxia and PDGF-BB could interact to enhance endothelial cell proliferation and
HIF-1α nuclear protein levels.
4. mTOR is strongly but not fully required for hypoxia- and PDGF-induced HIF-1α
nuclear accumulation.
5. ERK1/2 participates specifically in the regulation of growth factor-stimulated HIF-
1α nuclear accumulation.
6. mTOR modulates HIF-1α nuclear levels under hypoxia neither at transcriptional
nor at translational level.
7. HIF-1α is not critical for cell proliferation but can reinforce induction of pro-
proliferation via mTOR.
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6. OUTLOOK
Hypoxia induces activation of a set of distinct signaling pathways for cells to survive
in an altered environment. Studies highlighting the role of TSC1/TSC2 complex in
hypoxic regulation of mTOR, S6K1 and 4E-BP1 are emerging 292. Thus, it will be
important to determine what role the TSC1/TSC2 complex plays in hypoxia-mediated
mTOR-phosphorylation on Ser2448 or even other phosphorylation sites in mTOR, -
nuclear translocation, -stabilization of HIF-1α and cell proliferation.
mTOR catalytic or kinase function is influenced by a growing list of directly interacting
binding proteins such as mKOG1 (raptor), mAVO3 (rictor) and mLST8 (GβL) that
determine two differently composed mTOR complexes (mTORC1 and mTORC2) 233-
235,237. The latter complexes may be differentially activated by hypoxia generating
differential responses to hypoxia. Therefore, insights into the mTOR-interacting
proteins within the mTORCs in relation to HIF-1α under hypoxia will shed light on
activation and inhibition of mTOR by hypoxia. Also, one of the two mTORCs may
mediate the regulation of HIF-1α.
Closely related to HIF-1α, HIF-2α and HIF-3α, may play important roles in cells
under hypoxia. Thus, it is interesting to know how the latter two HIF alpha isoforms
respond to hypoxia and how these factors co-operate to produce the coordinated
responses for cell to adapt to the low oxygen environment. At the same time, it is
possible that these hypoxia-inducible factors are also regulated by mTOR-mediated,
protective protein modifications.
A promising utility of the in vitro assay of endothelial cell (EC) spheroid sprouting is to
investigate the angiogenic potentials of transfected ECs with different target genes.
The assay per se may be useful for high throughput screening for agonists and
antagonists engaged in angiogenesis.
82
7. REFERENCES
1. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000;103:253-262
2. Hoch RV, Soriano P. Roles of PDGF in animal development. Development. 2003;130:4769-
4784
3. Schaeffer HJ, Weber MJ. Mitogen-activated protein kinases: specific messages from
ubiquitous messengers. Mol Cell Biol. 1999;19:2435-2444
4. Carmeliet P. Manipulating angiogenesis in medicine. J Intern Med. 2004;255:538-561
5. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389-395
6. Hanahan D. Signaling vascular morphogenesis and maintenance. Science. 1997;277:48-50
7. Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc
Res. 2001;49:507-521
8. Kutryk MJ, Stewart DJ. Angiogenesis of the heart. Microsc Res Tech. 2003;60:138-158
9. Flamme I, Baranowski A, Risau W. A new model of vasculogenesis and angiogenesis in vitro
as compared with vascular growth in the avian area vasculosa. Anat Rec. 1993;237:49-57
10. Arnold F, West DC, Schofield PF, Kumar S. Angiogenic activity in human wound fluid. Int J
Microcirc Clin Exp. 1987;5:381-386
11. Ortega S, Ittmann M, Tsang SH, Ehrlich M, Basilico C. Neuronal defects and delayed wound
healing in mice lacking fibroblast growth factor 2. Proc Natl Acad Sci U S A. 1998;95:5672-
5677
12. Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, DiPietro LA. Vascular endothelial
growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am
J Pathol. 1998;152:1445-1452
13. Swift ME, Kleinman HK, DiPietro LA. Impaired wound repair and delayed angiogenesis in aged
mice. Lab Invest. 1999;79:1479-1487
14. Modlich U, Kaup FJ, Augustin HG. Cyclic angiogenesis and blood vessel regression in the
ovary: blood vessel regression during luteolysis involves endothelial cell detachment and
vessel occlusion. Lab Invest. 1996;74:771-780
15. Albrecht ED, Robb VA, Pepe GJ. Regulation of placental vascular endothelial
growth/permeability factor expression and angiogenesis by estrogen during early baboon
pregnancy. J Clin Endocrinol Metab. 2004;89:5803-5809
83
16. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner
JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis
in physiological and pathological neovascularization. Circ Res. 1999;85:221-228
17. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W,
Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K,
Benezra R, Rafii S. Impaired recruitment of bone-marrow-derived endothelial and
hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7:1194-
1201
18. Walsh DA. Angiogenesis and arthritis. Rheumatology (Oxford). 1999;38:103-112
19. Bonnet CS, Walsh DA. Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford).
2004
20. Semble EL, Turner RA, McCrickard EL. Rheumatoid arthritis and osteoarthritis synovial fluid
effects on primary human endothelial cell cultures. J Rheumatol. 1985;12:237-241
21. Giatromanolaki A, Sivridis E, Athanassou N, Zois E, Thorpe PE, Brekken RA, Gatter KC, Harris
AL, Koukourakis IM, Koukourakis MI. The angiogenic pathway "vascular endothelial growth
factor/flk-1(KDR)-receptor" in rheumatoid arthritis and osteoarthritis. J Pathol. 2001;194:101-
108
22. Noon JP, Walker BR, Webb DJ, Shore AC, Holton DW, Edwards HV, Watt GC. Impaired
microvascular dilatation and capillary rarefaction in young adults with a predisposition to high
blood pressure. J Clin Invest. 1997;99:1873-1879
23. Angoulvant D, Fazel S, Li RK. Neovascularization derived from cell transplantation in ischemic
myocardium. Mol Cell Biochem. 2004;264:133-142
24. Gowdak LH, Poliakova L, Wang X, Kovesdi I, Fishbein KW, Zacheo A, Palumbo R, Straino S,
Emanueli C, Marrocco-Trischitta M, Lakatta EG, Anversa P, Spencer RG, Talan M, Capogrossi
MC. Adenovirus-mediated VEGF(121) gene transfer stimulates angiogenesis in normoperfused
skeletal muscle and preserves tissue perfusion after induction of ischemia. Circulation.
2000;102:565-571
25. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific
growth factors and blood vessel formation. Nature. 2000;407:242-248
26. Strauer BE. Significance of coronary circulation in hypertensive heart disease for development
and prevention of heart failure. Am J Cardiol. 1990;65:34G-41G
27. Henrich HA, Romen W, Heimgartner W, Hartung E, Baumer F. Capillary rarefaction
characteristic of the skeletal muscle of hypertensive patients. Klin Wochenschr. 1988;66:54-60
84
28. Isoyama S. Hypertension and age-related changes in the heart. Implications for drug therapy.
Drugs Aging. 1994;5:102-115
29. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267:10931-10934
30. Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic
prospects. J Mol Med. 1995;73:333-346
31. Kiefer FN, Misteli H, Kalak N, Tschudin K, Fingerle J, Van der Kooij M, Stumm M, Sumanovski
LT, Sieber CC, Battegay EJ. Inhibition of NO biosynthesis, but not elevated blood pressure,
reduces angiogenesis in rat models of secondary hypertension. Blood Press. 2002;11:116-124
32. Rieder MJ, Roman RJ, Greene AS. Reversal of microvascular rarefaction and reduced renal
mass hypertension. Hypertension. 1997;30:120-127
33. Emanuelia C, Madeddu P. Human tissue kallikrein: a new bullet for the treatment of ischemia.
Curr Pharm Des. 2003;9:589-597
34. Rubanyi GM, Johns A, Kauser K. Effect of estrogen on endothelial function and angiogenesis.
Vascul Pharmacol. 2002;38:89-98
35. Kauser K, Rubanyi GM. Potential cellular signaling mechanisms mediating upregulation of
endothelial nitric oxide production by estrogen. J Vasc Res. 1997;34:229-236
36. Gilligan DM, Quyyumi AA, Cannon RO, 3rd. Effects of physiological levels of estrogen on
coronary vasomotor function in postmenopausal women. Circulation. 1994;89:2545-2551
37. Greene AS. Life and death in the microcirculation: a role for angiotensin II. Microcirculation.
1998;5:101-107
38. Achard J, Fournier A, Mazouz H, Caride VJ, Penar PL, Fernandez LA. Protection against
ischemia: a physiological function of the renin-angiotensin system. Biochem Pharmacol.
2001;62:261-271
39. Chung NA, Beevers DG, Lip G. Effects of losartan versus hydrochlorothiazide on indices of
endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension.
Blood Press. 2004;13:183-189
40. Walther T, Menrad A, Orzechowski HD, Siemeister G, Paul M, Schirner M. Differential
regulation of in vivo angiogenesis by angiotensin II receptors. Faseb J. 2003;17:2061-2067
41. Forder JP, Munzenmaier DH, Greene AS. Angiogenic Protection from Focal Ischemia with
Angiotensin II Type 1 Receptor Blockade in the Rat. Am J Physiol Heart Circ Physiol. 2004
42. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA. Early expression
of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med.
2000;342:626-633
85
43. Simons M, Ware JA. Food for starving hearts. Nat Med. 1996;2:519-520
44. Ware JA, Simons M. Angiogenesis in ischemic heart disease. Nat Med. 1997;3:158-164
45. Freedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease. Ann Intern
Med. 2002;136:54-71
46. Henry TD. Therapeutic angiogenesis. Bmj. 1999;318:1536-1539
47. Khan TA, Sellke FW, Laham RJ. Gene therapy progress and prospects: therapeutic
angiogenesis for limb and myocardial ischemia. Gene Ther. 2003;10:285-291
48. Syed IS, Sanborn TA, Rosengart TK. Therapeutic angiogenesis: a biologic bypass. Cardiology.
2004;101:131-143
49. Schumacher B, Pecher P, von Specht BU, Stegmann T. Induction of neoangiogenesis in
ischemic myocardium by human growth factors: first clinical results of a new treatment of
coronary heart disease. Circulation. 1998;97:645-650
50. Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K,
Isner JM. Gene therapy for myocardial angiogenesis: initial clinical results with direct
myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation.
1998;98:2800-2804
51. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible or
angiogenesis. J Exp Med. 1971;133:275-288
52. Brem S, Brem H, Folkman J, Finkelstein D, Patz A. Prolonged tumor dormancy by prevention
of neovascularization in the vitreous. Cancer Res. 1976;36:2807-2812
53. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation
and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1:149-153
54. Christofori G. The implications of angiogenesis on tumor invasiveness. Angiogenesis.
1998;2:21-23
55. Fox SB, Harris AL. Markers of tumor angiogenesis: clinical applications in prognosis and anti-
angiogenic therapy. Invest New Drugs. 1997;15:15-28
56. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage
EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of
metastases by a Lewis lung carcinoma. Cell. 1994;79:315-328
57. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen
BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell.
1997;88:277-285
86
58. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257
59. Bae DG, Gho YS, Yoon WH, Chae CB. Arginine-rich anti-vascular endothelial growth factor
peptides inhibit tumor growth and metastasis by blocking angiogenesis. J Biol Chem.
2000;275:13588-13596
60. Borgstrom P, Gold DP, Hillan KJ, Ferrara N. Importance of VEGF for breast cancer
angiogenesis in vivo: implications from intravital microscopy of combination treatments with an
anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res. 1999;19:4203-
4214
61. Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, Adelman D, Stalter S,
Breed J. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular
endothelial growth factor in combination with chemotherapy in patients with advanced cancer:
pharmacologic and long-term safety data. J Clin Oncol. 2001;19:851-856
62. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron
A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab
plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med.
2004;350:2335-2342
63. Lin P, Buxton JA, Acheson A, Radziejewski C, Maisonpierre PC, Yancopoulos GD, Channon
KM, Hale LP, Dewhirst MW, George SE, Peters KG. Antiangiogenic gene therapy targeting the
endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci U S A. 1998;95:8829-
8834
64. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau
W, Ullrich A, Hirth KP, McMahon G. SU5416 is a potent and selective inhibitor of the vascular
endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor
vascularization, and growth of multiple tumor types. Cancer Res. 1999;59:99-106
65. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J,
Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F,
Shenoy N, Hirth KP, McMahon G, Cherrington. SU6668 is a potent antiangiogenic and
antitumor agent that induces regression of established tumors. Cancer Res. 2000;60:4152-
4160
66. Griggs J, Metcalfe JC, Hesketh R. Targeting tumour vasculature: the development of
combretastatin A4. Lancet Oncol. 2001;2:82-87
67. Papandreou I, Powell A, Lim AL, Denko N. Cellular reaction to hypoxia: sensing and
responding to an adverse environment. Mutat Res. 2005;569:87-100
68. Roy S, Khanna S, Bickerstaff AA, Subramanian SV, Atalay M, Bierl M, Pendyala S, Levy D,
Sharma N, Venojarvi M, Strauch A, Orosz CG, Sen CK. Oxygen sensing by primary cardiac
fibroblasts: a key role of p21(Waf1/Cip1/Sdi1). Circ Res. 2003;92:264-271
87
69. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular
aspects. J Natl Cancer Inst. 2001;93:266-276
70. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and
cellular response. Oncologist. 2004;9 Suppl 5:4-9
71. Rumsey WL, Pawlowski M, Lejavardi N, Wilson DF. Oxygen pressure distribution in the heart
in vivo and evaluation of the ischemic "border zone". Am J Physiol. 1994;266:H1676-1680
72. Zagorska A, Dulak J. HIF-1: the knowns and unknowns of hypoxia sensing. Acta Biochim Pol.
2004;51:563-585
73. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest
PJ, van der Wall E. Levels of hypoxia-inducible factor-1alpha independently predict prognosis
in patients with lymph node negative breast carcinoma. Cancer. 2003;97:1573-1581
74. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis
binds to the human erythropoietin gene enhancer at a site required for transcriptional
activation. Mol Cell Biol. 1992;12:5447-5454
75. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-
helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A.
1995;92:5510-5514
76. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible
factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol.
2003;23:9361-9374
77. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A.
Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene
promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem.
1996;271:32529-32537
78. Stolze I, Berchner-Pfannschmidt U, Freitag P, Wotzlaw C, Rossler J, Frede S, Acker H,
Fandrey J. Hypoxia-inducible erythropoietin gene expression in human neuroblastoma cells.
Blood. 2002;100:2623-2628
79. Hogenesch JB, Chan WK, Jackiw VH, Brown RC, Gu YZ, Pray-Grant M, Perdew GH, Bradfield
CA. Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts
with components of the dioxin signaling pathway. J Biol Chem. 1997;272:8581-8593
80. Kung AL, Zabludoff SD, France DS, Freedman SJ, Tanner EA, Vieira A, Cornell-Kennon S,
Lee J, Wang B, Wang J, Memmert K, Naegeli HU, Petersen F, Eck MJ, Bair KW, Wood AW,
Livingston DM. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible
factor pathway. Cancer Cell. 2004;6:33-43
88
81. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription
factor selectively expressed in endothelial cells. Genes Dev. 1997;11:72-82
82. Freeburg PB, Abrahamson DR. Divergent expression patterns for hypoxia-inducible factor-
1beta and aryl hydrocarbon receptor nuclear transporter-2 in developing kidney. J Am Soc
Nephrol. 2004;15:2569-2578
83. Gu YZ, Moran SM, Hogenesch JB, Wartman L, Bradfield CA. Molecular characterization and
chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha.
Gene Expr. 1998;7:205-213
84. Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H, Cao Y, Berkenstam A,
Poellinger L. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene
expression. Nature. 2001;414:550-554
85. Makino Y, Kanopka A, Wilson WJ, Tanaka H, Poellinger L. Inhibitory PAS domain protein
(IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J
Biol Chem. 2002;277:32405-32408
86. Maynard MA, Qi H, Chung J, Lee EH, Kondo Y, Hara S, Conaway RC, Conaway JW, Ohh M.
Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3
ubiquitin ligase complex. J Biol Chem. 2003;278:11032-11040
87. Hoffman EC, Reyes H, Chu FF, Sander F, Conley LH, Brooks BA, Hankinson O. Cloning of a
factor required for activity of the Ah (dioxin) receptor. Science. 1991;252:954-958
88. Reyes H, Reisz-Porszasz S, Hankinson O. Identification of the Ah receptor nuclear translocator
protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science.
1992;256:1193-1195
89. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of
hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res. 1999;59:3915-
3918
90. Hellwig-Burgel T, Rutkowski K, Metzen E, Fandrey J, Jelkmann W. Interleukin-1beta and tumor
necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood.
1999;94:1561-1567
91. Wanner RM, Spielmann P, Stroka DM, Camenisch G, Camenisch I, Scheid A, Houck DR,
Bauer C, Gassmann M, Wenger RH. Epolones induce erythropoietin expression via hypoxia-
inducible factor-1 alpha activation. Blood. 2000;96:1558-1565
92. Gothie E, Richard DE, Berra E, Pages G, Pouyssegur J. Identification of alternative spliced
variants of human hypoxia-inducible factor-1alpha. J Biol Chem. 2000;275:6922-6927
89
93. Lee JW, Bae SH, Jeong JW, Kim SH, Kim KW. Hypoxia-inducible factor (HIF-1)alpha: its
protein stability and biological functions. Exp Mol Med. 2004;36:1-12
94. Chun YS, Choi E, Yeo EJ, Lee JH, Kim MS, Park JW. A new HIF-1 alpha variant induced by
zinc ion suppresses HIF-1-mediated hypoxic responses. J Cell Sci. 2001;114:4051-4061
95. Chun YS, Choi E, Kim TY, Kim MS, Park JW. A dominant-negative isoform lacking exons 11
and 12 of the human hypoxia-inducible factor-1alpha gene. Biochem J. 2002;362:71-79
96. Chun YS, Lee KH, Choi E, Bae SY, Yeo EJ, Huang LE, Kim MS, Park JW. Phorbol ester
stimulates the nonhypoxic induction of a novel hypoxia-inducible factor 1alpha isoform:
implications for tumor promotion. Cancer Res. 2003;63:8700-8707
97. Jiang BH, Zheng JZ, Leung SW, Roe R, Semenza GL. Transactivation and inhibitory domains
of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J
Biol Chem. 1997;272:19253-19260
98. Heidbreder M, Frohlich F, Johren O, Dendorfer A, Qadri F, Dominiak P. Hypoxia rapidly
activates HIF-3alpha mRNA expression. Faseb J. 2003;17:1541-1543
99. Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, Gassmann M, Gearhart JD,
Lawler AM, Yu AY, Semenza GL. Cellular and developmental control of O2 homeostasis by
hypoxia-inducible factor 1 alpha. Genes Dev. 1998;12:149-162
100. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721-732
101. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH, Gassmann M. Induction of HIF-
1alpha in response to hypoxia is instantaneous. Faseb J. 2001;15:1312-1314
102. Pellequer JL, Brudler R, Getzoff ED. Biological sensors: More than one way to sense oxygen.
Curr Biol. 1999;9:R416-418
103. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1alpha is mediated
by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl
Acad Sci U S A. 1998;95:7987-7992
104. Dery MA, Michaud MD, Richard DE. Hypoxia-inducible factor 1: regulation by hypoxic and non-
hypoxic activators. Int J Biochem Cell Biol. 2005;37:535-540
105. Brahimi-Horn C, Mazure N, Pouyssegur J. Signalling via the hypoxia-inducible factor-1alpha
requires multiple posttranslational modifications. Cell Signal. 2005;17:1-9
106. Richard DE, Berra E, Gothie E, Roux D, Pouyssegur J. p42/p44 mitogen-activated protein
kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the
transcriptional activity of HIF-1. J Biol Chem. 1999;274:32631-32637
90
107. Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA, Gutkind JS. The Kaposi's sarcoma-
associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth
factor expression and secretion through mitogen-activated protein kinase and p38 pathways
acting on hypoxia-inducible factor 1alpha. Cancer Res. 2000;60:4873-4880
108. Gradin K, Takasaki C, Fujii-Kuriyama Y, Sogawa K. The transcriptional activation function of
the HIF-like factor requires phosphorylation at a conserved threonine. J Biol Chem.
2002;277:23508-23514
109. Sang N, Stiehl DP, Bohensky J, Leshchinsky I, Srinivas V, Caro J. MAPK signaling up-
regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem.
2003;278:14013-14019
110. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science.
2001;294:1337-1340
111. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen
E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin
J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ. C. elegans EGL-9 and mammalian
homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell.
2001;107:43-54
112. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. HIF prolyl-hydroxylase 2 is
the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. Embo J.
2003;22:4082-4090
113. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh
CW, Maher ER, Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible
factors for oxygen-dependent proteolysis. Nature. 1999;399:271-275
114. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG.
Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von
Hippel-Lindau protein. Nat Cell Biol. 2000;2:423-427
115. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW. Activation of
HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor
complex. Proc Natl Acad Sci U S A. 2000;97:10430-10435
116. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and
VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001;15:2675-2686
117. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF
transactivation domain a hypoxic switch. Science. 2002;295:858-861
91
118. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. FIH-1 is an asparaginyl
hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor.
Genes Dev. 2002;16:1466-1471
119. Masson N, Ratcliffe PJ. HIF prolyl and asparaginyl hydroxylases in the biological response to
intracellular O(2) levels. J Cell Sci. 2003;116:3041-3049
120. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? Embo J.
2000;19:1176-1179
121. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, Yoo MA, Song EJ, Lee KJ, Kim KW.
Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell.
2002;111:709-720
122. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung
HY, Kim CW, Kim KW. Histone deacetylases induce angiogenesis by negative regulation of
tumor suppressor genes. Nat Med. 2001;7:437-443
123. Pugh CW, Ratcliffe PJ. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1
(HIF-1) degradation, and cancer pathogenesis. Semin Cancer Biol. 2003;13:83-89
124. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A,
Semenza GL, Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of
hypoxia-inducible factor 1alpha. Genes Dev. 2000;14:34-44
125. Bae MK, Ahn MY, Jeong JW, Bae MH, Lee YM, Bae SK, Park JW, Kim KR, Kim KW. Jab1
interacts directly with HIF-1alpha and regulates its stability. J Biol Chem. 2002;277:9-12
126. Seeler JS, Dejean A. Nuclear and unclear functions of SUMO. Nat Rev Mol Cell Biol.
2003;4:690-699
127. Saitoh H, Hinchey J. Functional heterogeneity of small ubiquitin-related protein modifiers
SUMO-1 versus SUMO-2/3. J Biol Chem. 2000;275:6252-6258
128. Bohren KM, Nadkarni V, Song JH, Gabbay KH, Owerbach D. A M55V polymorphism in a novel
SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is
associated with susceptibility to type I diabetes mellitus. J Biol Chem. 2004;279:27233-27238
129. Tatham MH, Jaffray E, Vaughan OA, Desterro JM, Botting CH, Naismith JH, Hay RT.
Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by
SAE1/SAE2 and Ubc9. J Biol Chem. 2001;276:35368-35374
130. Hilgarth RS, Murphy LA, Skaggs HS, Wilkerson DC, Xing H, Sarge KD. Regulation and
function of SUMO modification. J Biol Chem. 2004;279:53899-53902
92
131. Girdwood D, Bumpass D, Vaughan OA, Thain A, Anderson LA, Snowden AW, Garcia-Wilson
E, Perkins ND, Hay RT. P300 transcriptional repression is mediated by SUMO modification.
Mol Cell. 2003;11:1043-1054
132. Bae SH, Jeong JW, Park JA, Kim SH, Bae MK, Choi SJ, Kim KW. Sumoylation increases HIF-
1alpha stability and its transcriptional activity. Biochem Biophys Res Commun. 2004;324:394-
400
133. Sumbayev VV, Budde A, Zhou J, Brune B. HIF-1 alpha protein as a target for S-nitrosation.
FEBS Lett. 2003;535:106-112
134. Yasinska IM, Sumbayev VV. S-nitrosation of Cys-800 of HIF-1alpha protein activates its
interaction with p300 and stimulates its transcriptional activity. FEBS Lett. 2003;549:105-109
135. Bhattacharya S, Michels CL, Leung MK, Arany ZP, Kung AL, Livingston DM. Functional role of
p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. Genes Dev.
1999;13:64-75
136. Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B. Insulin induces transcription of
target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. Embo J. 1998;17:5085-
5094
137. Bilton RL, Booker GW. The subtle side to hypoxia inducible factor (HIFalpha) regulation. Eur J
Biochem. 2003;270:791-798
138. Richard DE, Berra E, Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-
inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem. 2000;275:26765-26771
139. Page EL, Robitaille GA, Pouyssegur J, Richard DE. Induction of hypoxia-inducible factor-
1alpha by transcriptional and translational mechanisms. J Biol Chem. 2002;277:48403-48409
140. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. Hypoxia enhances vascular cell
proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. Faseb J.
2002;16:771-780
141. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW,
Semenza GL. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal
growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate
cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000;60:1541-
1545
142. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E. Insulin stimulates
hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-
dependent signaling pathway. J Biol Chem. 2002;277:27975-27981
93
143. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT.
Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target
of rapamycin. Mol Cell Biol. 2002;22:7004-7014
144. Wolf G, Schroeder R, Stahl RA. Angiotensin II induces hypoxia-inducible factor-1 alpha in PC
12 cells through a posttranscriptional mechanism: role of AT2 receptors. Am J Nephrol.
2004;24:415-421
145. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases
the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-
mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001;21:3995-4004
146. Zimmer M, Doucette D, Siddiqui N, Iliopoulos O. Inhibition of hypoxia-inducible factor is
sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res. 2004;2:89-95
147. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE,
Johnson RS, Jefferson AB, Stokoe D, Giaccia AJ. Loss of PTEN facilitates HIF-1-mediated
gene expression. Genes Dev. 2000;14:391-396
148. Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: evidence that the
oxygen sensor is a heme protein. Science. 1988;242:1412-1415
149. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-
inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction.
Blood. 1993;82:3610-3615
150. Yuan Y, Hilliard G, Ferguson T, Millhorn DE. Cobalt inhibits the interaction between hypoxia-
inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible
factor-alpha. J Biol Chem. 2003;278:15911-15916
151. Linden T, Katschinski DM, Eckhardt K, Scheid A, Pagel H, Wenger RH. The antimycotic
ciclopirox olamine induces HIF-1alpha stability, VEGF expression, and angiogenesis. Faseb J.
2003;17:761-763
152. Skinner HD, Zhong XS, Gao N, Shi X, Jiang BH. Arsenite induces p70S6K1 activation and HIF-
1alpha expression in prostate cancer cells. Mol Cell Biochem. 2004;255:19-23
153. Elson DA, Thurston G, Huang LE, Ginzinger DG, McDonald DM, Johnson RS, Arbeit JM.
Induction of hypervascularity without leakage or inflammation in transgenic mice
overexpressing hypoxia-inducible factor-1alpha. Genes Dev. 2001;15:2520-2532
154. Vincent KA, Shyu KG, Luo Y, Magner M, Tio RA, Jiang C, Goldberg MA, Akita GY, Gregory
RJ, Isner JM. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA
encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation. 2000;102:2255-2261
94
155. Li J, Post M, Volk R, Gao Y, Li M, Metais C, Sato K, Tsai J, Aird W, Rosenberg RD, Hampton
TG, Sellke F, Carmeliet P, Simons M. PR39, a peptide regulator of angiogenesis. Nat Med.
2000;6:49-55
156. Warnecke C, Griethe W, Weidemann A, Jurgensen JS, Willam C, Bachmann S, Ivashchenko
Y, Wagner I, Frei U, Wiesener M, Eckardt KU. Activation of the hypoxia-inducible factor-
pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. Faseb
J. 2003;17:1186-1188
157. Sun X, Kanwar JR, Leung E, Lehnert K, Wang D, Krissansen GW. Gene transfer of antisense
hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy.
Gene Ther. 2001;8:638-645
158. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential
tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;359:845-848
159. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W, Ullrich A. High
affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of
vasculogenesis and angiogenesis. Cell. 1993;72:835-846
160. Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, Usuki K, Takaku F,
Risau W, Heldin CH. Identification of angiogenic activity and the cloning and expression of
platelet-derived endothelial cell growth factor. Nature. 1989;338:557-562
161. Montesano R, Vassalli JD, Baird A, Guillemin R, Orci L. Basic fibroblast growth factor induces
angiogenesis in vitro. Proc Natl Acad Sci U S A. 1986;83:7297-7301
162. Maxwell M, Naber SP, Wolfe HJ, Hedley-Whyte ET, Galanopoulos T, Neville-Golden J,
Antoniades HN. Expression of angiogenic growth factor genes in primary human astrocytomas
may contribute to their growth and progression. Cancer Res. 1991;51:1345-1351
163. Benson JR. Role of transforming growth factor beta in breast carcinogenesis. Lancet Oncol.
2004;5:229-239
164. Senger DR, Asch BB, Smith BD, Perruzzi CA, Dvorak HF. A secreted phosphoprotein marker
for neoplastic transformation of both epithelial and fibroblastic cells. Nature. 1983;302:714-715
165. Plouet J, Schilling J, Gospodarowicz D. Isolation and characterization of a newly identified
endothelial cell mitogen produced by AtT-20 cells. Embo J. 1989;8:3801-3806
166. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth
factor is a secreted angiogenic mitogen. Science. 1989;246:1306-1309
167. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular
endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem.
1992;267:26031-26037
95
168. Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, Orpana A, Pettersson
RF, Alitalo K, Eriksson U. Vascular endothelial growth factor B, a novel growth factor for
endothelial cells. Proc Natl Acad Sci U S A. 1996;93:2576-2581
169. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N,
Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-
3) and KDR (VEGFR-2) receptor tyrosine kinases. Embo J. 1996;15:290-298
170. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA. Vascular
endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2
(Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A. 1998;95:548-553
171. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. Isolation of a human placenta
cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A.
1991;88:9267-9271
172. Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M. A novel type of vascular
endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and
carries a potent mitotic activity without heparin-binding domain. J Biol Chem. 1998;273:31273-
31282
173. Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, Ziche M, Lanz C,
Buttner M, Rziha HJ, Dehio C. A novel vascular endothelial growth factor encoded by Orf virus,
VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-
1) receptor tyrosine kinases. Embo J. 1999;18:363-374
174. Shweiki D, Itin A, Neufeld G, Gitay-Goren H, Keshet E. Patterns of expression of vascular
endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally
regulated angiogenesis. J Clin Invest. 1993;91:2235-2243
175. Drouart M, Saas P, Billot M, Cedoz JP, Tiberghien P, Wendling D, Toussirot E. High serum
vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin
Exp Immunol. 2003;132:158-162
176. Fleisch M, Billinger M, Eberli FR, Garachemani AR, Meier B, Seiler C. Physiologically
assessed coronary collateral flow and intracoronary growth factor concentrations in patients
with 1- to 3-vessel coronary artery disease. Circulation. 1999;100:1945-1950
177. Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor
secreted by a variety of human and rodent tumor cell lines. Cancer Res. 1986;46:5629-5632
178. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal
transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J
Biol Chem. 1994;269:26988-26995
96
179. Ortega N, Hutchings H, Plouet J. Signal relays in the VEGF system. Front Biosci. 1999;4:D141-
152
180. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease.
Cancer Cell. 2002;1:219-227
181. Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem
Soc Trans. 2003;31:1171-1177
182. Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, Strawn LM. Dominant-
negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res.
1996;56:1615-1620
183. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, Rosenfield K, Razvi S, Walsh
K, Symes JF. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in
patient with ischaemic limb. Lancet. 1996;348:370-374
184. Zhu Z, Rockwell P, Lu D, Kotanides H, Pytowski B, Hicklin DJ, Bohlen P, Witte L. Inhibition of
vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-
containing receptor single-chain antibodies from a phage display library. Cancer Res.
1998;58:3209-3214
185. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular
endothelial growth factor gene by hypoxia. J Biol Chem. 1995;270:13333-13340
186. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of
vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell
Biol. 1996;16:4604-4613
187. Arbiser JL, Moses MA, Fernandez CA, Ghiso N, Cao Y, Klauber N, Frank D, Brownlee M,
Flynn E, Parangi S, Byers HR, Folkman J. Oncogenic H-ras stimulates tumor angiogenesis by
two distinct pathways. Proc Natl Acad Sci U S A. 1997;94:861-866
188. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY. Epidermal growth factor
stimulates vascular endothelial growth factor production by human malignant glioma cells: a
model of glioblastoma multiforme pathophysiology. Mol Biol Cell. 1993;4:121-133
189. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS. Neutralizing
antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-
regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo:
angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol.
1997;151:1523-1530
190. Blann AD, Li JL, Li C, Kumar S. Increased serum VEGF in 13 children with Wilms' tumour falls
after surgery but rising levels predict poor prognosis. Cancer Lett. 2001;173:183-186
97
191. Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plenat F, Leclere J, Duprez A,
Weryha G. Increased expression of the vascular endothelial growth factor is a pejorative
prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2001;86:656-658
192. Wu Y, Saldana L, Chillar R, Vadgama JV. Plasma vascular endothelial growth factor is useful
in assessing progression of breast cancer post surgery and during adjuvant treatment. Int J
Oncol. 2002;20:509-516
193. Larcher F, Murillas R, Bolontrade M, Conti CJ, Jorcano JL. VEGF/VPF overexpression in skin
of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor
development. Oncogene. 1998;17:303-311
194. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene delivery to
myocardium: deleterious effects of unregulated expression. Circulation. 2000;102:898-901
195. Antoniades HN, Scher CD, Stiles CD. Purification of human platelet-derived growth factor. Proc
Natl Acad Sci U S A. 1979;76:1809-1813
196. Heldin CH, Westermark B, Wasteson A. Platelet-derived growth factor: purification and partial
characterization. Proc Natl Acad Sci U S A. 1979;76:3722-3726
197. Raines EW, Ross R. Platelet-derived growth factor. I. High yield purification and evidence for
multiple forms. J Biol Chem. 1982;257:5154-5160
198. Betsholtz C, Johnsson A, Heldin CH, Westermark B, Lind P, Urdea MS, Eddy R, Shows TB,
Philpott K, Mellor AL, et al. cDNA sequence and chromosomal localization of human platelet-
derived growth factor A-chain and its expression in tumour cell lines. Nature. 1986;320:695-699
199. Li X, Ponten A, Aase K, Karlsson L, Abramsson A, Uutela M, Backstrom G, Hellstrom M,
Bostrom H, Li H, Soriano P, Betsholtz C, Heldin CH, Alitalo K, Ostman A, Eriksson U. PDGF-C
is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol. 2000;2:302-309
200. Kazlauskas A. A new member of an old family. Nat Cell Biol. 2000;2:E78-79
201. Gilbertson DG, Duff ME, West JW, Kelly JD, Sheppard PO, Hofstrand PD, Gao Z, Shoemaker
K, Bukowski TR, Moore M, Feldhaus AL, Humes JM, Palmer TE, Hart CE. Platelet-derived
growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. J
Biol Chem. 2001;276:27406-27414
202. LaRochelle WJ, Jeffers M, McDonald WF, Chillakuru RA, Giese NA, Lokker NA, Sullivan C,
Boldog FL, Yang M, Vernet C, Burgess CE, Fernandes E, Deegler LL, Rittman B, Shimkets J,
Shimkets RA, Rothberg JM, Lichenstein HS. PDGF-D, a new protease-activated growth factor.
Nat Cell Biol. 2001;3:517-521
203. Bergsten E, Uutela M, Li X, Pietras K, Ostman A, Heldin CH, Alitalo K, Eriksson U. PDGF-D is
a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol. 2001;3:512-516
98
204. Hart CE, Seifert RA, Ross R, Bowen-Pope DF. Synthesis, phosphorylation, and degradation of
multiple forms of the platelet-derived growth factor receptor studied using a monoclonal
antibody. J Biol Chem. 1987;262:10780-10785
205. Hart CE, Forstrom JW, Kelly JD, Seifert RA, Smith RA, Ross R, Murray MJ, Bowen-Pope DF.
Two classes of PDGF receptor recognize different isoforms of PDGF. Science. 1988;240:1529-
1531
206. Heldin CH, Backstrom G, Ostman A, Hammacher A, Ronnstrand L, Rubin K, Nister M,
Westermark B. Binding of different dimeric forms of PDGF to human fibroblasts: evidence for
two separate receptor types. Embo J. 1988;7:1387-1393
207. Heldin CH, Ostman A, Ronnstrand L. Signal transduction via platelet-derived growth factor
receptors. Biochim Biophys Acta. 1998;1378:F79-113
208. Li X, Eriksson U. Novel PDGF family members: PDGF-C and PDGF-D. Cytokine Growth Factor
Rev. 2003;14:91-98
209. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth
factor. Physiol Rev. 1999;79:1283-1316
210. Kaetzel DM, Coyne DW, Fenstermaker RA. Transcriptional control of the platelet-derived
growth factor subunit genes. Biofactors. 1993;4:71-81
211. Daniel TO, Gibbs VC, Milfay DF, Garovoy MR, Williams LT. Thrombin stimulates c-sis gene
expression in microvascular endothelial cells. J Biol Chem. 1986;261:9579-9582
212. Harlan JM, Thompson PJ, Ross RR, Bowen-Pope DF. Alpha-thrombin induces release of
platelet-derived growth factor-like molecule(s) by cultured human endothelial cells. J Cell Biol.
1986;103:1129-1133
213. Kourembanas S, Morita T, Liu Y, Christou H. Mechanisms by which oxygen regulates gene
expression and cell-cell interaction in the vasculature. Kidney Int. 1997;51:438-443
214. Claesson-Welsh L. Platelet-derived growth factor receptor signals. J Biol Chem.
1994;269:32023-32026
215. Holmgren L, Glaser A, Pfeifer-Ohlsson S, Ohlsson R. Angiogenesis during human
extraembryonic development involves the spatiotemporal control of PDGF ligand and receptor
gene expression. Development. 1991;113:749-754
216. Battegay EJ, Rupp J, Iruela-Arispe L, Sage EH, Pech M. PDGF-BB modulates endothelial
proliferation and angiogenesis in vitro via PDGF beta-receptors. J Cell Biol. 1994;125:917-928
99
217. Nicosia RF, Nicosia SV, Smith M. Vascular endothelial growth factor, platelet-derived growth
factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am J Pathol.
1994;145:1023-1029
218. Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal
smooth muscle accumulation after angioplasty by an antibody to PDGF. Science.
1991;253:1129-1132
219. Sirois MG, Simons M, Edelman ER. Antisense oligonucleotide inhibition of PDGFR-beta
receptor subunit expression directs suppression of intimal thickening. Circulation. 1997;95:669-
676
220. Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, Ostman A. Inhibition of
PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer
Res. 2002;62:5476-5484
221. Tsutsumi N, Yonemitsu Y, Shikada Y, Onimaru M, Tanii M, Okano S, Kaneko K, Hasegawa M,
Hashizume M, Maehara Y, Sueishi K. Essential role of PDGFRalpha-p70S6K signaling in
mesenchymal cells during therapeutic and tumor angiogenesis in vivo: role of PDGFRalpha
during angiogenesis. Circ Res. 2004;94:1186-1194
222. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation
in PDGF-B-deficient mice. Science. 1997;277:242-245
223. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol.
1996;14:483-510
224. Dumont FJ, Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci.
1996;58:373-395
225. Rowinsky EK. Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol.
2004;16:564-575
226. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant
rapamycin in yeast. Science. 1991;253:905-909
227. Jacinto E, Hall MN. Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol. 2003;4:117-
126
228. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR.
Genes Dev. 2001;15:807-826
229. Kunz J, Schneider U, Howald I, Schmidt A, Hall MN. HEAT repeats mediate plasma membrane
localization of Tor2p in yeast. J Biol Chem. 2000;275:37011-37020
100
230. Bosotti R, Isacchi A, Sonnhammer EL. FAT: a novel domain in PIK-related kinases. Trends
Biochem Sci. 2000;25:225-227
231. Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12-rapamycin complex
interacting with the binding domain of human FRAP. Science. 1996;273:239-242
232. Helliwell SB, Wagner P, Kunz J, Deuter-Reinhard M, Henriquez R, Hall MN. TOR1 and TOR2
are structurally and functionally similar but not identical phosphatidylinositol kinase homologues
in yeast. Mol Biol Cell. 1994;5:105-118
233. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe
P, Hall MN. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles
in cell growth control. Mol Cell. 2002;10:457-468
234. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN. Mammalian TOR complex
2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004;6:1122-1128
235. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini
DM. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell
growth machinery. Cell. 2002;110:163-175
236. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa
K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell.
2002;110:177-189
237. Kim DH, Sarbassov dos D, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H, Tempst P,
Sabatini DM. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the
nutrient-sensitive interaction between raptor and mTOR. Mol Cell. 2003;11:895-904
238. Sarbassov dos D, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P,
Sabatini DM. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and
raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14:1296-1302
239. Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, Abraham RT.
Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol
Chem. 1995;270:815-822
240. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL. A mammalian
protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369:756-758
241. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian
protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast
TORs. Cell. 1994;78:35-43
242. Chiu MI, Katz H, Berlin V. RAPT1, a mammalian homolog of yeast Tor, interacts with the
FKBP12/rapamycin complex. Proc Natl Acad Sci U S A. 1994;91:12574-12578
101
243. Chen Y, Chen H, Rhoad AE, Warner L, Caggiano TJ, Failli A, Zhang H, Hsiao CL, Nakanishi K,
Molnar-Kimber KL. A putative sirolimus (rapamycin) effector protein. Biochem Biophys Res
Commun. 1994;203:1-7
244. Lench NJ, Macadam R, Markham AF. The human gene encoding FKBP-rapamycin associated
protein (FRAP) maps to chromosomal band 1p36.2. Hum Genet. 1997;99:547-549
245. Chen J, Zheng XF, Brown EJ, Schreiber SL. Identification of an 11-kDa FKBP12-rapamycin-
binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization
of a critical serine residue. Proc Natl Acad Sci U S A. 1995;92:4947-4951
246. Fox HL, Kimball SR, Jefferson LS, Lynch CJ. Amino acids stimulate phosphorylation of p70S6k
and organization of rat adipocytes into multicellular clusters. Am J Physiol. 1998;274:C206-213
247. Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C, Avruch J. Amino acid sufficiency
and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J
Biol Chem. 1998;273:14484-14494
248. Fox HL, Pham PT, Kimball SR, Jefferson LS, Lynch CJ. Amino acid effects on translational
repressor 4E-BP1 are mediated primarily by L-leucine in isolated adipocytes. Am J Physiol.
1998;275:C1232-1238
249. Lindsley JE, Rutter J. Nutrient sensing and metabolic decisions. Comp Biochem Physiol B
Biochem Mol Biol. 2004;139:543-559
250. Patel J, Wang X, Proud CG. Glucose exerts a permissive effect on the regulation of the
initiation factor 4E binding protein 4E-BP1. Biochem J. 2001;358:497-503
251. Kwon G, Marshall CA, Pappan KL, Remedi MS, McDaniel ML. Signaling elements involved in
the metabolic regulation of mTOR by nutrients, incretins, and growth factors in islets. Diabetes.
2004;53 Suppl 3:S225-232
252. Pende M, Kozma SC, Jaquet M, Oorschot V, Burcelin R, Le Marchand-Brustel Y, Klumperman
J, Thorens B, Thomas G. Hypoinsulinaemia, glucose intolerance and diminished beta-cell size
in S6K1-deficient mice. Nature. 2000;408:994-997
253. Kimball SR, Siegfried BA, Jefferson LS. Glucagon represses signaling through the mammalian
target of rapamycin in rat liver by activating AMP-activated protein kinase. J Biol Chem.
2004;279:54103-54109
254. Harrington LS, Findlay GM, Lamb RF. Restraining PI3K: mTOR signalling goes back to the
membrane. Trends Biochem Sci. 2005;30:35-42
255. Crozier SJ, Anthony JC, Schworer CM, Reiter AK, Anthony TG, Kimball SR, Jefferson LS.
Tissue-specific regulation of protein synthesis by insulin and free fatty acids. Am J Physiol
Endocrinol Metab. 2003;285:E754-762
102
256. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated
mitogenic activation of mTOR signaling. Science. 2001;294:1942-1945
257. Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G. Mammalian TOR: a
homeostatic ATP sensor. Science. 2001;294:1102-1105
258. Kimura N, Tokunaga C, Dalal S, Richardson C, Yoshino K, Hara K, Kemp BE, Witters LA,
Mimura O, Yonezawa K. A possible linkage between AMP-activated protein kinase (AMPK)
and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells. 2003;8:65-79
259. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and
suppresses mTOR signalling. Nat Cell Biol. 2002;4:648-657
260. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and
survival. Cell. 2003;115:577-590
261. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18:1926-1945
262. Cheng SW, Fryer LG, Carling D, Shepherd PR. Thr2446 is a novel mammalian target of
rapamycin (mTOR) phosphorylation site regulated by nutrient status. J Biol Chem.
2004;279:15719-15722
263. Nave BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR. Mammalian target of rapamycin is
a direct target for protein kinase B: identification of a convergence point for opposing effects of
insulin and amino-acid deficiency on protein translation. Biochem J. 1999;344 Pt 2:427-431
264. Sekulic A, Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM, Abraham RT. A direct
linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian
target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 2000;60:3504-
3513
265. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor
signals and coordinator of cell growth and cell cycle progression. Oncogene. 2004;23:3151-
3171
266. Fang Y, Park IH, Wu AL, Du G, Huang P, Frohman MA, Walker SJ, Brown HA, Chen J. PLD1
regulates mTOR signaling and mediates Cdc42 activation of S6K1. Curr Biol. 2003;13:2037-
2044
267. Chen Y, Zheng Y, Foster DA. Phospholipase D confers rapamycin resistance in human breast
cancer cells. Oncogene. 2003;22:3937-3942
268. Chung J, Grammer TC, Lemon KP, Kazlauskas A, Blenis J. PDGF- and insulin-dependent
pp70S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature. 1994;370:71-75
103
269. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu
H, Sawyers CL. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
Proc Natl Acad Sci U S A. 2001;98:10314-10319
270. Tee AR, Proud CG. DNA-damaging agents cause inactivation of translational regulators linked
to mTOR signalling. Oncogene. 2000;19:3021-3031
271. Horton LE, Bushell M, Barth-Baus D, Tilleray VJ, Clemens MJ, Hensold JO. p53 activation
results in rapid dephosphorylation of the eIF4E-binding protein 4E-BP1, inhibition of ribosomal
protein S6 kinase and inhibition of translation initiation. Oncogene. 2002;21:5325-5334
272. Kumar V, Sabatini D, Pandey P, Gingras AC, Majumder PK, Kumar M, Yuan ZM, Carmichael
G, Weichselbaum R, Sonenberg N, Kufe D, Kharbanda S. Regulation of the rapamycin and
FKBP-target 1/mammalian target of rapamycin and cap-dependent initiation of translation by
the c-Abl protein-tyrosine kinase. J Biol Chem. 2000;275:10779-10787
273. Brenneisen P, Wenk J, Wlaschek M, Krieg T, Scharffetter-Kochanek K. Activation of p70
ribosomal protein S6 kinase is an essential step in the DNA damage-dependent signaling
pathway responsible for the ultraviolet B-mediated increase in interstitial collagenase (MMP-1)
and stromelysin-1 (MMP-3) protein levels in human dermal fibroblasts. J Biol Chem.
2000;275:4336-4344
274. Zhang Y, Dong Z, Nomura M, Zhong S, Chen N, Bode AM. Signal transduction pathways
involved in phosphorylation and activation of p70S6K following exposure to UVA irradiation. J
Biol Chem. 2001;276:20913-20923
275. Cheatham B, Vlahos CJ, Cheatham L, Wang L, Blenis J, Kahn CR. Phosphatidylinositol 3-
kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and
glucose transporter translocation. Mol Cell Biol. 1994;14:4902-4911
276. Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N, Hay N. 4E-BP1, a repressor of mRNA
translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev.
1998;12:502-513
277. Sharma PM, Egawa K, Huang Y, Martin JL, Huvar I, Boss GR, Olefsky JM. Inhibition of
phosphatidylinositol 3-kinase activity by adenovirus-mediated gene transfer and its effect on
insulin action. J Biol Chem. 1998;273:18528-18537
278. Wishart MJ, Dixon JE. PTEN and myotubularin phosphatases: from 3-phosphoinositide
dephosphorylation to disease. Trends Cell Biol. 2002;12:579-585
279. Scott PH, Brunn GJ, Kohn AD, Roth RA, Lawrence JC, Jr. Evidence of insulin-stimulated
phosphorylation and activation of the mammalian target of rapamycin mediated by a protein
kinase B signaling pathway. Proc Natl Acad Sci U S A. 1998;95:7772-7777
104
280. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. Tuberous sclerosis
complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin
(mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A. 2002;99:13571-13576
281. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous
sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide
3-kinase/akt pathway. Mol Cell. 2002;10:151-162
282. Potter CJ, Pedraza LG, Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell
Biol. 2002;4:658-665
283. Peng XD, Xu PZ, Chen ML, Hahn-Windgassen A, Skeen J, Jacobs J, Sundararajan D, Chen
WS, Crawford SE, Coleman KG, Hay N. Dwarfism, impaired skin development, skeletal muscle
atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2.
Genes Dev. 2003;17:1352-1365
284. Saucedo LJ, Gao X, Chiarelli DA, Li L, Pan D, Edgar BA. Rheb promotes cell growth as a
component of the insulin/TOR signalling network. Nat Cell Biol. 2003;5:566-571
285. Castro AF, Rebhun JF, Clark GJ, Quilliam LA. Rheb binds tuberous sclerosis complex 2
(TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent
manner. J Biol Chem. 2003;278:32493-32496
286. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E,
Bos JL, Thomas G. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is
inhibited by TSC1 and 2. Mol Cell. 2003;11:1457-1466
287. Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, Burley SK, Polakiewicz RD,
Wyslouch-Cieszynska A, Aebersold R, Sonenberg N. Hierarchical phosphorylation of the
translation inhibitor 4E-BP1. Genes Dev. 2001;15:2852-2864
288. Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold R,
Sonenberg N. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes
Dev. 1999;13:1422-1437
289. Thomas G. An encore for ribosome biogenesis in the control of cell proliferation. Nat Cell Biol.
2000;2:E71-72
290. Tang H, Hornstein E, Stolovich M, Levy G, Livingstone M, Templeton D, Avruch J, Meyuhas O.
Amino acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-
kinase-mediated signaling, is partially inhibited by rapamycin, and is independent of S6K1 and
rpS6 phosphorylation. Mol Cell Biol. 2001;21:8671-8683
291. Shima H, Pende M, Chen Y, Fumagalli S, Thomas G, Kozma SC. Disruption of the
p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase.
Embo J. 1998;17:6649-6659
105
292. Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW,
Kaelin WG, Jr. Regulation of mTOR function in response to hypoxia by REDD1 and the
TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004;18:2893-2904
293. Thomas G, Hall MN. TOR signalling and control of cell growth. Curr Opin Cell Biol. 1997;9:782-
787
294. Dennis PB, Pullen N, Kozma SC, Thomas G. The principal rapamycin-sensitive p70(s6k)
phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive
kinase kinases. Mol Cell Biol. 1996;16:6242-6251
295. Dufner A, Thomas G. Ribosomal S6 kinase signaling and the control of translation. Exp Cell
Res. 1999;253:100-109
296. Peterson RT, Desai BN, Hardwick JS, Schreiber SL. Protein phosphatase 2A interacts with the
70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc
Natl Acad Sci U S A. 1999;96:4438-4442
297. Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR,
Roberts JM. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase
inhibitor prevented by rapamycin. Nature. 1994;372:570-573
298. Reynolds THt, Bodine SC, Lawrence JC, Jr. Control of Ser2448 phosphorylation in the
mammalian target of rapamycin by insulin and skeletal muscle load. J Biol Chem.
2002;277:17657-17662
299. Shioi T, McMullen JR, Kang PM, Douglas PS, Obata T, Franke TF, Cantley LC, Izumo S.
Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol. 2002;22:2799-
2809
300. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR
and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002;16:1472-1487
301. Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, Mueller M, Fumagalli S, Kozma
SC, Thomas G. S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-
terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-
dependent S6 kinase pathway. Mol Cell Biol. 2004;24:3112-3124
302. Lynch M, Fitzgerald C, Johnston KA, Wang S, Schmidt EV. Activated eIF4E-binding protein
slows G1 progression and blocks transformation by c-myc without inhibiting cell growth. J Biol
Chem. 2004;279:3327-3339
303. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke
C, Farkas S, Anthuber M, Jauch KW, Geissler EK. Rapamycin inhibits primary and metastatic
tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med.
2002;8:128-135
106
304. Arsham AM, Howell JJ, Simon MC. A novel hypoxia-inducible factor-independent hypoxic
response regulating mammalian target of rapamycin and its targets. J Biol Chem.
2003;278:29655-29660
305. English J, Pearson G, Wilsbacher J, Swantek J, Karandikar M, Xu S, Cobb MH. New insights
into the control of MAP kinase pathways. Exp Cell Res. 1999;253:255-270
306. Murray AW. MAP kinases in meiosis. Cell. 1998;92:157-159
307. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. Mitogen-
activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev.
2001;22:153-183
308. Payne DM, Rossomando AJ, Martino P, Erickson AK, Her JH, Shabanowitz J, Hunt DF, Weber
MJ, Sturgill TW. Identification of the regulatory phosphorylation sites in pp42/mitogen-activated
protein kinase (MAP kinase). Embo J. 1991;10:885-892
309. Zhang J, Zhang F, Ebert D, Cobb MH, Goldsmith EJ. Activity of the MAP kinase ERK2 is
controlled by a flexible surface loop. Structure. 1995;3:299-307
310. Doza YN, Cuenda A, Thomas GM, Cohen P, Nebreda AR. Activation of the MAP kinase
homologue RK requires the phosphorylation of Thr-180 and Tyr-182 and both residues are
phosphorylated in chemically stressed KB cells. FEBS Lett. 1995;364:223-228
311. Robinson MJ, Cheng M, Khokhlatchev A, Ebert D, Ahn N, Guan KL, Stein B, Goldsmith E,
Cobb MH. Contributions of the mitogen-activated protein (MAP) kinase backbone and
phosphorylation loop to MEK specificity. J Biol Chem. 1996;271:29734-29739
312. Frodin M, Gammeltoft S. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal
transduction. Mol Cell Endocrinol. 1999;151:65-77
313. Tibbles LA, Woodgett JR. The stress-activated protein kinase pathways. Cell Mol Life Sci.
1999;55:1230-1254
314. Mielke K, Herdegen T. JNK and p38 stresskinases--degenerative effectors of signal-
transduction-cascades in the nervous system. Prog Neurobiol. 2000;61:45-60
315. Jin N, Hatton N, Swartz DR, Xia X, Harrington MA, Larsen SH, Rhoades RA. Hypoxia activates
jun-N-terminal kinase, extracellular signal-regulated protein kinase, and p38 kinase in
pulmonary arteries. Am J Respir Cell Mol Biol. 2000;23:593-601
316. Conrad PW, Millhorn DE, Beitner-Johnson D. Hypoxia differentially regulates the mitogen- and
stress-activated protein kinases. Role of Ca2+/CaM in the activation of MAPK and p38 gamma.
Adv Exp Med Biol. 2000;475:293-302
107
317. Conrad PW, Freeman TL, Beitner-Johnson D, Millhorn DE. EPAS1 trans-activation during
hypoxia requires p42/p44 MAPK. J Biol Chem. 1999;274:33709-33713
318. Salceda S, Beck I, Srinivas V, Caro J. Complex role of protein phosphorylation in gene
activation by hypoxia. Kidney Int. 1997;51:556-559
319. Agani F, Semenza GL. Mersalyl is a novel inducer of vascular endothelial growth factor gene
expression and hypoxia-inducible factor 1 activity. Mol Pharmacol. 1998;54:749-754
320. Shemirani B, Crowe DL. Hypoxic induction of HIF-1alpha and VEGF expression in head and
neck squamous cell carcinoma lines is mediated by stress activated protein kinases. Oral
Oncol. 2002;38:251-257
321. Minet E, Arnould T, Michel G, Roland I, Mottet D, Raes M, Remacle J, Michiels C. ERK
activation upon hypoxia: involvement in HIF-1 activation. FEBS Lett. 2000;468:53-58
322. Berra E, Milanini J, Richard DE, Le Gall M, Vinals F, Gothie E, Roux D, Pages G, Pouyssegur
J. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol.
2000;60:1171-1178
323. Zhu WH, Han J, Nicosia RF. Requisite role of p38 MAPK in mural cell recruitment during
angiogenesis in the rat aorta model. J Vasc Res. 2003;40:140-148
324. Korff T, Kimmina S, Martiny-Baron G, Augustin HG. Blood vessel maturation in a 3-dimensional
spheroidal coculture model: direct contact with smooth muscle cells regulates endothelial cell
quiescence and abrogates VEGF responsiveness. Faseb J. 2001;15:447-457
325. Kotch LE, Iyer NV, Laughner E, Semenza GL. Defective vascularization of HIF-1alpha-null
embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev Biol.
1999;209:254-267
326. Kiefer FN, Munk VC, Humar R, Dieterle T, Landmann L, Battegay EJ. A versatile in vitro assay
for investigating angiogenesis of the heart. Exp Cell Res. 2004;300:272-282
327. Gerasimovskaya EV, Tucker DA, Stenmark KR. Activation of phosphatidylinositol 3-kinase,
Akt, and mammalian target of rapamycin is necessary for hypoxia-induced pulmonary artery
adventitial fibroblast proliferation. J Appl Physiol. 2005;98:722-731
328. Schwarzer R, Tondera D, Arnold W, Giese K, Klippel A, Kaufmann J. REDD1 integrates
hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase. Oncogene.
2004
329. Shoshani T, Faerman A, Mett I, Zelin E, Tenne T, Gorodin S, Moshel Y, Elbaz S, Budanov A,
Chajut A, Kalinski H, Kamer I, Rozen A, Mor O, Keshet E, Leshkowitz D, Einat P, Skaliter R,
Feinstein E. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801,
involved in apoptosis. Mol Cell Biol. 2002;22:2283-2293
108
330. Kim JE, Chen J. Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is
involved in rapamycin-sensitive signaling and translation initiation. Proc Natl Acad Sci U S A.
2000;97:14340-14345
331. Zhang X, Shu L, Hosoi H, Murti KG, Houghton PJ. Predominant nuclear localization of
mammalian target of rapamycin in normal and malignant cells in culture. J Biol Chem.
2002;277:28127-28134
332. Sheta EA, Trout H, Gildea JJ, Harding MA, Theodorescu D. Cell density mediated pericellular
hypoxia leads to induction of HIF-1alpha via nitric oxide and Ras/MAP kinase mediated
signaling pathways. Oncogene. 2001;20:7624-7634
333. Stavri GT, Hong Y, Zachary IC, Breier G, Baskerville PA, Yla-Herttuala S, Risau W, Martin JF,
Erusalimsky JD. Hypoxia and platelet-derived growth factor-BB synergistically upregulate the
expression of vascular endothelial growth factor in vascular smooth muscle cells. FEBS Lett.
1995;358:311-315
334. Petersen W, Pufe T, Zantop T, Tillmann B, Mentlein R. Hypoxia and PDGF have a synergistic
effect that increases the expression of the angiogenetic peptide vascular endothelial growth
factor in Achilles tendon fibroblasts. Arch Orthop Trauma Surg. 2003;123:485-488
335. Comerford KM, Leonard MO, Karhausen J, Carey R, Colgan SP, Taylor CT. Small ubiquitin-
related modifier-1 modification mediates resolution of CREB-dependent responses to hypoxia.
Proc Natl Acad Sci U S A. 2003;100:986-991
336. Shao R, Zhang FP, Tian F, Anders Friberg P, Wang X, Sjoland H, Billig H. Increase of SUMO-1
expression in response to hypoxia: direct interaction with HIF-1alpha in adult mouse brain and
heart in vivo. FEBS Lett. 2004;569:293-300
337. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y. A novel bHLH-PAS
factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF
expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci U
S A. 1997;94:4273-4278
338. Flamme I, Frohlich T, von Reutern M, Kappel A, Damert A, Risau W. HRF, a putative basic
helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1
alpha and developmentally expressed in blood vessels. Mech Dev. 1997;63:51-60
339. Scortegagna M, Ding K, Oktay Y, Gaur A, Thurmond F, Yan LJ, Marck BT, Matsumoto AM,
Shelton JM, Richardson JA, Bennett MJ, Garcia JA. Multiple organ pathology, metabolic
abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice. Nat
Genet. 2003;35:331-340
340. Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivieres S, Mercep L, Ferrari S. Rapamycin
inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein
stability. J Biol Chem. 1998;273:14424-14429
109
341. Gaben AM, Saucier C, Bedin M, Barbu V, Mester J. Rapamycin inhibits cdk4 activation, p
21(WAF1/CIP1) expression and G1-phase progression in transformed mouse fibroblasts. Int J
Cancer. 2004;108:200-206
110
8. ABBREVIATIONS
ACE angiotensin-converting enzyme
Akt v-akt murine thymoma viral oncogene homolog
AMPK 5’AMP-activated protein kinase
Ang Angiopoietin
Ang II angiotensin II
ARD1 arrest defective-1 protein
ARNT aryl hydrocarbon receptor nuclear translocator
AT receptor angiotensin receptor
(m)AVO (mammalian) adheres voraciously to TOR2
BM basement membrane
BSA bovine serum albumin
CBP CREB binding protein
cdk cyclin-dependent kinase
CPX ciclopirox olamine
CREB cAMP responsive element binding protein
DFX desferrioxamine
DMEM Dulbecco's Modified Eagle's Medium
4E-BP eIF4E-binding protein
EC endothelial cell
ECM extracellular matrix
EDNO endothelial nitric oxide
EGF epidermal growth factor
eIF Eukaryotic translation initiation factor
EPO erythropoietin
EPX epoxomicin
ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, HER2/neu
ERK extracellular signal-regulated kinase
FAT FRAP, AMT, TRRAP domain
FATC FAT carboxy-terminal domain
FCS fetal calf serum
FFA free fatty acid
FGF fibroblast growth factor
FIH-1 factor inhibiting HIF-1
111
FKBP FK506 binding protein
Flk-1 Fetal liver kinase-1, VEGFR2, KDR
Flt-1 FMS-like tyrosine kinase-1, VEGFR1
FRAP FKBP12-rapamycin associated protein
FRB FKBP12-rapamycin binding
GAP GTPase-activating protein
GβL G protein β-subunit-like protein
HDAC histone deacetylase
HGF Hepatocyte growth factor
HIF hypoxia-inducible factor
HIF-1α hypoxia-inducible factor-1 alpha subunit
HLH helix-loop-helix
HOG high osmolarity glycerol
HRE hypoxia response element
HSP90 heat shock protein 90
ID inhibitory domain
IL Interleukin
IPAS inhibitory PAS domain protein
IRS insulin receptor substrates
Jab Jun activation domain-binding protein
JNK c-Jun N-terminal kinase
kDa/kD kiloDalton
KDR kinase insert domain receptor, VEGFR2, Flk-1
Kip1 cyclin-dependent kinase inhibitor 1
(m)KOG (mammalian) kontroller of growth
(m)LST (mammalian) lethal with sec thirteen
MAPK mitogen-activated protein kinase
MEF mouse embryonic fibroblast
MEK MAPK kinase (MAP2K)
MEKK MAPK kinase kinase (MAP3K)
NO nitric oxide
OA osteoarthritis
ODD oxygen-dependent degradation domain
P38 p38 MAP kinase
PA phosphatidic acid
112
PAC PAS-associated C-terminal domain
PAS period(Per)-Aryl hydrocarbon receptor nuclear translocator (Arnt)-
single-minded protein (Sim)
PC peri-endothelial cell
PDGF platelet-derived growth factor
PDGFR platelet-derived growth factor receptor
PECAM-1 Platelet-Endothelial Cell Adhesion Molecule-1, CD31
PHAS phosohorylated heat and acid-stable protein regulated by insulin
PHD prolyl hydroxylase domain protein
PI3K phosphatidylinositol 3-kinase
PIKK phosphoinositol kinase-related protein kinase
PKB protein kinase B, Akt
PLD phospholipase D
PML promyelocytic leukemia protein
PP2A type 2A phosphatase
PTEN phosphatase and tensin homolog
pVHL von Hippel-Lindau protein
RA rheumatoid arthritis
RAAS renin-angiotensin-aldosterone system
RAEC rat aortic endothelial cell
RAFT rapamycin and FKBP12 target
RAPT rapamycin target
raptor regulatory associated protein of TOR, mKOG1
REDD regulated in development and DNA damage responses
Ref redox factor
Rheb Ras homolog enriched in brain
rictor rapamycin-insensitive companion of mTOR
RNAi RNA interference
RPM rapamycin
RTK receptor tyrosine kinase
S6K ribosomal protein S6 kinase
SAPK stress-activated protein kinase
SEP Sirolimus effector protein
SRC steroid receptor co-activator
STAT signal transducer and activator of transcription
113
SUMO small ubiquitin-like modifier
TAD-N(C) N (C)-terminal transactivation domain
TGF transforming growth factor
Tie tyrosine kinase with immunoglobulin and EGF homology domains
TNF tumor necrosis factor
TOR target of rapamycin
TOS TOR signaling motifs
TSC tuberous sclerosis complex
(m)TOR (mammalian) target of rapamycin
(m)TORC (mammalian) target of rapamycin complex
VEGF vascular endothelial cell growth factor
VEGFR vascular endothelial cell growth factor receptor
VSMC vascular smooth muscle cell
